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ABSTRACT 
Natural products and natural product derivatives have been the leading source of 
pharmaceutical compounds since the initial application of modern medicine. To fight the 
increasing occurrence of drug resistance and to reach the ultimate goal of personalized drugs for 
treating complicated symptoms, novel natural products are demanded. Lanthipeptides are 
ribosomal peptides with post-translationally incorporated thioether crosslinks named lanthionine. 
This family of natural products has garnered substantial attention during the past few decades 
due to their favorable biological activities and the potential for engineering.  
This thesis focuses on a subclass of lanthipeptides, the class II compounds, for which the 
synthesis of dehydroamino acids and the formation of thioether linkages are carried out by a 
bifunctional lanthionine synthetase. Chapter 2 presents the structural characterization of the 
enterococcal cytolysin, a lanthipeptide tightly linked to Enterococcus faecalis virulence. The 
stereoselectivity of lanthionine synthesis is discussed in chapters 3 and 4. A non-canonical 
configuration of lanthionines was discovered in a few lanthipeptides and the selective synthesis 
of the unusual stereochemistry was found to be induced by the peptide sequence rather than the 
lanthionine synthetase. Such a substrate-controlled stereoselectivity is rarely identified in 
naturally occurring enzymatic processes. Although it has been more than ten years since the first 
in vitro reconstitution of a class II lanthionine synthetase, no structural information was available 
for this class of proteins before the study presented in chapter 5 with respect to the cytolysin 
synthetase CylM. Unexpectedly, the CylM dehydratase domain resembles the catalytic core of 
lipid kinases despite the absence of notable sequence homology. Mutagenesis study of CylM 
provides further insights into the mechanism of the modification process. The maturation of 
lanthipeptides typically requires a proteolytic step that removes the leader peptide from the 
modified precursor peptides. Characterization of two peptidases involved in the synthesis of 
lichenicidin and cytolysin, described in chapters 6 and 7, provides mechanistic insights into these 
subtilisin-like proteins and reveals their potential as sequence-specific proteases. In addition, 
structural elucidation of four prochlorosins, a set of lanthipeptides synthesized by a highly 
substrate-tolerant synthetase ProcM in marine bacteria, is included as chapter 8. The unveiled 
structural information of these lanthipeptides and the biochemical studies with respect to the 
biosynthetic process described in this thesis may assist the genome mining and synthetic biology 
efforts towards novel lanthipeptides for therapeutic purposes and other applications. 
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Chapter 1. Lanthipeptides and Their Biosynthesis 
 
1.1 Ribosomally synthesized and post-translationally modified peptides  
Natural products and natural product derivatives have been key sources of pharmaceutical 
compounds over the last century (1). Although libraries of large size can be prepared for 
selection purposes, synthetic compound libraries have been less efficient in identifying lead 
compounds presumably due to lower structural complexity (2). Natural products have been 
categorized into several subclasses that differ by their biosynthetic routes, including terpenoids, 
alkaloids, polyketides, and non-ribosomal peptides. As a rapidly expanding family of 
compounds, ribosomally synthesized and post-translationally modified peptides (RiPPs) have 
also been recognized as a major family of natural products (Figure 1.1) (3). The burst of 
available genomic information has lead to the identification of numerous biosynthetic pathways 
related to RiPP production, especially in the past decade (4). Furthermore, these molecules are 
produced in all three kingdoms of life and their structures are extremely diverse as a 
consequence of many different post-translational modifications (Figure 1.1) (5). Different 
biological activities have also been assigned to this family of natural products (6-9). 
Compared to other natural products, RiPPs have several unique and potential favorable 
features. First, RiPPs are highly evolvable as their precursor peptides are encoded in the genome 
and synthesized by the ribosome. The biosynthetic pathways responsible for RiPP production are 
generally short, thus can be more easily identified and manipulated than those of non-
ribosomally synthesized compounds (10). As vast sequence information becomes available, 
genome mining for new RiPPs could be extremely fruitful. In addition, derivatives of RiPPs can 
be accessed by mutating the genes that encode the precursor peptides. These mutated precursor 
peptides are often still accepted by the corresponding post-translational modification machinery 
as most of the biosynthetic enzymes have been confirmed to be promiscuous and can tolerate 
non-natural substrates (11-14). As a result, RiPPs have been the focus of scientific research for 
the past several decades not only for developing new compounds with pharmaceutical potential 
but also for the novel mechanistic insights hiding behind these post-translational modification 
processes. 
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Figure 1.1 Representative members of ribosomally synthesized and post-translationally modified 
peptides (RiPPs) (3). Nisin is one of the longest known RiPPs, which belongs to the lanthipeptide family 
(vide infra) with characteristic lanthionine and methyllanthionine residues (15). Plantazolicin is a 14-mer 
peptide extensively modified by 10 thiazole and (methyl)oxazole heterocycles (16, 17). Thiostrepton A is 
a thiopeptide with post-translationally incorporated pyridinyl macrocycles in addition to thiazole 
heterocycles and dehydroamino acids (8). Bottromycins are a series of related compounds unique due to 
the presence of a macrocyclic amidine and a decarboxylated thiazole at the C-terminus (18-21). 
 
1.2 Lanthipeptides 
Lanthipeptides (lanthionine-containing peptides) are one of the best studied classes of the 
RiPP family (22). They are polycyclic peptides characterized by the presence of intramolecular 
thioether crosslinks. The general biosynthetic route to lanthipeptides is similar to that of most 
other RiPPs (22). A linear precursor peptide is first generated by the ribosome with a leader 
peptide at the N-terminus that is important for recognition by the post-translational modification 
machinery. The modifications take place in the core peptide that is located at the C-terminus of 
the precursor peptide (Figure 1.2a) (22, 23). Typically, dehydroamino acids, dehydroalanine 
(Dha) and dehydrobutyrine (Dhb), synthesized from serine and threonine residues by a 
dehydratase, respectively (Figure 1.2a and 1.2b), are attacked by cysteine thiols through a 
Michael-type addition catalyzed by a cyclase. The resulting thioether cross-linked amino acids 
are termed lanthionine (Lan) and methyllanthionine (MeLan), which define the lanthipeptides 
(Figure 1.2a and 1.2b). Lanthionine synthetases typically catalyze the formation of (Me)Lan 
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residues in a highly stereoselective manner, resulting in the formation of a DL configuration 
((2S, 6R)-Lan and (2S, 3S, 6R)-MeLan). The discovery of LL-(Me)Lan ((2R, 6R) for Lan and 
(2R, 3R, 6R) for MeLan) in the enterococcal cytolysin serves as the first example of a different 
stereochemistry for these intramolecular thioether cross-linkages in the lanthipeptide family, 
which will be discussed in chapter 2. Further characterization revealed that the stereoselectivity 
is encoded in the substrate sequences rather than dominated by the enzymes (for details, see 
chapters 3 and 4). Other modifications, such as D-alanine, 3-hydroxy-L-aspartic acid and S-
aminovinyl D-methylcysteine, may also be incorporated by other enzymes encoded in the 
lanthipeptide biosynthetic gene cluster (24). After installation of the post-translational 
modifications, the leader peptide is removed by one or more proteases and the mature 
lanthipeptide is exported outside the producer cells (Figure 1.2a) (25). Lanthipeptides with 
antimicrobial activities are termed lantibiotics and some of these exhibit potent growth inhibition 
activities against various pathogens (26, 27). 
 
Figure 1.2 Biosynthesis of lanthipeptides. (a) Generic pathway of lanthipeptide biosynthesis using 
lacticin 481 as an example. The precursor peptide is synthesized by the ribosome with an N-terminal 
leader peptide and a C-terminal core peptide. The dehydration of Ser and Thr residues to Dha and Dhb 
residues and the Michael-type addition by Cys residues onto these α,β-unsaturated amino acids are 
catalyzed by the dehydratase and the cyclase encoded in the lanthipeptide gene cluster, respectively. The 
leader peptide is then removed by one or more proteases, affording the mature lanthipeptide. (b) 
Dehydration and cyclization reactions that take place during lanthipeptide post-translational modification. 
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1.3 Four classes of lanthionine synthetases 
Lanthipeptides are currently classified into four classes, differentiated by the biosynthetic 
enzymes responsible for installation of the thioether rings (Figure 1.3a) (22). For class I 
lanthipeptides, the dehydration and cyclization reactions are catalyzed by separate enzymes 
named LanB and LanC (28-30), whereas for class II lanthipeptides, the two reactions are carried 
out by a single bifunctional enzyme LanM (31). Class III and IV lanthionine synthetases are 
trifunctional enzymes with Ser/Thr kinase, phosphoSer/phosphoThr lyase, and cyclase domains 
(32, 33).  
Class I dehydratases LanBs are tRNA-dependent enzymes that activate the hydroxyl side 
chain of Ser/Thr residues by forming an ester bond to facilitate the elimination step (Figure 
1.3b) (29). These proteins are usually about 1,000 amino acids in size and contain two separate 
domains responsible for ester formation and subsequent elimination, respectively. In particular, 
NisB, the dehydratase involved in the biosynthesis of the class I lantibiotic nisin, catalyzes the 
dehydration reaction through Ser/Thr glutamylation and glutamate elimination steps (Figure 
1.3b) (28). The biochemical process has been reconstituted in vitro and the catalytic mechanism 
has been partially revealed by crystallography of the NisB protein (28, 29). The cyclization 
reactions of class I lanthipeptides are carried out by LanC cyclases, which contain a conserved 
cysteine-cysteine-histidine triad coordinating a zinc ion that is essential for enzyme activity 
(Figure 1.3a) (30). LanB and LanC proteins have been reported to interact with each other in 
cells and catalyze the dehydration and cyclization reactions of their LanA substrates interactively 
(34, 35). The majority of currently known class I lanthipeptides exhibit antimicrobial activities 
against Gram-positive bacteria, some of which are actively investigated for their potential 
pharmaceutical utilization (24). 
The dehydration and cyclization reactions of class II lanthipeptides are carried out by 
bifunctional synthetases LanMs (Figure 1.3a) (31). These proteins are typically also about 1,000 
amino acids in length with two distinct domains. The N-terminal domain has been assigned to its 
dehydration activity (36). However, the dehydratase domain of LanM proteins shares no 
homology to the class I LanB dehydratases or any other known proteins in the protein database. 
Mutagenesis studies of LanM proteins have suggested that they catalyze dehydration reactions 
through a phosphorylation-elimination mechanism, different from what has been observed for 
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class I dehydratases (Figure 1.3b) (36). The C-terminus of LanM proteins is homologous to the 
class I cyclase NisC, including the conserved zinc-binding ligands that are critical for NisC 
catalysis. Interestingly, analogs of the dehydratase domain of LanM proteins have been identified 
in a few biosynthetic pathways responsible for the production of non-lanthipeptide RiPPs, such 
as polytheonamides (37). These LanM dehydratase-like proteins account for the incorporation of 
dehydro amino acids into the corresponding RiPP products. Different from LanM proteins, these 
enzymes do not contain a C-terminal cyclase domain, suggesting that the genes corresponding to 
the dehydratase domain of LanM proteins might have been horizontally transferred and adapted 
by different biosynthetic machinery to increase the diversity of natural products produced by the 
producer organisms. No structural information is available for LanM proteins before the work 
included in this thesis. Characterization of LanMs, focusing on CylM involved in the 
enterococcal cytolysin biosynthesis, is one of the major projects for my PhD study. The in vitro 
reconstituted activity and crystallization of CylM will be described in chapter 5. CylM is the first 
and thus far the only LanM with structural information available.  
Class III synthetases are trifunctional enzymes with a C-terminal putative cyclase domain 
that lacks the zinc ligands that are conserved in other lanthipeptide cyclases (Figure 1.3a) (32). 
These proteins contain a phosphoserine or phosphothreonine lyase domain at the N-terminus and 
a Ser/Thr kinase domain located in the middle (Figure 1.3a). As a result, class III synthetases are 
named LanKC (for lanthionine kinase cyclase). Uniquely, LanKC proteins can catalyze the 
formation of labionin, for which the enolate resulting from the initial Michael-type addition onto 
the first Dha is not protonated, but instead attacks a second dehydro amino acid to form a carbon-
carbon bond. It remains unclear how these cyclizations are carried out as LanKC proteins do not 
have the conserved zinc ligands that are essential for the activity of the other three classes of 
synthetases. Class IV synthetases (LanLs) are also trifunctional enzymes that contain an N-
terminal phosphoSer/phosphoThr lyase domain and a central kinase domain like class III 
synthetases (Figure 1.3a) (33). However, the C-terminal cyclase domain bears homology to the 
class I cyclase NisC and possesses the zinc ligands (Figure 1.3a). 
In the four classes of lanthipeptides, three distinct mechanisms have been revealed for the 
dehydration reaction, whereas at least two catalytic routes have evolved for the cyclization 
reaction, differentiated by whether the process is zinc-dependent or not. These observations 
suggest that the formation of dehydro amino acids and (methyl)lanthionine residues may provide 
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selection privileges to producer organisms, and thus has been independently accessed several 
times during evolution. 
 
Figure 1.3 Four classes of lanthipeptide synthetases. (a) Schematic representation of four classes of 
lanthionine synthetases. Zinc ligands are shown as black horizontal bars. (b) Different mechanisms of 
activation adopted by class I and class II dehydratases. 
 
1.4 Proteolytic maturation of lanthipeptides 
After the installation of the post-translational modifications, the leader peptides are removed 
by proteases and the mature lanthipeptides are exported; the leader-containing peptides typically 
do not exhibit the biological activities of the final mature products (38). These proteases are 
generally encoded by lanP or lanT genes in the lanthipeptide gene cluster. However, compared 
to the well-characterized lanthionine synthetases, proteases required for lanthipeptide maturation 
are much less studied, presumably because these proteins are hard to access with heterologous 
expression systems. 
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The maturation of class I lanthipeptides generally requires LanP proteins for leader peptide 
removal (Figure 1.4a) (24). These LanP proteins are homologous to the serine protease subtilisin 
including a conserved catalytic triad (Asp, His and Ser). They have different sizes and cellular 
locations depending on the presence or absence of an N-terminal secretion signal peptide and a 
C-terminal cell wall anchor sequence. Knock-out experiments have provided evidence that these 
LanP proteins are essential for the production of class I lanthipeptides (40). However, thus far 
only three class I LanPs have been heterologously expressed, purified and characterized in vitro, 
including NisP encoded in the nisin gene cluster, EpiP involved in epidermin biosynthesis, and 
ElxP required for epilancin 15X production (39, 41-44). Crystal structures of NisP and a 
homolog of EpiP have reinforced that these proteins resemble the characteristic conformation 
and active site geometry of subtilisin-like proteases (43, 45). In vitro study of ElxP revealed that 
the sequence spanning the region –5 to +1 of ElxA is important for enzyme recognition, shining 
light on the substrate specificity of LanP proteins (39). 
 
Figure 1.4 Proteases responsible for leader peptide removal of lanthipeptides. (a) Schematic 
representation of three currently identified types of proteases involved in class I, II and III lanthipeptide 
biosynthesis. (b) Markov chain Monte Carlo (MCMC) phylogenetic tree of LanP enzymes responsible for 
class I and II lanthipeptide maturation. Two representative class II LanP proteins, LicP and CylA, are 
included, whereas all others are members of the class I LanP family. Panel B is adapted from a recent 
published paper focusing on the characterization of the class I LanP ElxP (39). 
 
In contrast, leader peptide removal of class II lanthipeptides usually requires a bifunctional 
LanT transporter protein, which contains an N-terminal papain-like cysteine protease domain 
that typically cleaves after a double Gly-type motif (GG/GA/GS) (Figure 1.4a) (46, 47). These 
LanT proteins maturate lanthipeptides by cleaving off their leader peptides and transporting the 
peptides into the extracellular medium in an ATP-dependent manner (48). As a result, class II 
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LanT proteins are slightly larger in size than class I transporter proteins due to the presence of 
the protease domain. Although the leader peptide removal step of most class II lanthipeptides is 
carried out solely by LanT proteins, a few require one more cleavage process performed by 
subtilisin-like LanP proteases (Figure 1.4a) (49-52). These serine proteases are homologous to 
class I lanthipeptide leader peptidases but are located in a separate clade in a Markov chain 
Monte Carlo (MCMC) phylogenetic tree (Figure 1.4b) (39). They appear to remove a short 
oligopeptide after a LanT protein removes the majority of the leader peptide at a double Gly-type 
cleavage site. Several examples of LanPs have been identified in class II lanthipeptide 
biosynthetic pathways, yet few of them have been characterized with respect to either proteolytic 
activity or substrate specificity, and thus far, no structural information is available for class II 
LanP proteins. Chapters 6 and 7 will be focusing on biochemical and structural characterization 
of this subclass of lanthipeptidases. 
The proteolytic maturation of class III and class IV lanthipeptides remains largely 
uncharacterized. Recently, a prolyloligopeptidase-type protease has been linked to the synthesis 
of the class  III  lanthipeptide flavipeptin (Figure 1.4b) (53), suggesting that class  III  and class 
IV lanthipeptides may employ different types of proteases for their leader peptide removal. 
 
1.5 Summary and outlook 
The research on lanthipeptides has been advanced significantly in the past two decades, 
resulting in discovery of compounds with favorable biological activities, new post-translational 
modifications, new classes of biosynthetic machinery, and novel mechanistic insights into 
enzymes involved in these processes (22). The convergent evolution of lanthionine synthetases 
discussed in section 1.3 indicates that the presence of (methyl)lanthionine residues provides 
selective advantages for producer organisms to adapt to the environment, as they can produce 
natural products of high structural diversity at low genetic cost with such post-translational 
machinery. One particular example, prochlorosins produced by cyanobacteria, will be discussed 
in chapter 8. Although some lanthipeptides and their biosynthetic routes have been investigated, 
many more await exploration. For example, post-translational modifications other than 
dehydration and cyclization can significantly enhance the chemical diversity of lanthipeptides, 
yet they are underexplored so far. Moreover, only a few class III and class IV lanthipeptides have 
been identified at present and how LanKC and LanL enzymes install the thioether crosslinks and 
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labionin residues is currently obscure. Mining novel class III and class IV lanthipeptides as well 
as mechanistic characterization of how they are synthesized can further expand our knowledge 
and understanding of lanthipeptides. More importantly, despite the fact that some structural 
information of lanthionine synthetases is available (29, 30), how the enzymes bind to the 
substrate remains largely unknown. Such information could be valuable for the engineering 
efforts of lanthipeptides (54). In an era when massive sequence and genomic information 
becomes available, I am expecting more and more novel RiPPs and lanthipeptides to be 
identified using modern genome-mining strategies in the future, continuously advancing our 
understanding of these biological systems and enriching our collections of natural products.   
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Chapter 2. Structural Characterization of the Enterococcal Cytolysin Reveals 
Unusual Lanthionine Stereochemistry 
 
2.1 Introduction 
The enterococcal cytolysin is a two-component lantibiotic made up of the post-translationally 
modified peptides CylLL” and CylLS” (cytolysin L and S). It is produced by many clinical isolates 
of Enterococcus faecalis and is toxic to a broad range of gram positive bacteria (1-3). The 
enterococcal cytolysin is a unique lantibiotic in that it has hemolytic activity against eukaryotic 
cells in addition to its antimicrobial activity (2, 4). The production of cytolysin enhances virulence 
in infection models and its association with acute patient mortality is supported by epidemiological 
data (5-7). Despite the intensive research focused on the biological functions and biosynthesis of 
the enterococcal cytolysin (8-10), its structure has never been reported until the work described in 
this chapter. 
Like other members in the lantibiotic family (11), each component of the enterococcal 
cytolysin is initially expressed as a linear precursor peptide (CylLL and CylLS) consisting of an 
N-terminal leader peptide and a C-terminal core peptide. The lanthionine synthetase CylM then 
dehydrates Ser and Thr residues in the core peptide followed by Michael-type addition of the thiols 
of Cys residues to the resulting dehydroamino acids to generate lanthionine (Lan) and 
methyllanthionine (MeLan) structures, respectively (8, 12). CylB then removes most of the leader 
peptide and secretes the cyclized peptides (13). Extracellularly, six additional residues are 
removed from the N-terminus of each peptide by CylA to generate CylLL” and CylLS”, which 
make up mature cytolysin (8, 14, 15). 
 
 
 
 
 
 
 
 
Reproduced in part with the permission from:  
Tang, W., and van der Donk, W. A. (2013) The sequence of the enterococcal cytolysin imparts 
unusual lanthionine stereochemistry, Nat. Chem. Biol. 9, 157-159. 
Copyright 2013 Nature America, Inc. 
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Intrigued by the unique properties of the enterococcal cytolysin and its contribution to the 
virulence of E. faecalis, I set out to characterize its structure by determining the ring topology and 
the stereochemistry of its (Me)Lan residues. Because high level production of cytolysin in E. 
faecalis requires contact with target mammalian cells (10), only relatively small amounts of 
material can be obtained, which probably has contributed to the lack of prior structural studies. 
 
2.2 Results 
In this work, CylLL” and CylLS” were both produced in E. coli. First, cylLL and cylLS encoding 
the precursor peptides as well as cylM encoding the lanthionine synthetase were synthesized with 
codon optimization for use in E. coli. Each precursor peptide was co-expressed as an N-terminal 
His6-tag fusion peptide with untagged CylM from a pRSF-Duet-1 vector, as previously reported 
for a few other lantibiotics (16). After purification by immobilized metal affinity chromatography, 
the CylM-modified CylLL and CylLS exhibited mass losses of approximately 130 Da and 72 Da, 
respectively. The exact mass shift was confirmed by subsequent endoproteinase AspN digest to 
remove the first 25 and 37 residues of the leader peptides of CylLL and CylLS, respectively (Figure 
2.1). Mass spectrometric analysis of the modified CylLL indicated that the major product had 
undergone 7 dehydrations, whereas purified CylM-modified CylLS treated with AspN displayed a 
mass consistent with 4 dehydrations (Figure 2.1). These results match the reported masses of 
CylLL” and CylLS”, for which 7 and 4 dehydrations were suggested, respectively (15). To verify 
the formation of the thioether linkages and resolve the intramolecular ring topology, tandem mass 
spectrometry (MS) was employed to analyze the fragmentation pattern of the 7-fold dehydrated 
CylLL and 4-fold dehydrated CylLS (Figure 2.2). Fragmentation was suppressed at stretches of 
sequence comprising residues 1-5, 14-18, and 34-38 for the core peptide of modified CylLL, 
suggesting 3 rings were present in these regions. Similarly, suppressed fragmentation was detected 
between residues 1-5 and 17-21 of modified CylLS, suggesting it had 2 rings spanning these 
residues. The fragmentation pattern of modified CylLL also suggested that Thr27 escaped 
dehydration by CylM. Collectively, these data suggest the structures shown in Figure 2.2 for 
modified CylLL and CylLS, respectively. 
The AspN digestion resulted in smaller fragments that allowed tandem MS analysis but did 
not afford the mature peptides because five residues of the leader peptide remained. To obtain 
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mature CylLL” and CylLS”, a Glu−1Lys mutation was introduced in CylLL and CylLS for 
subsequent leader peptide removal with trypsin. After co-expression with CylM, 
His6-CylLL-E−1K exhibited a mass loss consistent with 7 dehydrations and CylLS-E−1K 
displayed a mass consistent with loss of 4 water molecules. Tandem MS analysis verified that 
modified CylLL-E−1K and CylLS-E−1K displayed the same fragmentation patterns as those of the 
modified wild type peptides (data not shown). CylLL” and CylLS” were successfully obtained by 
digesting CylM-modified CylLL-E−1K and CylLS-E−1K with trypsin followed by HPLC 
purification (Figures 2.3c and 2.4c). 
 
Figure 2.1 ESI-Q/TOF mass spectra of (a) 7-fold dehydrated CylLL, and (b) 4-fold dehydrated CylLS 
core peptides modified by CylM in E. coli and digested by AspN. [M+3H]
3+
 is shown for the CylLL core 
peptides, and [M+2H]
2+
 is shown for the CylLS core peptide. Both core peptides contain five additional 
amino acids at their N-terminus originating from the leader peptides as a result of AspN cleavage. The 
sequences of the leader peptides of CylLL and CylLS are MENLSVVPSFEELSVEEMEAIQGSGDVQAE 
and MLNKENQENYSNKLELVGPSFEELSLEEMEAIQGSGDVQAE, respectively. The leader peptide 
residues remaining after cleavage with AspN are underlined. 
18 
 
 
Figure 2.2 Tandem MS analysis of CylM-modified CylLL (a) and CylLS (b) produced in E. coli. Both 
core peptides contain five residues at their N-terminus that remain from the leader peptides after AspN 
cleavage. The b2 fragment ions observed for modified CylLL and CylLS are attributed to in-ring 
fragmentation. Similar fragmentation has been observed in the A rings of nisin and geobacillin II (16, 17). 
Dha, dehydroalanine; Dhb, dehydrobutyrine. 
 
Although the analysis of the tandem MS fragmentation data suggests that the A rings in both 
CylLL” and CylLS” are formed between Dhb1 and Cys5, it is difficult to rule out by tandem MS 
alone that Cys5 is not linked to Dhb2. If this were the case, the final products should have an 
N-terminal 2-oxobutyryl group as a result of spontaneous hydrolysis of Dhb1, and the final 
product should display a 1 Da mass increase. To confirm the proposed topology of the A ring, 
CylLL” and CylLS” were analyzed by high resolution electrospray ionization MS (18). The 
observed masses of CylLL” and CylLS” were 3435.6870 Da and 2031.0260 Da, respectively, 
consistent with structures containing a MeLan at their N-terminus with calculated masses of 
3435.7059 and 2031.0122 (errors of 5.5 ppm and 6.8 ppm, respectively, Figures 2.3 and 2.4). The 
data are inconsistent with 2-oxobutyryl as the N-terminal residue. Therefore, the A rings of CylLL” 
and CylLS” were unambiguously assigned to MeLan residues formed from Cys5 and Dhb1. 
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Figure 2.3 Simulated mass spectra of CylLL” with a 2-oxobutyryl group (a) or with a MeLan group 
(b) at the N-terminus, and comparison with the observed ESI-Q/TOF mass spectrum of CylLL” (c). 
Note that the 3+ ions are shown and hence that the calculated mass difference is correspondingly smaller for 
the structures drawn (i.e. mass difference is less than 1 Da). 
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Figure 2.4 Simulated mass spectra of CylLS” with a 2-oxobutyryl group (a) or with a MeLan group 
(b) at the N-terminus, and comparison with the observed ESI-Q/TOF mass spectrum of CylLS” (c). 
Note that the 2+ ions are shown and hence that the calculated mass difference is correspondingly smaller for 
the structures drawn (i.e. expected mass difference is less than 1 Da). 
 
Based on the characterization of select lantibiotics in previous studies (19), all the 
enzymatically formed Lan and MeLan residues in lantibiotics are generally believed to exhibit a 
“DL” configuration, i.e. the D-configuration at the α-carbon of the former Ser/Thr residue and the 
L-configuration at the α-carbon of the former Cys residue ((2S,6R) for Lan and (2S,3S,6R) for 
MeLan, Figure 2.6a, left panel). To confirm the expected stereochemistry of the (Me)Lan residues 
in CylLL” and CylLS”, the peptides were hydrolyzed in 6 M HCl, derivatized to their 
corresponding pentafluoropropionamide methyl esters, and analyzed by GC-MS with a chiral 
stationary phase. Lan and MeLan standards of different stereochemistry were synthesized and 
derivatized using previously reported methods (20, 21). A Chirasil-L-Val coated GC column was 
used for analysis and the GC trace was monitored for a characteristic fragment of 365 Da for Lan 
and 379 Da for MeLan residues using electron-impact mass spectrometry. Figure 2.5 displays the 
GC-MS traces for the three Lan and two MeLan standards after deivatization. Unexpectedly, the 
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MeLan residues in both CylM-modified CylLL and CylLS had the (2R,3R,6R) configuration 
(Figure 2.6a, right panel; Figures 2.6b and 2.6c, left panels) by comparison with synthetic 
standards (i.e. both alpha carbons have the L-configuration, hereafter referred to as LL). These 
findings indicate that the Michael-type addition still occurs with overall anti stereochemistry, but 
with opposite face selectivity for both the attack of the Cys nucleophile onto the Dhb and the 
protonation of the resulting enolate. This observation constitutes the first example of alternative 
stereochemistry in lantibiotics. Perhaps even more surprising is the finding that the Lan residue in 
modified CylLS exhibits the traditional meso configuration (DL) (Figure 2.6a, left panel), and that 
the two Lan residues in modified CylLL are present in a 1:1 ratio of DL and LL configurations 
(Figures 2.6b and 2.6c, right panels). These data show that CylM can catalyze the Michael-type 
addition with different stereochemistries in a single polypeptide substrate. The 1:1 ratio of DL and 
LL configurations of the Lan in modified CylLL could be either a mixture of stereoisomers for both 
the B and C rings, or it could be a consequence of one ring having the DL configuration and the 
other ring having the LL configuration. To distinguish between these possibilities, the mutants 
CylLL-S14T and CylLL-S15T were co-expressed with CylM in E. coli, purified, hydrolyzed, 
derivatized, and analyzed by chiral GC-MS (Figures 2.9 and 2.10). The modified CylLL-S14T was 
found to contain LL-MeLan and only DL-Lan whereas CylM-modified CylLL-S15T exhibited a 
similar GC trace as the modified wild type CylLL (LL-MeLan, and a 1:1 ratio of LL-Lan and 
DL-Lan). These results suggest that the B ring of CylLL is formed between Ser14 and Cys18 and 
has a LL configuration, whereas the C ring has the DL configuration. With this information, the 
final structures of CylLL’’ and CylLS’’ are established (Figure 2.11). 
 
Figure 2.5 GC-MS traces (selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan) of 
derivatized (Me)Lan standards. (a) Derivatized DL-MeLan (solid line) and  LL-MeLan standards 
(dashed line). (b) Derivatized DD-Lan (short dashed line), DL-Lan (solid line) and LL-Lan (long dashed 
line) standards. 
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Figure 2.6 GC-MS analysis of CylM-modified CylLL and CylLS. (a) Canonical (DL, left) and unusual 
(LL, right) stereochemistries of (Me)Lan residues in previously characterized lantibiotics and in the 
enterococcal cytolysin, respectively. (b) GC-MS traces of hydrolyzed and derivatized MeLan and Lan 
residues from CylM-modified CylLL. (c) GC-MS traces of hydrolyzed and derivatized MeLan and Lan 
residues from CylM-modified CylLS. Selected ion chromatogram is shown by extracting the total ion 
chromatogram with characteristic fragment masses of 379 Da for MeLan and 365 Da for Lan, respectively. 
Stereochemistries of MeLan and Lan residues were assigned by co-injection with synthetic standards 
derivatized using the same procedure (Figures 2.7 and 2.8). For preparation of the (Me)Lan standards, see 
section 2.3. 
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Figure 2.7 GC-MS traces for co-injections of synthetic, derivatized Lan/MeLan standards and 
hydrolyzed/derivatized Lan/MeLan residues obtained from in vivo modified CylLL (selected ion 
monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized MeLan 
residues from modified CylLL (red line) and co-injected with derivatized DL-MeLan (2S,3S,6R) standard 
(blue line). (b) Hydrolyzed and derivatized MeLan residues from modified CylLL (red line) and 
co-injected with derivatized LL-MeLan (2R,3R,6R) standard (blue line). (c) Hydrolyzed and derivatized 
Lan residues from modified CylLL (red line) and co-injected with derivatized DD-Lan (2S,6S) standard 
(blue line). (d) Hydrolyzed and derivatized Lan residues from modified CylLL (red line) and co-injected 
with derivatized DL-Lan (meso) standard (blue line). (e) Hydrolyzed and derivatized Lan residues from 
modified CylLL (red line) and co-injected with derivatized LL-Lan (2R,6R) standard (blue line). Traces of 
derivatized Lan and MeLan residues from modified CylLL (red lines) used for overlay were adjusted to 70% 
intensity for clarity. A small amount of epimerization of the (Me)Lan occurs during acid hydrolysis of the 
peptides as has been reported previously (22). 
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Figure 2.8 GC-MS traces for co-injections of synthetic, derivatized Lan/MeLan standards and 
hydrolyzed/derivatized Lan/MeLan residues obtained from in vivo modified CylLS (selected ion 
monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized MeLan 
residues from modified CylLS (red line) and co-injected with derivatized DL-MeLan standard (blue line). 
(b) Hydrolyzed and derivatized MeLan residues from modified CylLS (red line) and co-injected with 
derivatized LL-MeLan standard (blue line). (c) Hydrolyzed and derivatized Lan residues from modified 
CylLS (red line) and co-injected with derivatized DD-Lan standard (blue line). (d) Hydrolyzed and 
derivatized Lan residues from modified CylLS (red line) and co-injected with derivatized DL-Lan standard 
(blue line). (e) Hydrolyzed and derivatized Lan residues from modified CylLS (red line) and co-injected 
with derivatized LL-Lan standard (blue line). Traces of derivatized Lan and MeLan residues from 
modified CylLS (red lines) used for overlay were adjusted to 70% intensity for clarity. A small amount of 
epimerization of the (Me)Lan occurs during acid hydrolysis of the peptides as has been reported 
previously (22). 
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Figure 2.9 GC-MS traces for hydrolyzed/derivatized Lan/MeLan residues obtained from in vivo 
modified CylLL S14T and co-injections with derivatized Lan/MeLan standards (selected ion 
monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized MeLan 
residues from modified CylLL S14T. (b) Hydrolyzed and derivatized Lan residues from modified CylLL 
S14T. (c) Hydrolyzed and derivatized MeLan residues from modified CylLL S14T (red line) and 
co-injected with derivatized DL-MeLan standard (blue line). (d) Hydrolyzed and derivatized MeLan 
residues from modified CylLL S14T (red line) and co-injected with derivatized LL-MeLan standard (blue 
line). (e) Hydrolyzed and derivatized Lan residues from modified CylLL S14T (red line) and co-injected 
with derivatized DD-Lan standard (blue line). (f) Hydrolyzed and derivatized Lan residues from modified 
CylLL S14T (red line) and co-injected with derivatized DL-Lan standard (blue line). (g) Hydrolyzed and 
derivatized Lan residues from modified CylLL S14T (red line) and co-injected with derivatized LL-Lan 
standard (blue line). Traces of derivatized Lan and MeLan residues from modified CylLL S14T (red lines) 
used for overlay were adjusted to 70% intensity for clarity. A small amount of epimerization of the 
(Me)Lan occurs during acid hydrolysis of the peptides as has been reported previously (22). 
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Figure 2.10 GC-MS traces for hydrolyzed/derivatized Lan/MeLan residues obtained from in vivo 
modified CylLL S15T and co-injections with derivatized Lan/MeLan standards (selected ion 
monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized MeLan 
residues from modified CylLL S15T. (b) Hydrolyzed and derivatized Lan residues from modified CylLL 
S15T. (c) Hydrolyzed and derivatized MeLan residues from modified CylLL S15T (red line) and 
co-injected with derivatized DL-MeLan standard (blue line). (d) Hydrolyzed and derivatized MeLan 
residues from modified CylLL S15T (red line) and co-injected with derivatized LL-MeLan standard (blue 
line). (e) Hydrolyzed and derivatized Lan residues from modified CylLL S15T (red line) and co-injected 
with derivatized DD-Lan standard (blue line). (f) Hydrolyzed and derivatized Lan residues from modified 
CylLL S15T (red line) and co-injected with derivatized DL-Lan standard (blue line). (g) Hydrolyzed and 
derivatized Lan residues from modified CylLL S15T (red line) and co-injected with derivatized LL-Lan 
standard (blue line). Traces of derivatized Lan and MeLan residues from modified CylLL S15T (red lines) 
used for overlay were adjusted to 70% intensity for clarity. A small amount of epimerization of the 
(Me)Lan occurs during acid hydrolysis of the peptides as has been reported previously (22). 
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Figure 2.11 Structure of cytolysin. (a) CylLL”. (b) CylLS”. Abu, α-aminobutyric acid. Overall, these 
peptides are highly hydrophobic except for the positively charged N-termini and residues (Lys and His) 
near the C-terminus (marked in dark yellow). Production of cytolysin in E. coli allows investigation of the 
importance of these residues for the unique hemolytic activity of this lantibiotic. 
 
The data clearly demonstrate that LL-MeLan can be formed in the same peptide that also 
contains Lan with the more common DL-stereochemistry. This highly unusual observation appears 
to be at odds with the typical high stereochemical fidelity of enzymes. Interestingly, all (Me)Lan 
residues that exhibited the LL configuration are formed from a Dhx-Dhx-Xxx-Xxx-Cys motif in 
which Dhx represents Dha or Dhb, and Xxx represents amino acids other than Dha, Dhb and Cys 
(Figure 2.12). To probe whether this outcome extends to other naturally occurring lantibiotics, I 
performed searches for the Dhx-Dhx-Xxx-Xxx-Cys motif in documented lantibiotics (Figure 
2.13a). Several such motifs were found (17, 18, 23, 24) allowing experimental probing of the 
hypothesis. Halβ, one subunit of the two-component lantibiotic haloduracin produced by Bacillus 
halodurans C-125 (18), was chosen as an example. Halβ was obtained by co-expression of the 
precursor peptide HalA2 with its lanthionine synthetase HalM2 in E. coli (16). To investigate the 
stereochemistry of the (Me)Lan in the A ring, the HalM2-modified HalA2 was hydrolyzed, and the 
amino acids were derivatized and analyzed by chiral GC-MS. The data show clearly that the 
product contained a 1:2 ratio of LL:DL MeLan and only DL-Lan (Figures 2.13b and 2.14), 
consistent with the hypothesis because only one of the three MeLan structures in Halβ is generated 
from a Dhx-Dhx-Xxx-Xxx-Cys motif (the A ring). The assignment of the LL-MeLan to this A ring 
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of Halβ was supported by GC-MS analysis of the HalM2-modified mutant HalA2-C5A, for which 
the peak for LL-MeLan was reduced to a basal level (Figure 2.15). These results therefore show 
that LL-MeLan residues are present in other lantibiotics, and that their formation is not a special 
property of CylM. The LL stereochemistry is also not caused by expression in E. coli because the 
same results were obtained for Halβ isolated from B. halodurans (Figure 2.16). Analysis of the 
databases suggest that other lantibiotics that have been previously reported but for which the 
stereochemistry has not been determined are also likely to contain LL-(Me)Lan residues (Figure 
2.13a). In turn, these studies also indicate that the sequence of the substrate peptide can determine 
the stereoselectivity of (Me)Lan formation, which was unanticipated prior to this study and has 
important implications for lantibiotic engineering. Whether the determinant is the sequence itself 
or the position of the sequence within the precursor peptide, or both, required additional studies, 
some of which will be presented in chapter 3. 
 
Figure 2.12 Enzyme catalyzed formation of the canonical DL-(Me)Lan (top) and the unusual 
LL-(Me)Lan (bottom) from the Dhx-Dhx-Xxx-Xxx-Cys motif. 
 
Purified CylLL” and CylLS” were tested for their antimicrobial activity against Lactococcus 
lactis HP. Application of CylLL” and CylLS” separately did not result in growth inhibition, but 
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when applied together, a strong inhibition zone was observed (Figure 2.13c). Furthermore, when 
the two compounds were placed a short distance from each other, a synergistic zone of growth 
inhibition was only observed between the two spotted samples (Figure 2.13c). The hemolytic 
activity of cytolysin was investigated using rabbit red blood cells (Figure 2.13d). CylLL” and 
CylLS” together lead to maximal cell lysis in 90 min at a concentration as low as 200 nM, whereas 
either CylLL” or CylLS” alone induced minimal cell lysis at a concentration of 800 nM. The 
synergistic anti-microbial and hemolytic activities of the CylLL” and CylLS” prepared in E. coli, 
along with the MS characterization, suggests that the cytolysin produced in this work has the same 
structure as that obtained from the producing strains in previous studies (1, 25). 
 
 
 
Figure 2.13 Alignment of 7 lantibiotic core peptides, stereochemical analysis of Halβ, and bioactivity 
of CylLL” and CylLS”. (a) Alignment of lantibiotic core peptides that are transformed to intermediates 
with the Dhx-Dhx-Xxx-Xxx-Cys motifs that are highlighted in grey. The amino acid sequences of SmbA2 
and BhtA2 are identical, but it is unclear whether they are modified into the same structure. (b) GC-MS 
traces of hydrolyzed and derivatized MeLan and Lan residues from HalM2-modified HalA2. (c) 
Antimicrobial activity assay of CylLL” and CylLS” against L. lactis HP. The amounts of compounds applied 
are indicated (scale bar 1 cm). (d) Hemolytic assay of CylLL” and CylLS” against rabbit red blood cells. At 
each time point, the hemoglobin released from the lysed cells was quantified in triplicate by measuring 
the absorbance of the supernatant at 415 nm. Error bars indicate the standard deviation of three separate 
experiments. The lytic curve was fit with a Growth-Sigmoidal-Dose Response function, which does not 
necessarily correlates to the kinetic properties of the lytic reaction. 
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Figure 2.14 GC-MS traces for co-injections of synthetic, derivatized Lan/MeLan standards and 
hydrolyzed/derivatized Lan/MeLan residues obtained from in vivo modified HalA2Xa (selected ion 
monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized MeLan 
residues from modified HalA2Xa (red line) and co-injected with derivatized DL-MeLan standard (blue 
line). (b) Hydrolyzed and derivatized MeLan residues from modified HalA2Xa (red line) and co-injected 
with derivatized LL-MeLan standard (blue line). (c) Hydrolyzed and derivatized Lan residues from 
modified HalA2Xa (red line) and co-injected with derivatized DD-Lan standard (blue line). (d) 
Hydrolyzed and derivatized Lan residues from modified HalA2Xa (red line) and co-injected with 
derivatized DL-Lan standard (blue line). (e) Hydrolyzed and derivatized Lan residues from modified 
HalA2Xa (red line) and co-injected with derivatized LL-Lan standard (blue line). Traces of derivatized 
Lan and MeLan residues from modified HalA2Xa (red lines) used for overlay were adjusted to 70% 
intensity for clarity. HalA2Xa is a derivative of HalA2 in which a Factor Xa cleavage site has been 
introduced between the leader and core peptides (26). A small amount of epimerization of the (Me)Lan 
occurs during acid hydrolysis of the peptides as has been reported previously (22). 
  
31 
 
 
Figure 2.15 GC-MS traces for hydrolyzed/derivatized Lan/MeLan residues obtained from in vivo 
modified HalA2Xa C5A and their co-injections with derivatized Lan/MeLan standards (selected ion 
monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized MeLan 
residues from modified HalA2Xa C5A. (b) Hydrolyzed and derivatized Lan residues from modified 
HalA2Xa C5A. (c) Hydrolyzed and derivatized MeLan residues from modified HalA2Xa C5A (red line) 
and co-injected with derivatized DL-MeLan standard (blue line). (d) Hydrolyzed and derivatized MeLan 
residues from modified HalA2Xa C5A (red line) and co-injected with derivatized LL-MeLan standard 
(blue line). (e) Hydrolyzed and derivatized Lan residues from modified HalA2Xa C5A (red line) and 
co-injected with derivatized DD-Lan standard (blue line). (f) Hydrolyzed and derivatized Lan residues 
from modified HalA2Xa C5A (red line) and co-injected with derivatized DL-Lan standard (blue line). (g) 
Hydrolyzed and derivatized Lan residues from modified HalA2Xa C5A (red line) and co-injected with 
derivatized LL-Lan standard (blue line). Traces of derivatized Lan and MeLan residues from modified 
HalA2Xa C5A (red lines) used for overlay were adjusted to 70% intensity for clarity. A small amount of 
epimerization of the (Me)Lan occurs during acid hydrolysis of the peptides as has been reported 
previously (22). 
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Figure 2.16 GC-MS traces for hydrolyzed/derivatized Hal isolated from B. halodurans C-125 and 
co-injections with derivatized Lan/MeLan standards (selected ion monitoring, SIM, at 365 Da for Lan 
and 379 Da for MeLan). (a) Hydrolyzed and derivatized MeLan residues from modified Hal. (b) 
Hydrolyzed and derivatized Lan residues from Hal. (c) Hydrolyzed and derivatized MeLan residues 
from Hal (red line) and co-injected with derivatized DL-MeLan standard (blue line). (d) Hydrolyzed and 
derivatized MeLan residues from Hal (red line) and co-injected with derivatized LL-MeLan standard 
(blue line). (e) Hydrolyzed and derivatized Lan residues from Hal (red line) and co-injected with 
derivatized DD-Lan standard (blue line). (f) Hydrolyzed and derivatized Lan residues from Hal (red line) 
and co-injected with derivatized DL-Lan standard (blue line). (g) Hydrolyzed and derivatized Lan 
residues from Hal (red line) and co-injected with derivatized LL-Lan standard (blue line). Traces of 
derivatized Lan and MeLan residues from Hal (red lines) used for overlay were adjusted to 70% 
intensity for clarity. A small amount of epimerization of the (Me)Lan occurs during acid hydrolysis of the 
peptides as has been reported previously (22). 
 
As a summary of this chapter, I have developed a heterologous production system for the 
enterococcal cytolysin that is strongly linked to virulence, and unambiguously characterized its 
structure. Three non-overlapping five-amino acid rings are present in CylLL” and two such rings 
are present in CylLS”. The MeLan residues in the A rings of both CylLL” and CylLS” and the Lan 
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residue in the B ring of CylLL” exhibit the LL configuration that is different from all previously 
characterized lantibiotics. LL-(Me)Lan residues are predicted to also be present in other 
lantibiotics, and this prediction was confirmed for the A ring of Halβ. These results emphasize the 
importance of determining the stereochemistry of lantibiotics, which has thus far only been 
performed for a handful of family members (19-21, 27). With a good supply route to the 
enterococcal cytolysin as well as analogs, the mechanism of its virulence activity can now be 
further investigated (28). 
 
2.3 Methods 
General methods 
Genes encoding CylM, CylLL and CylLS were synthesized by GeneArt (Invitrogen) with 
codon usage optimized for E. coli expression (for DNA sequences, see Table 2.1). All polymerase 
chain reactions (PCR) were carried out on a C1000 thermal cycler (Bio-Rad). DNA sequencing 
was performed by ACGT, Inc. Preparative HPLC was performed using a Waters Delta 600 
instrument equipped with appropriate columns. Absorbance of rabbit hemoglobin in 96-well 
plates was measured with a Synergy H4 Microplate Reader (BioTek). GC-MS analysis was 
performed at the Roy J. Carver Metabolomics Center (UIUC) or Mass Spectrometry Laboratory 
(School of Chemical Sciences, UIUC) on an Agilent 7890 gas chromatograph (Agilent). 
LC-ESI-Q/TOF MS analyses were conducted using a Synapt MS system equipped with an 
Acquity UPLC (Waters). High resolution electrospray ionization (HR-ESI) MS was performed on 
a Micromass Q-Tof Ultima instrument (Waters). 
 
Table 2.1 Synthetic DNA sequences for cylM, cylLL and cylLS with codon usage optimized for E. coli 
expression. 
cylM 
ATGGAAGATAATCTGATTAATGTGCTGAGCATTAATGAACGTTGCTTTCTGCTGAAACAGAGCGGCAA
AGAAAAATATGATATTAAAAATCTGCAGGCCTGGAAAGAACGTAAAAGCGTTCTGAAACAGGATGAT
CTGGATTATCTGATTAAATATAAATATGAAAGCCTGGATAATTTTGGCCTGGGTATTACCCCGATTGAA
AATTTTCCGGATAAAGAAGTGGCCATTCAGTATATTAAAGATCAGAGTTGGTATATTTTTTTTGAAAGC
ATTCTGGATAGCTATAATGATAGCGAAGAAAAACTGCTGGAAGTTGATGCAAGCTATCCGTTTCGTTA
TTTTCTGCAGTATGCACGTCTGTTTCTGCTGGATCTGAATAGCGAACTGAATATTTGCACCAAAGAATT
TATTATTAATCTGCTGGAAACCCTGACCCAGGAACTGATTCATCTGACCAGCAAAACCCTGGTTCTGG
ATCTGCATACCTTTAAAAAAAATGAACCGCTGAAAGGCAATGATAGCAGCAAACGCTTTATTTATTAT 
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Table 2.1 (cont.) 
CTGAAAAAACGCTTTAATAGCAAAAAAGATATTATTGCCTTTTATACCTGCTATCCGGAACTGATGCGT
ATTACCGTTGTTCGTATGCGCTATTTCCTGGATAACACCAAACAAATGCTGATTCGTGTTACCGAAGAT
CTGCCGAGCATTCAGAATTGCTTTAATATTCAGAGCAGTGAACTGAATAGCATTAGCGAAAGCCAGGG
TGATAGCCATAGCCGTGGTAAAACCGTTAGCACCCTGACCTTTAGTGATGGTAAAAAAATTGTGTATA
AACCGAAAATTAATAGCGAAAATAAACTGCGCGATTTTTTTGAATTTCTGAATAAAGAACTGGAAGCC
GATATTTATATTGTGAAAAAAGTGACCCGCAATACCTATTTTTATGAAGAATATATCGATAACATTGA
AATCAATAACATCGAAGAAGTGAAAAAATATTACGAACGCTATGGCAAACTGATTGGCATTGCCTTTC
TGTTTAATGTTACCGATCTGCATTATGAAAACATCATTGCCCATGGCGAATATCCGGTGATTATTGATA
ATGAAACCTTTTTTCAGCAGAATATTCCGATTGAATTTGGTAATAGCGCAACCGTTGATGCCAAATACA
AATATCTGGATAGCATTATGGTGACCGGTCTGGTTCCGTATCTGGCAATGAAAGATAAAAGCGATAGC
AAAGATGAAGGCGTTAATCTGAGCGCACTGAATTTTAAAGAACAGAGCGTGCCGTTTAAAATTCTGAA
AATTAAAAATACCTTTACCGATGAAATGCGCTTTGAATATCAGACCCATATTATGGATACCGCAAAAA
ATACCCCGATTATGAATAATGAAAAAATCAGCTTTATCAGCTATGAAAAATATATTGTGACCGGCATG
AAAAGCATTCTGATGAAAGCCAAAGATAGCAAAAAAAAAATTCTGGCCTATATTAATAATAATCTGCA
GAATCTGATTGTGCGCAATGTTATTCGTCCGACCCAGCGTTATGCAGATATGCTGGAATTTAGCTATCA
TCCGAATTGCTTTAGCAATGCCATTGAACGTGAAAAAGTGCTGCATAATATGTGGGCCTATCCGTATA
AAAATAAAAAAGTGGTGCATTATGAATTTTCAGATCTGATTGATGGCGATATTCCGATTTTTTATAATA
ATATTAGCAAAACCAGCCTGATTGCCAGTGATGGTTGTCTGGTTGAAGATTTTTATCAGGAAAGTGCC
CTGAATCGCTGCCTGAATAAAATTAATGATCTGTGTGATGAAGATATTAGCATTCAGACCGTGTGGCT
GGAAATTGCACTGAATATTTATAACCCGTACAAATATATCAATGATCTGAAAAACCAGAATAGCAACA
AATATATTTATACCGGTCTGGAACTGAATGGCAAAATTATTCAGGCCTGCCAGAAAATTGAAAAAAAA
ATCTTTAAACGTGCCATCTTTAACAAAAAAACCAATACCGTGAATTGGATTGATATTAAACTGGATCA
GGATTGGAATGTGGGCATTCTGAATAATAATATGTATGATGGCCTGCCTGGTATTTTTATTTTTTATGT
GGCCCTGAAATATATTACCAAAAACCATAAATATGATTATGTGATCGAATGCATTAAAAATAGCATTT
ATACCATTCCGAGCGAAGATATTCTGAGCGCATTTTTTGGTAAAGGCAGCCTGATTTATCCGCTGCTGG
TTGATTATCGCCTGAATAATGATATTAATAGCCTGAATGTGGCCGTGGAAATTGCCGATATGCTGATTG
AAAAAAAACCGATTAATAATGGCGAACTGAAAAATGATTGGATTCATGGCCATAATAGCATTATTAAA
GTGCTGCTGCTGCTGAGCGAAATTACCGAAGATGAAAAATATCGCAAATTTAGCCTGGAAATTTTTGA
AAAACTGAGCGAAGAACCGTATTTTAATTTTCGTGGTTTTGGCCATGGCATTTATAGCTATGTTCATCT
GCTGAGCAAATTTAATCGCATTGATAAAGCCAATAGCCTGCTGCATAAAATTAAAGAAAGCTATTTTG
AAGAAGAACCGAAAAATAATTCCTGGTGTAAAGGCACCGTTGGTGAACTGCTGGCAACCATTGAACT
GTATGATGATAATATTAGTAACATCGATATTAACAAAACCATTGCCTATAAAAATAAAGATTGCCTGT
GCCATGGCAATGCAGGCACCCTGGAAGGTCTGATTCAGCTGGCAAAAAAAGATCCGGAAACCTATCA
GTATAAAAAAAATAAACTGATCAGCTATATGCTGAATGATTTTGAAAAAAATAATACCCTGAAAGTGG
CAGGCAGCGAATATCTGGAAAGCCTGGGTTTTTTTGTTGGTATTAGCGGTGTTGGTTATGAACTGCTGC
GTAATCTGGATAGCGAAATTCCGAATGCACTGCTGTTTGAACTGTAATAA 
cylLL 
ATGGAAAATCTGAGCGTTGTTCCGAGCTTTGAAGAACTGAGCGTTGAAGAAATGGAAGCAATTCAGG
GTAGCGGTGATGTTCAGGCAGAAACCACACCGGTTTGTGCAGTTGCAGCAACCGCAGCAGCAAGCAG
CGCAGCATGTGGTTGGGTTGGTGGTGGTATTTTTACCGGTGTTACCGTTGTTGTTAGCCTGAAACATTG
CTAATAA 
cylLS 
ATGCTGAATAAAGAAAATCAGGAAAATTATTATAGCAATAAACTGGAACTGGTGGGTCCGAGCTTTGA
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AGAACTGAGCCTGGAAGAAATGGAAGCAATTCAGGGTAGCGGTGATGTTCAGGCAGAAACCACACCG
GCATGTTTTACCATTGGTCTGGGTGTTGGTGCACTGTTTAGCGCAAAATTTTGCTAATAA 
 
Materials 
All oligonucleotides were purchased from Integrated DNA Technologies and used as received. 
Restriction endonucleases, DNA polymerases, and T4 DNA ligase were from New England 
Biolabs. Media components were obtained from Difco Laboratories. Trypsin was purchased from 
Worthington Biochemical Corporation and other endoproteinases were ordered from Roche 
Biosciences. Unless specified otherwise, chemicals were purchased from Sigma Aldrich or Fisher 
Scientific. Defibrinated rabbit blood was ordered from Hemostat Laboratories and used within 10 
days of receipt. 
 
Strains and plasmids 
The indicator strain, Lactococcus lactis HP, and the haloduracin producer strain Bacillus 
halodurans C-125 was obtained from American Type Culture Collection. E. coli DH5α and E. coli 
BL21 (DE3) cells were used as host for cloning and plasmid propagation, and host for expression, 
respectively. Co-expression vector pRSFDuet-1 was obtained from Novagen. 
 
Construction of pRSFDuet-1 derivatives for co-expression of CylM and CylLL/CylLS 
The gene encoding CylM was first cloned into the multiple cloning site 2 of the pRSFDuet-1 
vector (without His-tag sequence) using NdeI and KpnI restriction sites to generate 
pRSFDuet-1/CylM-2. The cylLL and cylLS genes were then cloned into the multiple cloning site 1 
(MCS1) of pRSFDuet-1/CylM-2 (with His-tag sequence) using EcoRI and NotI restriction sites to 
generate pRSFDuet-1/CylLL/CylM-2 and pRSFDuet-1/CylLS/CylM-2 plasmids, respectively. 
Primer sequences are shown in Table 2.2. 
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Table 2.2 Primer sequences for cloning of cylM, cylLL, cylLS, halA2 and their mutants. Mutation 
codons are underlined. 
Primer Name Primer Sequence (5'-3') 
CylM_NdeI_FP_Duet AAAAA CATATG GAAGATA ATCTGATTAA T 
CylM_KpnI_RP_Duet AAAAA GGTACC TTACAGT TCAAACAGCA G 
CylLL_EcoRI_FP_Duet AAAAA GAATTCG GAAAATC TGAGCGTTGT T 
CylLL_NotI_RP_Duet AAAAA GCGGCCGC TTAGCAA TGTTTCAGGC T 
CylLS_EcoRI_FP_Duet AAAAA GAATTCG CTGAATA AAGAAAATCA G 
CylLS_NotI_RP_Duet AAAAA GCGGCCGC TTAGCAA AATTTTGCGC T 
CylLL_E-1K_FP ACC ACA CCG GTT TGT GCA GTT 
CylLL_E-1K_RP ACA AAC CGG TGT GGT TTT TGC CTG AAC ATC ACC 
CylLS_E-1K_FP ACC ACA CCG GCA TGT TTT ACC 
CylLS_E-1K_RP ACA TGC CGG TGT GGT TTT TGC CTG AAC ATC ACC 
CylLL_S14T_FP GCA ACC GCA GCA GCA ACC AGC GCA GCA TGT GGT 
CylLL_S15T_FP GCA ACC GCA GCA GCA AGC ACC GCA GCA TGT GGT 
CylLL_S14/15T_RP  TGC TGC TGC GGT TGC TGC AAC 
HalA2_BamHI_FP_Duet AAAAA GGATCC G ATGGTAAATT CAAAAGATTT 
HalA2_HindIII_RP_Duet AAAAA AAGCTT TTAGCACTGG CTTGTACACT 
 
Construction of pRSFDuet-1 derivatives for co-expression of CylM and CylLL/CylLS-E−1K, 
CylLL-S14T, and CylLL-S15T 
Site-directed mutagenesis of pRSFDuet-1/CylLL/CylM-2 and pRSFDuet-1/CylLS/CylM-2 
constructs was performed by multi-step overlap extension PCR. Negative numbers are used for 
amino acids in the leader peptide counting backwards from the leader peptide cleavage site. First, 
the amplification of the 5’ part of cylLL/cylLS was carried out by 30 cycles of denaturing (95 °C for 
10 s), annealing (55 °C for 30 s), and extending (72 °C for 15 s) using the cylLL/cylLS EcoRI 
forward primer (FP) and an appropriate mutant reverse primer (Table 2.2) to generate a forward 
megaprimer (FMP). The PCR mixture included Phusion DNA polymerase (Finnzymes; 0.04 
U/μL), dNTP (2 mM each), primers (1 μM each), and appropriate buffers. In parallel, a PCR 
reaction using an appropriate mutant forward primer (Table 2.2) and the cylLL/cylLS NotI reverse 
primer (RP) was also performed to produce 3’ fragments (termed reverse megaprimer, RMP). The 
5’ FMP fragment and the 3’ RMP fragment were purified by 2% agarose gel and combined in 
equal amounts (by mol, approximately 20 ng each for a 50 μL PCR reaction) and amplified using 
the same PCR conditions with cylLL/cylLS EcoRI FP and cylLL/cylLS NotI RP. The resulting PCR 
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products were then cloned into the MCS1 of pRSFDuet-1/CylM-2 to generate 
pRSFDuet-1/CylLL-E−1K/CylM-2, pRSFDuet-1/CylLS-E−1K/CylM-2, 
pRSFDuet-1/CylLL-S14T/CylM-2 and pRSFDuet-1/CylLL-S15T/CylM-2. 
 
Construction of pRSFDuet-1 derivatives for co-expression of HalM2 and HalA2-C5A 
The gene encoding HalA2-C5A was amplified by PCR from a pET15b/HalA2Xa-C5A vector 
reported previously (26), and cloned into the multiple cloning site 1 of pRSFDuet-1/HalM2-2 (16) 
using BamHI and HindIII restriction sites to generate the pRSFDuet-1/HalA2-C5A/HalM2-2 
plasmid. Primer sequences used are shown in Table 2.2. 
 
Expression and purification of modified His6-CylLL and His6-CylLS peptides 
E. coli BL21 (DE3) cells were transformed with the pRSFDuet-1/CylM-2-CylLL or 
pRSFDuet-1/ CylLS/CylM-2 plasmids and plated on LB plates containing 50 mg/L kanamycin. A 
single colony was picked and grown in 50 mL of LB with kanamycin at 37 
o
C for 12 h and the 
resulting culture was used to inoculate 3 L of LB. Cells were cultured at 37 
o
C until the OD at 600 
nm reached 0.5, cooled and IPTG was added to a final concentration of 0.1 mM. Cells were 
cultured at 18 
o
C for another 18 h before harvesting. The cell pellet was resuspended at room 
temperature in LanA start buffer (20 mM NaH2PO4, pH 7.5 at 25
 o
C, 500 mM NaCl, 0.5 mM 
imidazole, 20% glycerol) and lysed by sonication. The sample was centrifuged at 23,700×g for 30 
min and the supernatant was kept. The pellet was then resuspended in LanA buffer 1 (6 M 
guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25
 o
C, 500 mM NaCl, 0.5 mM imidazole) 
and sonicated again. The insoluble portion was removed by centrifugation at 23,700×g for 30 min 
and the soluble portion was kept. Both soluble portions were passed through 0.45-µm syringe 
filters and the His-tagged modified peptides were purified by immobilized metal affinity 
chromatography (IMAC) as previously described (29). The eluted fractions were desalted by 
preparative reversed phase (RP) HPLC using a Waters Delta-pak C4 column (15 µm; 300 Å; 25 x 
100 mm). The desalted peptides were lyophilized and stored at −20 oC for future use. 
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Protease cleavage and purification of core peptides  
Modified CylLL and CylLS precursor peptides were dissolved in H2O to a concentration of 3 
mg/mL. To 85 μL of peptide solution, 10 μL of 500 mM HEPES buffer (pH 7.5) was added, 
followed by 5 μL of 0.02 mg/mL AspN protease (for wild type peptides) or 5 mg/mL trypsin (for 
the E−1K mutants). The protease cleavage reaction mixtures were kept at 25 oC (for wild type 
peptides) or 37 
oC (for the E−1K mutants) for 6 to 16 h, respectively, and were then quenched with 
0.5% TFA. The generation of the desired products was confirmed by MALDI-TOF MS and the 
products were purified by reversed phase (RP) HPLC using a Jupiter proteo C12 column (5 µm; 90 
Å; 250 x 4.6 mm; Phenomenex). Solvents for RP-HPLC were solvent A (0.1% TFA in water) and 
solvent B (0.086% TFA in 80% acetonitrile/20% water). The desired core peptides eluted from the 
column between 50 and 70% solvent B and pure fractions were collected and lyophilized for 
further usage. Large scale purification was conducted by RP HPLC using a Jupiter proteo C12 
semi-preparative column (5 µm; 90 Å; 250 x 10.0 mm). 
 
LC-ESI-Q/TOF MS and MSMS analyses 
A 5 μL volume of sample (approximately 100 μg/mL) was injected on a Waters Acquity 
UPLC system equipped with a BEH C8 column (1.7 um, 100 mm x 1.0 mm; Waters). The column 
was pre-equilibrated in aqueous solvent. The solvents used for LC were: solvent A = 0.1% formic 
acid in water and solvent B = 0.1% formic acid in methanol. A solvent gradient of 3%-97% B over 
15 min was employed and the fractionated sample was directly subjected to ESI-Q/TOF MS 
analysis using a Waters Synapt mass spectrometer. The mass spectrometer was calibrated before 
samples were applied. Data was acquired in ESI positive mode with the capillary voltage set to 
3.0-3.5 kV. The ionization source and desolvation gas were heated to 120 °C and 300 °C, 
respectively. Cone gas was set to 0 L/h and desolvation gas was set to 600 L/h. The transfer 
collision energy was set to 4 V for both MS and MSMS analyses. The trap collision energy was set 
to 6 V for MS analysis. For MS/MS analysis, a trap collision energy ramp ranging from 20-40 V 
was applied on multiply charged parent ions to achieve fragmentation. Suitable trap collision 
energy was determined by choosing the spectra where both fragment peaks and parent peak could 
be observed. [Glu
1
]-Fibrinopeptide B (Sigma) was directly infused as lock mass with lock spray 
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sampling if desired. The acquired spectra were processed using MaxEnt3 software and analyzed 
by Protein/Peptide Editor in BioLynx 4.1 (Waters). 
 
Antimicrobial activity assay of CylLL” and CylLS” 
CylLL” and CylLS” were obtained as described above by trypsin cleavage of CylM-modified 
CylLL E−1K and CylLS E−1K followed by HPLC purification. Peptides were dissolved in 2:1 
acetonitrile:H2O to achieve a concentration of 100 μM. The peptide solutions were diluted with 
phosphate buffered saline (PBS) to prepare a 10 μM solution. L. lactis HP cells were grown in 
GM17 media under anaerobic conditions at 25 °C for 16 h. Agar plates were prepared by 
combining 20 mL of melted GM17 agar (cooled to 42 °C for 5 min) with 200 μL of dense 
overnight cell culture. The seeded agar was poured into a sterile 100 mm round dish (VWR) and 
allowed to solidify at 25 °C for 30 min. Samples were directly spotted on the solidified agar. Plates 
were incubated at 30 °C for 16 h and the antimicrobial activity was determined by the presence or 
absence of zones of growth inhibition. A negative control was conducted using solutions with 
identical make-up but leaving out the peptides. 
 
Hemolytic assay of CylLL” and CylLS” 
A sample of 1 mL of defibrinated rabbit blood was diluted with 20 mL of PBS in a 50 mL 
conical tube on ice and mixed well by gently inverting the tube. The PBS-diluted blood sample 
was centrifuged at 1,000×g for 5 min at 4 °C and the supernatant containing lysed blood cells and 
released hemoglobin was discarded. The process was repeated 2 to 4 times until the supernatant 
was clear. The blood cells were then diluted with PBS to make a 5% solution, which was 
immediately used to test the hemolytic activity of the peptides. Rabbit blood was used within 10 
days after receipt to minimize autolysis. CylLL” and CylLS” peptide solutions made as described 
above were diluted with PBS to prepare a 10 μM solution. To a 96-well plate, 100 μL of 5% 
washed rabbit blood sample was added to each well followed by the addition of the desired peptide 
samples or controls. In each sample well, CylLL” was added and mixed well for 5 min before 
CylLS” was added. PBS was used to adjust the final volume to 150 μL. The 96-well plate was kept 
in a 37 
o
C incubator to allow the lytic reaction to proceed. At each time point, 20 μL of each 
reaction mixture was taken out, diluted with 200 μL of fresh PBS and centrifuged at 1,000×g for 5 
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min. The supernatant (120 μL) was transferred to a new well and the absorbance was measured at 
415 nm (wave length was optimized for rabbit hemoglobin). The absorbance of prepared blood 
sample at each time point was analyzed in triplicate and the maximum absorbance was determined 
by adding 50 μL of 0.1% Triton in PBS to 100 μL of 5% blood sample and using the same analysis 
procedure. 
 
Purification of Halβ from Bacillus halodurans C-125 
The isolation of Halβ from Bacillus halodurans C-125 was performed according to a 
previously reported procedure (30). 
 
GC-MS analysis 
The synthesis of Lan and MeLan standards and the preparation of samples for GC-MS 
analysis were carried out following a reported procedure published elsewhere (20, 21). The NMR 
spectra of the synthetic standards matched the literature values. The modified precursor peptides 
with their leader sequences attached were hydrolyzed and the resulting solutions were dried and 
directly used for derivatization. The derivatized samples were analyzed by GC-MS using an 
Agilent 7890 gas chromatograph equipped with a Varian CP-Chirasil-L-Val fused silica column 
(25 m x 0.25 mm x 0.15 µm). Samples were dissolved in methanol and introduced to the 
instrument via a splitless/split (1:20) injection at a flow rate of 1.7 or 2.0 mL/min helium gas. The 
temperature method used was 160 
o
C for 5 min, 160 
o
C to 180 
o
C at 3 
o
C/min, and 180 
o
C for 6 min. 
The mass spectrometer was operated in simultaneous scan/selected-ion monitoring (SIM) mode, 
monitoring at the characteristic fragment masses of 365 Da for Lan and 379 Da for MeLan 
residues. 
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Chapter 3. Substrate Control in Stereoselective Lanthionine Biosynthesis 
 
3.1 Introduction 
The stereochemical outcome of chemical reactions between chiral molecules in which one or 
more new stereocenters are generated is often governed by the stereochemistry of the substrate or 
reagent, resulting in substrate or reagent controlled processes (1). For enzymatic reactions, the 
well-organized chiral environment of the enzyme active site typically results in reagent control for 
physiological processes. In this chapter, I describe a rare case where the substrate controls the 
stereochemical outcome of an enzyme-catalyzed Michael-type addition during the biosynthesis of 
lanthipeptides (for an introduction about lanthipeptides, see section 1.2 of chapter 1). The 
biosynthetic route of class II lanthipeptides is illustrated in Figure 3.1a using the enterococcal 
cytolysin as an example.     
Lanthipeptides have been extensively studied over the past 30 years, with structural 
information available for a subset of compounds (2). Until recently, it was generally assumed that 
the cysteine addition always gave (2S, 6R)-Lan (hereafter called DL-Lan) and (2S, 3S, 6R)-MeLan 
(hereafter DL-MeLan) (Figure 3.1b). This assumption was recently challenged by the discovery 
of (2R, 3R, 6R)-MeLan (LL-MeLan, Figure 3.1b) in two class II lantibiotics - the cytolysin from 
Enterococcus faecalis and haloduracin produced by Bacillus halodurans (see chapter 2) (3). The 
enterococcal cytolysin consists of two peptides called cytolysin L (CylLL’’, Figure 3.1c) and 
cytolysin S (CylLS’’, Figure 3.1a), which are generated from the precursor peptides CylLL and 
CylLS, respectively, by a single lanthionine synthetase CylM. The production of cytolysin 
enhances virulence in infection models of E. faecalis and is associated with acute patient mortality 
(4-7). Haloduracin is an antimicrobial substance that also consists of two peptides (Figure 3.1c) 
(8). Based on sequence homology of the rings containing the LL-MeLan residues in cytolysin and 
haloduracin, it has been suggested that a Dhb-Dhb-Xxx-Xxx-Cys motif (Xxx represents amino 
acids other than Dha, Dhb and Cys) (Figure 3.1) induces the formation of the unusual MeLan 
xxxxxx 
 
 
 
 
Reproduced in part with the permission from:  
Tang, W., Jiménez-Osés, G., Houk, K. N., and van der Donk, W. A. (2015) Substrate control in 
stereoselective lanthionine biosynthesis, Nat. Chem. 7, 57-64. 
Copyright 2015 Nature America, Inc. 
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Figure 3.1 Biosynthesis of class II lanthipeptides. (a) Generic pathway of class II lanthipeptide 
biosynthesis with cytolysin S as an example. The CylLS peptide is synthesized by the ribosome as a linear 
precursor peptide with an N-terminal leader peptide and a C-terminal core peptide. The dehydration of Ser 
and Thr residues to Dha and Dhb residues as well as the Michael-type addition by Cys residues onto these 
α,β-unsaturated amino acids is catalyzed by the bi-functional lanthionine synthetase CylM. The leader 
peptide is then removed by the proteases CylB and CylA, affording mature cytolysin S. (b) Dehydration 
and cyclization reactions catalyzed by LanM enzymes that result in (Me)Lan residues with the canonical 
DL (i.e. D configuration at the α carbon originating from Ser or Thr and L configuration at the α carbon of 
the former Cys) and unusual LL (L configuration for both α carbons) stereochemistries. (c) The structures 
of haloduracin (Halα and Halβ) and cytolysin L. Abu, α-aminobutyric acid. 
 
stereochemistry (3). In this model, the LL stereochemistry is formed by anti-addition of cysteine to 
the Re face of the alkene because of a conformational preference of the substrate that is unique to 
this motif (3). 
These findings have raised a number of intriguing questions. First, given that cytolysin and 
haloduracin contain both LL- and DL-(Me)Lan, how can one enzyme catalyze similar conjugate 
additions with different stereochemistries in a single polypeptide substrate? Second, does the 
substrate sequence indeed govern the diastereoselectivity? And third, is it possible to manipulate 
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the stereochemical outcome by mutating the peptide substrate? In this chapter, I show that the 
formation of LL-MeLan from the Dhb-Dhb-Xxx-Xxx-Cys sequence is not specific to the enzymes 
involved in cytolysin or haloduracin biosynthesis. Furthermore, I demonstrate that a Dhb-to-Ala 
mutation at the second position of the motif results in MeLan formation with the canonical DL 
stereochemistry, supporting the substrate control hypothesis. Quantum mechanical simulations of 
dehydrated peptides (performed by Dr. Gonzalo Jiménez-Osés and Prof. K. N. Houk, Department 
of Chemistry and Biochemistry, University of California, Los Angeles) confirm an intrinsic 
preference for Re face or Si face addition depending on the sequence of the substrate peptide.  
 
3.2 Results 
3.2.1 Generality of LL-MeLan formation from Dhb-Dhb-Xxx-Xxx-Cys 
To test the hypothesis that the substrate peptide sequence containing the 
Dhb-Dhb-Xxx-Xxx-Cys motif determines the formation of LL stereochemistry independent of the 
identity of the lanthionine synthetase, a series of chimeric peptides were generated with the CylLS 
core peptide connected to leader peptides from different class II lanthipeptides. These leader 
peptides were expected to be recognized by their cognate lanthionine synthetases that carry out the 
dehydration and cyclization reactions in the core peptide. The gene halA2-cylLS that encodes a 
chimeric peptide consisting of the leader peptide of the haloduracin α precursor peptide (HalA2) 
fused to the CylLS core peptide (Figure 3.2a) was co-expressed in E. coli with halM2 encoding the 
Halβ synthetase HalM2 (9). Modified HalA2-CylLS was purified and analysis by matrix-assisted 
laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) showed the 
desired four dehydrations (Figure 3.2b). The modified chimeric peptide was hydrolyzed in 6 M 
HCl to individual amino acid residues, which were derivatized and analyzed by gas 
chromatography (GC) MS using a chiral GC column to reveal the stereochemistry of the (Me)Lan 
residues as described in chapter 2 (3, 10). Signals corresponding to LL-MeLan and DL-Lan were 
observed as the predominant products by comparison with synthetic standards derivatized in the 
same way (Figure 3.3 and Table 3.1). Hence, HalM2 catalyzes the cyclization of the CylLS core 
peptide with the same stereochemical selectivity as CylM.  
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Figure 3.2 Chimeric peptide HalA2-CylLS modified by HalM2 in E. coli. (a) HalA2-CylLS chimeric 
peptide that was modified by the Halβ synthetase HalM2 in E. coli. A generic protein structure is shown for 
the enzyme. (b) MALDI/TOF mass spectrum of HalM2-modified HalA2-CylLS core peptide. The core 
peptide contains five additional amino acids at its N terminus originating from the leader peptide as a result 
of AspN cleavage (calculated M−4 H2O: 2581.3, monoisotopic; observed: 2582.9, monoisotopic, M−4 
H2O+H
+
). 
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Figure 3.3 GC-MS traces for derivatized Lan/MeLan residues obtained from hydrolysis of 
HalA2-CylLS modified by HalM2 in E. coli and co-injections with derivatized Lan/MeLan standards 
(selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized 
MeLan residues from modified HalA2-CylLS. (b) Hydrolyzed and derivatized Lan residues from modified 
HalA2-CylLS. (c) Hydrolyzed and derivatized MeLan residues from modified HalA2-CylLS (red line) and 
co-injected with derivatized DL-MeLan standard (blue line). (d) Hydrolyzed and derivatized MeLan 
residues from modified HalA2-CylLS (red line) and co-injected with derivatized LL-MeLan standard 
(blue line). (e) Hydrolyzed and derivatized Lan residues from modified HalA2-CylLS (red line) and 
co-injected with derivatized DD-Lan standard (blue line). (f) Hydrolyzed and derivatized Lan residues 
from modified HalA2-CylLS (red line) and co-injected with derivatized DL-Lan standard (blue line). (g) 
Hydrolyzed and derivatized Lan residues from modified HalA2-CylLS (red line) and co-injected with 
derivatized LL-Lan standard (blue line). Traces of derivatized Lan and MeLan residues from modified 
HalA2-CylLS (red lines) used for overlay were adjusted to 70% intensity for clarity. A small amount of 
epimerization of the (Me)Lan occurs during acid hydrolysis of the peptides as has been reported 
previously (11). 
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This result was perhaps not too surprising since HalM2 converts a Dhb-Dhb-Trp-Pro-Cys 
sequence into an LL-MeLan cross-link in its native substrate HalA2 (Figure 3.1c) (3). Therefore, I 
turned to LanM enzymes that only form DL-(Me)Lan in their natural substrates. The lanthionine 
synthetase LtnM2 involved in the biosynthesis of the lantibiotic lacticin 3147 A2 (12) was 
evaluated next. An LtnA2-CylLS peptide consisting of the leader peptide from the natural LtnM2 
substrate (LtnA2) and the core peptide from CylLS was co-expressed with LtnM2 in E. coli. 
MALDI-TOF MS analysis of the peptide product illustrated the desired four dehydrations (Figure 
3.4). Hydrolysis and derivatization of the modified LtnA2-CylLS peptide once again resulted in 
almost exclusive LL-MeLan and DL-Lan signals in GC-MS experiments (Figure 3.5 and Table 
3.1), demonstrating that LtnM2 also preferentially forms the LL stereochemistry when guided by 
the substrate sequence. 
 
 
 
Figure 3.4 Chimeric peptide LtnA2-CylLS modified by LtnM2 in E. coli. (a) LtnA2-CylLS chimera that 
was modified by the Ltnβ synthetase LtnM2 in E. coli. A generic protein structure is shown for the enzyme. 
(b) MALDI/TOF mass spectrum of LtnM2-modified LtnA2-CylLS peptide (calculated M−4 H2O: 7606; 
observed: 7607, M−4 H2O+H
+
). 
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Figure 3.5 GC-MS traces for derivatized Lan/MeLan residues obtained from hydrolysis of 
LtnA2-CylLS modified by LtnM2 in E. coli and co-injections with derivatized Lan/MeLan standards 
(selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized 
MeLan residues from modified LtnA2-CylLS. (b) Hydrolyzed and derivatized Lan residues from modified 
LtnA2-CylLS. (c) Hydrolyzed and derivatized MeLan residues from modified LtnA2-CylLS (red line) and 
co-injected with derivatized DL-MeLan standard (blue line). (d) Hydrolyzed and derivatized MeLan 
residues from modified LtnA2-CylLS (red line) and co-injected with derivatized LL-MeLan standard 
(blue line). (e) Hydrolyzed and derivatized Lan residues from modified LtnA2-CylLS (red line) and 
co-injected with derivatized DD-Lan standard (blue line). (f) Hydrolyzed and derivatized Lan residues 
from modified LtnA2-CylLS (red line) and co-injected with derivatized DL-Lan standard (blue line). (g) 
Hydrolyzed and derivatized Lan residues from modified LtnA2-CylLS (red line) and co-injected with 
derivatized LL-Lan standard (blue line). Traces of derivatized Lan and MeLan residues from modified 
LtnA2-CylLS (red lines) used for overlay were adjusted to 70% intensity for clarity. A small amount of 
epimerization of the (Me)Lan occurs during acid hydrolysis of the peptides as has been reported 
previously (11). 
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I then chose ProcM as the next LanM target. ProcM is a lanthionine synthetase with 30 
natural substrates (ProcAs) that exhibits high substrate tolerance (Figure 3.6, also see chapter 8) 
(13). ProcM can generate many different ring topologies, and based on the currently structurally 
characterized ProcA products, they all have the DL-(Me)Lan stereochemistry (14). It has been 
suggested that it is the sequence of the ProcA peptides, rather than the ProcM enzyme, that 
primarily determines the cyclization patterns (15). As such, ProcM would be the perfect candidate 
to test the hypothesis that the unusual LL-MeLan stereochemistry produced from the 
Dhb-Dhb-Xxx-Xxx-Cys motif is determined by the substrate. The ProcA3.2 leader peptide was 
chosen for a chimeric ProcA3.2-CylLS peptide and the latter was co-expressed with ProcM in E. 
coli (Figure 3.7a). The modified ProcA3.2-CylLS peptide afforded several products that differed 
in the extent of dehydration with 2- and 4-fold dehydrated peptides as the major products (Figure 
3.7b). The modified peptides were hydrolyzed, and the resulting amino acids were derivatized and 
subjected to GC-MS analysis. In this case, an LL-MeLan peak with a relatively low intensity as 
well as a DL-Lan signal was observed (Figure 3.8 and Table 3.1). The low signal intensity of the 
derivatized MeLan compared with Lan could be the result of the observed incomplete dehydration 
of the non-cognate core peptide or because of partial cyclization by ProcM. Regardless, the MeLan 
that was generated clearly was formed with high selectivity for the LL stereochemistry.  
Collectively, these results demonstrate that class II LanM enzymes have a general preference 
for converting sequences containing the Dhb-Dhb-Xxx-Xxx-Cys motif into LL-MeLan (Figure 
3.9 and Table 3.1). 
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Figure 3.6 Sequences of 30 ProcAs encoded by the genome of Prochlorococcus MIT 9313 (16). 
 
 
Figure 3.7 Chimeric peptide ProcA3.2-CylLS modified by ProcM in E. coli. (a) ProcA3.2-CylLS that 
was modified by the ProcA synthetase ProcM in E. coli. A generic protein structure is shown for the enzyme. 
(b) MALDI/TOF mass spectrum of ProcM-modified ProcA3.2-CylLS core peptide. The core peptide 
contains five additional amino acids at its N terminus originating from the leader peptide after 
endoproteinase GluC cleavage (calculated M−4 H2O: 2372.2, monoisotopic; observed: 2374.1, 
monoisotopic, M−4 H2O+H
+
). The 0.9 Da mass difference is presumably introduced by application of 
external calibration instead of internal calibration of peptide standards. 
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Figure 3.8 GC-MS traces for derivatized Lan/MeLan residues obtained from hydrolysis of 
ProcA3.2-CylLS modified by ProcM in E. coli and co-injections with derivatized Lan/MeLan 
standards (selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and 
derivatized MeLan residues from modified ProcA3.2-CylLS. (b) Hydrolyzed and derivatized Lan residues 
from modified ProcA3.2-CylLS. (c) Hydrolyzed and derivatized MeLan residues from modified 
ProcA3.2-CylLS (red line) and co-injected with derivatized DL-MeLan standard (blue line). (d) 
Hydrolyzed and derivatized MeLan residues from modified ProcA3.2-CylLS (red line) and co-injected 
with derivatized LL-MeLan standard (blue line). (e) Hydrolyzed and derivatized Lan residues from 
modified ProcA3.2-CylLS (red line) and co-injected with derivatized DD-Lan standard (blue line). (f) 
Hydrolyzed and derivatized Lan residues from modified ProcA3.2-CylLS (red line) and co-injected with 
derivatized DL-Lan standard (blue line). (g) Hydrolyzed and derivatized Lan residues from modified 
ProcA3.2-CylLS (red line) and co-injected with derivatized LL-Lan standard (blue line). Traces of 
derivatized Lan and MeLan residues from modified ProcA3.2-CylLS (red lines) used for overlay were 
adjusted to 70% intensity for clarity. A small amount of epimerization of the (Me)Lan occurs during acid 
hydrolysis of the peptides as has been reported previously (11). 
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Figure 3.9 GC-MS analysis of in vivo modified HalA2-CylLS, LtnA2-CylLS and ProcA3.2-CylLS 
chimeric peptides. (a) HalA2-CylLS, LtnA2-CylLS and ProcA3.2-CylLS chimeras that were modified in E. 
coli by the lanthionine synthetases HalM2, LtnM2, and ProcM, respectively. A generic protein structure is 
shown for the three enzymes. GC-MS traces are shown for hydrolyzed and derivatized MeLan residues (b) 
and Lan residues (c) from modified HalA2-CylLS (blue), LtnA2-CylLS (red), and ProcA3.2-CylLS 
(magenta). All intensities were normalized with respect to the predominant product.  
 
3.2.2 Mutation of the Dhb-Dhb-Xxx-Xxx-Cys motif 
To probe whether the two consecutive dehydro amino acids in the motif impart formation of 
the LL stereochemistry, Thr2 in HalA2 was mutated to Ala. The HalA2-T2A peptide was 
co-expressed with its synthetase HalM2 in E. coli, resulting in the desired elimination of six water 
molecules. After leader peptide removal via an engineered Factor Xa cleavage site (9), the 
modified HalA2-T2A core peptide was subjected to tandem MS (MS/MS) analysis, which 
confirmed the formation of the expected ring pattern (Figure 3.10a). The modified peptide was 
then hydrolyzed, and the resulting amino acids were derivatized and analyzed by GC-MS. A 
DL-MeLan signal was almost exclusively observed, compared with a 2:1 ratio of DL:LL MeLan 
signals observed for the wild-type HalA2 peptide after HalM2 modification (the LL-MeLan 
residue originating from the A ring and two DL-MeLan residues originating from the C and D 
rings) (Figures 3.10b and 3.11; Table 3.1) (3); as expected the DL-configuration of the Lan 
residue (ring B) remained unchanged in the mutant (Figure 3.11). To rule out the possibility that 
the A ring of the HalA2-T2A mutant was not properly cyclized, which would mean that the 
observed DL-MeLan signal originated solely from the C and D rings, I used trypsin to remove the 
55 
 
leader peptide and analyzed the core peptide mass with liquid chromatography MS (LC-MS). If 
the A ring of the HalA2-T2A mutant was not properly cyclized, the core peptide would start with a 
Dhb, which would hydrolyze to a ketone after the removal of the leader peptide, giving a mass 
increase of 1 Da (8). Trypsin was chosen over Factor Xa because trypsin exhibits minimal bias in 
terms of digestion efficiency when the cleavage site is located next to a dehydrated amino acid (17). 
The observed mass for the HalA2-T2A core peptide by electrospray ionization (ESI) MS was 
2318.0476 Da (Figure 3.10c), in agreement with the calculated mass of the cyclized peptide 
(2318.0469 Da). No peak with a mass corresponding to the non-cyclized peptide (calculated 
2319.0309 Da) was observed in the LC trace. The mass spectrometer was calibrated before 
samples were applied and an internal standard sample was directly infused when analyzing the 
peptide samples to correct any possible mass drift. Collectively, these results show that the A ring 
of the HalA2-T2A mutant was successfully cyclized and had the DL stereochemistry, strongly 
suggesting that the 2
nd
 Dhb in the Dhb-Dhb-Trp-Pro-Cys sequence is critical for the formation of 
LL-MeLan by HalM2. By mutation of the 2
nd
 Dhb to Ala, the stereochemistry of the MeLan 
residue in the A ring of HalA2 could be successfully changed from LL to DL.  
 
Figure 3.10 Structural characterization of HalM2-modified HalA2-T2A peptide. (a) MS/MS analysis 
of the HalA2-T2A core peptide modified by HalM2 in E. coli. Fragmentation is suppressed in the sequences 
spanning residues 1-5, 11-15, 17-20 and 21-24 as a result of ring formation. The b3 ion is attributed to 
in-ring fragmentation, which is rare but has also been observed for cytolysin, nisin and geobacillin (3, 9, 18). 
(b) GC-MS traces for hydrolyzed and derivatized MeLan residues from HalM2-modified HalA2 peptide 
(blue) and HalM2-modified HalA2-T2A peptide (red). (c) Electrospray ionization (ESI) quadrupole TOF 
mass spectrum for modified HalA2-T2A core peptide. The [M+2H]
2+
 ion was observed with an m/z value of 
1160.0316 (calculated m/z of cyclized HalA2-T2A core peptide with 2 protons: 1160.0313). 
56 
 
 
Figure 3.11 GC-MS traces for derivatized Lan/MeLan residues obtained from hydrolysis of 
HalA2-T2A modified by HalM2 in E. coli and co-injections with derivatized Lan/MeLan standards 
(selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized 
MeLan residues from modified HalA2-T2A. (b) Hydrolyzed and derivatized Lan residues from modified 
HalA2-T2A. (c) Hydrolyzed and derivatized MeLan residues from modified HalA2-T2A (red line) and 
co-injected with derivatized DL-MeLan standard (blue line). (d) Hydrolyzed and derivatized MeLan 
residues from modified HalA2-T2A (red line) and co-injected with derivatized LL-MeLan standard (blue 
line). (e) Hydrolyzed and derivatized Lan residues from modified HalA2-T2A (red line) and co-injected 
with derivatized DD-Lan standard (blue line). (f) Hydrolyzed and derivatized Lan residues from modified 
HalA2-T2A (red line) and co-injected with derivatized DL-Lan standard (blue line). (g) Hydrolyzed and 
derivatized Lan residues from modified HalA2-T2A (red line) and co-injected with derivatized LL-Lan 
standard (blue line). Traces of derivatized Lan and MeLan residues from modified HalA2-T2A (red lines) 
used for overlay were adjusted to 70% intensity for clarity. A small amount of epimerization of the 
(Me)Lan occurs during acid hydrolysis of the peptides as has been reported previously (11). 
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3.2.3 Computational studies on the inherent cyclization stereoselectivity  
Computational simulations have been successfully applied previously to correlate inherent 
substrate reactivity with observed enzymatic selectivities (19, 20). To investigate the possible 
origins of the experimentally observed sequence-dependent stereochemical preferences, the 
cyclization reactions were studied computationally for the A rings of the CylLS and HalA2 core 
peptides (performed by Dr. Gonzalo Jiménez-Osés in Prof. K. N. Houk’s laboratory, Department 
of Chemistry and Biochemistry, University of California, Los Angeles). The stereo-determining 
transition structures (TS) turned out to be highly diverse with respect to conformations presumably 
due to the high flexibility of the target oligopeptides. Therefore, a stepwise approach combining 
molecular dynamics (MD) and quantum mechanical (QM) calculations was employed to locate the 
optimal pathways for either Re or Si face additions for each model peptide.  
The CylLS sequence leading to its A ring was found to prefer the LL stereochemistry by 
exhibiting a large difference in the activation barriers (ΔΔG‡ = 3.2 kcal mol-1) calculated for the 
Michael-type additions to the Re and Si faces of Dhb, corresponding to a stereoselectivity higher 
than 99% at room temperature (Figure 3.12). The A ring of HalA2 was also calculated to favor the 
Re face addition with activation energies that differed by 1.9 kcal mol
-
 (>96:4 d.r. at 25 ºC) (Figure 
3.13), although the predicted secondary structures of the sequence is quite different from those 
calculated to be optimal for the A ring of CylLS. The substitution of the 2
nd
 Dhb to Ala in the A ring 
of HalA2 resulted in minimal differences with respect to simulated structures comparing to the 
wild type A ring of HalA2. However, such a mutation had a strong impact on the calculated 
stereoselectivity, favoring the Si face approach by 2 kcal mol
-1
 (Figure 3.14). Collectively, 
computational studies of the intrinsic preferences for Re or Si face additions of three model peptide 
sequences corresponding to the A ring of CylLS, and the wild type and mutated A rings of HalA2 
are in accordance with the experimental observations, suggesting that such preferences for LL or 
DL stereochemistries are encoded in the substrate peptide sequences rather than dominated by the 
synthetases.  
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Figure 3.12 Lowest energy quantum mechanical transition structures for the Re and Si face 
Michael-type additions that generate the A ring in the CylLS core sequence. The depicted kinetic 
diastereomeric percentage was derived from these relative activation energies. Figure made by Dr. Gonzalo 
Jiménez-Osés. 
 
 
Figure 3.13 Lowest energy quantum mechanical transition structures for the Re and Si face 
Michael-type attack that generates the A ring in the HalA2 core sequence. The depicted kinetic 
diastereomeric percentages were derived from these relative activation energies. Figure made by Dr. 
Gonzalo Jiménez-Osés. 
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Figure 3.14 Lowest energy quantum mechanical transition structures for the Re and Si face 
Michael-type attack that generates the A ring of the HalA2-T2A core sequence. The depicted kinetic 
diastereomeric percentages were derived from these relative activation energies. Figure made by Dr. 
Gonzalo Jiménez-Osés. 
 
Table 3.1 Stereochemical outcome of lanthipeptide precursor peptides modified by different 
lanthionine synthetases. 
 
Peptide substrate 
 
Lanthionine 
synthetase 
Configuration of (Me)Lan 
residue  
 
 
Quantum mechanical 
prediction for A ring 
A ring
a 
Other rings 
CylLS CylM
b 
LL DL LL 
HalA2-CylLS HalM2 LL DL LL 
LtnA2-CylLS LtnM2 LL DL LL 
ProcA3.2-CylLS ProcM LL DL LL 
HalA2 HalM2
b
 LL DL LL 
HalA2-T2A HalM2 DL DL DL 
a. The ring that contains the Dhb-Dhb-Xxx-Xxx-Cys motif in all substrates except HalA2-T2A which 
contain Dhb-Ala-Trp-Pro-Cys. 
b. Reported previously (3). 
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3.3 Discussion 
The discovery of LL-MeLan residues in the enterococcal cytolysin and haloduracin formed 
from a conserved Dhb-Dhb-Xxx-Xxx-Cys substrate motif revealed the first examples of 
enzymatic formation of non-canonical stereochemistry of MeLan residues (chapter 2). Very 
recently, LL stereochemistry was also reported for the lantibiotic carnolysin that also contains this 
motif (21). In this chapter, I show that the unusual stereochemistry is inherent to this sequence 
motif, because four different class II lanthionine synthetases with low sequence identities in their 
cyclase domains (<25% identity) all converted this motif to LL-MeLan products even though the 
enzymes install other rings in the same peptide with DL stereochemistry. Indeed, two of the tested 
lanthionine synthetases only give products with DL stereochemistry in their natural substrates, 
making it highly unlikely that they would have evolved features that favor LL-MeLan-containing 
products. Furthermore, the stereoselectivity was changed from LL to DL when the second Dhb in 
such a motif in HalA2 was mutated to Ala. Thus, these Michael-type additions are rare examples 
of natural enzymatic processes in which stereochemistry is substrate-controlled; other similar 
examples were not found by searching the literature, but a related observation has been made in 
ketoreduction by iterative polyketides synthases where substrate length controlled the face 
selectivity of hydride transfer (22). Of course, reversal of stereoselectivity of enzymatic reactions 
has been observed routinely with non-natural substrate analogs or mutant enzymes (23-26). 
The computational studies also support a model in which the observed stereochemistry is 
determined to a large extent by the sequence of the substrate peptide, even though the transition 
state structures can differ substantially depending on the location of a Pro residue. Based on these 
observations, we suggest that for the formation of most (Me)Lan residues in lanthipeptides, the 
enzyme controls the face selectivity of attack and protonation, resulting in the predominantly 
observed DL stereochemistry. However, two consecutive Dhbs in the Dhb-Dhb-Xxx-Xxx-Cys 
motif may result in a conformational preference that is unfavorable for the canonical interaction 
with the enzyme active site. The enzyme is likely to still activate the Cys residue given the very 
slow rates of non-enzymatic (Me)Lan formation (27), but the face selectivity of attack is now 
governed by the substrate and not the enzyme. The role of the enzyme was investigated in more 
detail by decoupling the cyclization reaction from the dehydration reaction (see chapter 4). 
Structural information of substrate bound to the enzyme will be required to determine whether all 
calculated transition states can be attained in the context of the protein.  
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3.4 Methods 
General methods and materials 
Similar general methods and materials as what were described in chapter 2 were employed in 
this chapter unless specified otherwise. MALDI-TOF MS was carried out on a Bruker Daltonics 
UltrafleXtreme MALDI TOF/TOF instrument (Bruker). LC-ESI-Q/TOF MS and MS/MS analyses 
were conducted using a Synapt G1 instrument with an Acquity UPLC system (Waters), which was 
equipped with a Jupiter Proteo C12 column (5 µm; 90 Å; 100 x 1.0 mm) (Phenomenex). GC-MS 
analysis was performed in the Mass Spectrometry Laboratory (School of Chemical Sciences, 
UIUC) on an Agilent 7890 gas chromatograph (Agilent). Solid phase extraction was performed 
with Strata-X polymeric reverse phase columns (Phenomenex). Trypsin was purchased from 
Worthington Biochemical Corporation; Factor Xa was obtained from New England Biolabs and 
other endoproteinases were ordered from Roche Biosciences.  
 
Construction of pRSFDuet-1 derivatives for co-expression of HalM2, LtnM2 and ProcM 
with HalA2-CylLS, LtnA2-CylLS and ProcA3.2-CylLS, respectively 
Genes encoding the chimeric peptides were amplified by multi-step overlap extension PCR. 
First, the amplification of the 5’ leader part was carried out by 30 cycles of denaturing (95 °C for 
10 s), annealing (55 °C for 30 s), and extending (72 °C for 15 s) using appropriate primers (Table 
3.2) to generate a forward megaprimer (FMP). In parallel, PCR reactions using appropriate 
forward primers (FP, Table 3.2) and the cylLS reverse primer (RP) were also performed to produce 
3’ fragments (termed reverse megaprimer, RMP). The 5’ FMP fragment and the 3’ RMP fragment 
were purified by 2% agarose gel and combined in equal amounts (by mol, approximately 20 ng 
each for a 50 μL PCR reaction) and amplified using the same PCR conditions with 
halA2/ltnA2/procA3.2 FP and cylLS RP. The resulting PCR products were then cloned into the 
multiple cloning site 1 (MCS1) of pRSFDuet-1/HalM2-2(28), pRSFDuet-1/LtnM2-2 and 
pRSFDuet-1/ProcM-2 (28) vectors, respectively, to generate pRSFDuet-1/HalA2-CylLS/HalM2-2, 
pRSFDuet-1/LtnA2-CylLS/LtnM2-2, and pRSFDuet-1/ProcA3.2-CylLS/ProcM-2. 
pRSFDuet-1/LtnM2-2 was constructed by amplifying the ltnM2 gene out of the pBAC105 plasmid 
extracted from Lactococcus lactis IFPL105 (29) and cloning into the MCS 2 of a pRSFDuet-1 
vector using NdeI and KpnI restriction sites. 
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Construction of pRSFDuet-1 derivatives for co-expression of HalM2 and HalA2-T2A 
The halA2-T2A gene was amplified from a pET15b/HalA2-T2A plasmid which was 
constructed by Dr. Leigh Anne Furgerson and cloned into MCS1 of the pRSFDuet-1/HalM2-2 
vector using the BamHI and HindIII restriction sites to generate the 
pRSFDuet-1/HalA2-T2A/HalM2-2 plasmid. Primer sequences are listed in Table 3.2. 
 
Table 3.2 Primer sequences for cloning of halA2-cylLS, ltnA2-cylLS, procA3.2-cylLS and halA2-T2A.  
Primer Name Primer Sequence (5'-3') 
HalA2_BamHI_FP AAAAA GGATCC G ATGGTAAATT CAAAAGATTT 
HalA2_HindIII_RP AAAAA AAGCTT TTAGCACTGG CTTGTACACT 
CylLS_EcoRI_FP AAAAA GAATTCG CTGAATA AAGAAAATCA G 
CylLS_NotI_RP AAAAA GCGGCCGC TTAGCAA AATTTTGCGC T 
CylLS_HindIII_RP AAAAA AAGCTT TTAGCAA AATTTTGCGC T 
LtnM2_NdeI_FP AAAAA CATATG TTGGACCCAT CAATAAAAAA A 
LtnM2_KpnI_FP AAAAA GGTACC TTAGGATTTA TGGCAACCAT C 
LtnA2_BamHI_FP AAAAA GGATCCG ATGAAAGAAA AAAATATGAA A 
ProcA3.2_EcoRI_FP AAAAA GAATTCG ATGTCAGAAGAACAACTCAAG 
HalA2_Leader_RP TTGTGCAT GCACATCTCC TGA 
LtnA2-Leader_RP TCCTCCATGA GACTCATCCC C 
ProcA3.2_Leader_RP TCC CCCAGCCACA CCTTCCAG 
HalA2_CylLS_FP GATGTGCATGCACAAACCACACCGGCATGTTTTACC 
LtnA2_CylLS_FP GAGTCTCATGGAGGAACCACACCGGCATGTTTTACC 
ProcA3.2_CylLS_FP GGTGTGGCTGGGGGAACCACACCGGCATGTTTTACC 
 
Expression and purification of modified His6-HalA2-CylLS, His6-LtnA2-CylLS, 
His6-ProcA3.2-CylLS and His6-HalA2-T2A peptides 
E. coli BL21 (DE3) cells were transformed with the pRSFDuet-1/HalA2-CylLS/HalM2-2, 
pRSFDuet-1/LtnA2-CylLS/LtnM2-2, pRSFDuet-1/ProcA3.2-CylLS/ProcM-2 or 
pRSFDuet-1/HalA2-T2A/HalM2-2 plamids and plated on an LB plate containing 50 mg/L 
kanamycin. A single colony was picked and grown in 10 mL of LB with 50 mg/L kanamycin 
aerobically at 37 
o
C for 10-16 h and the resulting culture was used to inoculate 1 L of LB. Cells 
were cultured at 37 
o
C until the OD at 600 nm reached 0.5, cooled and IPTG was added to a final 
concentration of 0.1 mM. The cells were cultured at 18 
o
C for another 18 h before harvesting. The 
cell pellet was resuspended at room temperature in LanA start buffer (20 mM NaH2PO4, pH 7.5 at 
25
 o
C, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol) and lysed by sonication. The sample was 
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centrifuged at 23,700×g for 30 min and the supernatant was kept. The pellet was then resuspended 
in LanA buffer 1 (6 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25
 o
C, 500 mM NaCl, 
0.5 mM imidazole) and sonicated again. The insoluble portion was removed by centrifugation at 
23,700×g for 30 min and the soluble portion was kept. Both soluble portions were passed through 
0.45-µm syringe filters and the His-tagged modified peptides were purified by immobilized metal 
affinity chromatography (IMAC) as previously described (30). The eluted fractions were desalted 
with Strata-X polymeric reverse phase SPE columns. The desalted peptides were lyophilized and 
stored at −20 oC for future use. 
 
LC-ESI-Q/TOF MS and MS/MS analyses 
A 5 μL volume of sample (approximately 100 μg/mL) was applied onto the column (Jupiter 
Proteo C12 column; 5 µm; 90 Å; 100 x 1.0 mm; Phenomenex) that was pre-equilibrated in aqueous 
solvent A. The solvents used for LC were: solvent A = 0.1% formic acid in water and solvent B = 
0.1% formic acid in acetonitrile. A solvent gradient of 3%-97% B over 25 min was employed and 
the fractionated sample was directly subjected to ESI-Q/TOF MS analysis using a Waters Synapt 
G1 mass spectrometer. The mass spectrometer was calibrated before any sample was injected. 
Data were acquired in ESI positive mode with the capillary voltage set to 3.0-3.5 kV. The 
ionization source and desolvation gas were heated to 120 °C and 300 °C, respectively. Cone gas 
was set to 150 L/h and desolvation gas was set to 600 L/h. The transfer collision energy was set to 
4 V for both MS and MSMS analyses. The trap collision energy was set to 6 V for MS analysis. 
For MSMS analysis, a trap collision energy ramp ranging from 20-40 V was applied on multiply 
charged parent ions to achieve fragmentation. Suitable trap collision energy was determined by 
choosing the spectra where both fragment peaks and parent peak could be observed. 
[Glu
1
]-Fibrinopeptide B (Sigma) was directly infused as lock mass with lock spray sampling. The 
acquired spectra were processed using MaxEnt3 software and analyzed by Protein/Peptide Editor 
in BioLynx 4.1 (Waters). 
 
GC-MS analysis 
The synthesis of Lan and MeLan standards and the preparation of samples for GC-MS 
analysis were carried out following a reported procedure published elsewhere (10, 14). The 
modified full length peptides with their leader peptides attached were hydrolyzed and the resulting 
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solutions were dried and directly used for derivatization. The derivatized samples were analyzed 
by GC-MS using an Agilent 7890 gas chromatograph equipped with a CP-Chirasil-L-Val fused 
silica column (25 m x 0.25 mm x 0.15 µm). Samples were dissolved in methanol and introduced to 
the instrument via a split (1:20) injection at a flow rate of 1.7 mL/min helium gas. The temperature 
method used was 160 
o
C for 2 min, 160 
o
C to 180 
o
C at 3 
o
C/min, and 180 
o
C for 2 min. The 
selected-ion monitoring (SIM) was achieved by extracting the total ion spectra for peaks 
containing the characteristic fragment masses of 365 Da for Lan and 379 Da for MeLan residues. 
 
Protease cleavage of the leader peptides 
Modified HalA2-CylLS, ProcA3.2-CylLS and HalA2-T2A peptides were dissolved in H2O to 
a concentration of 3 mg/mL. To a total 200 μL reaction with a final peptide concentration of 200 
μM, 20 μL of 500 mM HEPES buffer (pH 7.5) was added, followed by 10 μL of 0.02 mg/mL 
AspN protease (for HalA2-CylLS), 1 mg/mL GluC protease (for ProcA3.2-CylLS), and 1 mg/mL 
Factor Xa or 5 mg/mL trypsin (for HalA2-T2A). The protease cleavage reactions were incubated 
at 25 
o
C for 6 to 16 h. 
 
Computational simulations  
All MD simulations and DFT calculations were performed by Dr. Gonzalo Jiménez-Osés and 
Dr. K. N. Houk. For detailed procedures, please refer to Tang, W., Jimenez-Oses, G., Houk, K. N., 
and van der Donk, W. A. (2015) Substrate control in stereoselective lanthionine biosynthesis, Nat. 
Chem. 7, 57-64. 
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Chapter 4. The Enterococcal Cytolysin Synthetase Coevolves with Substrate 
for Stereoselective Lanthionine Synthesis 
 
4.1 Introduction 
As a major family of natural products, RiPPs (chapter 1) are structurally diverse as a 
consequence of a multitude of different post-translational modifications, including disulfide 
formation, methylation, hydroxylation, decarboxylation, cyclodehydration, macrocyclization (1, 
2). Of all the structural elements, one particular feature that accounts significantly for diversity 
and complexity in other natural products, the stereochemistry, has not received much attention in 
research related to RiPPs. The de-emphasis of stereochemistry is in part because RiPPs are 
initially assembled by the ribosome with amino acid building blocks that always adopt the L 
configuration. However, new stereocenters may be introduced and existing stereocenters can be 
modified during the post-translational modification process (3-5). For instance, the presence of 
18 epimerized amino acids that adopt the non-canonical D configuration in polytheonamide, a 
RiPP of 48 amino acid residues, reinforces the idea that stereocenters inherited from the amino 
acid building blocks of the precursor peptide can be altered in the final natural product (3). 
Introduction of new stereocenters on side chains of selected amino acids as post-translational 
modifications can further increase the structural diversity of RiPPs. Thus far, little is known how 
these stereoselective modifications are achieved during RiPP synthesis.  
Lanthipeptides are a family of RiPPs that have been intensively studied over the past 40 
years (Figure 1.2) (6, 7). For an introduction of lanthipeptides and class II lanthionine 
synthetases, please chapters 1 and 3. The formation of dehydroamino acids as intermediates 
during lanthipeptide biosynthesis allows the possible generation of non-canonical one (Ser) or 
two (Thr) stereocenters from the amino acid building blocks in the final Lan- or MeLan-
containing products. Based on the characterization of a handful of members in the lanthipeptide 
family, it was generally assumed that the original L stereocenter of these residues is inverted to 
D during the Michael-type addition to form a DL stereochemistry in the resulting thioether 
crosslinked moiety (i.e. D configuration for the α carbon of the former Ser/Thr residue and L 
configuration for the α carbon of the former Cys residue; (2S, 6R) for Lan and (2S, 3S, 6R) for 
MeLan, Figure 2.6a, left panel) (8). As described in chapter 2, this assumption was only recently 
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challenged by the discovery of an unusual LL stereochemistry in the enterococcal cytolysin (i.e. 
L configuration for both α carbons; (2R, 6R) for Lan and (2R, 3R, 6R) for MeLan, Figure 2.6a, 
right panel) (9). The enterococcal cytolysin is produced by clinical isolates of Enterococcus 
faecalis and is made up of two post-translationally modified peptides named cytolysin L and S 
(chapter 2) (10). Due to its tight linkage with the virulence of E. faecalis, cytolysin has been 
intensively studied since the 1930s with respect to its biosynthesis and biological activities (11-
15). However, structural characterization of this compound revealed the existence of an 
unexpected stereochemistry of (Me)Lan residues that differs from all other lanthipeptides with 
documented structural information. Further investigation showed that the stereoselectivity is 
encoded in the substrate sequence rather than being governed by the enzyme, which is rare for 
naturally occurring enzymatic reactions (16). These discoveries bring to light the complexity of 
stereochemical control for RiPP biosynthesis and emphasize the importance of stereochemical 
characterization for unknown or even known RiPPs.  
Although it has been confirmed that the unusual LL stereochemistry in cytolysin is induced 
by the substrate sequence, the role that the cytolysin synthetase CylM plays during this process 
has thus far not been investigated. In this chapter, I provide evidence that CylM has coevolved 
with its substrate to enforce the desired stereoselectivity for lanthionine synthesis in cytolysin. 
Moreover, the dehydrated cytolysin peptide seems to adopt a pre-organized conformation that 
facilitates the formation of the desired cyclized product even without enzymatic catalysis, 
reinforcing the idea of substrate-controlled reactivity and selectivity in RiPP biosynthesis.  
 
4.2 Results 
Chapter 3 described that three different lanthionine synthetases sharing limited sequence 
homology with CylM in their cyclase domain (<25% identity) all formed the A ring in CylLS 
with the LL stereochemistry that is found in the natural product (16). In that study, the 
dehydration of the CylLS peptide was executed in tandem with the cyclization reaction in E. coli, 
which prevents the direct investigation of the Michael-type addition process. In order to study 
the cyclization reaction in isolation, I first targeted obtaining dehydrated CylLS peptide without 
the formation of thioether linkages. LanM proteins are bifunctional enzymes that catalyze both 
the dehydration and cyclization reactions in the substrate peptides and these two functions are 
executed by two distinct domains- an N-terminal dehydratase domain and a C-terminal cyclase 
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domain (17, 18). The crystal structure of CylM reveals that each domain has its own independent 
active site (chapter 5) (19). In addition, the activity of the dehydratase domain of one LanM 
protein, the lacticin 481 synthetase LctM, has recently been reconstituted in vitro (20), indicating 
that the dehydratase domain of LanM proteins can be catalytically competent without the partner 
cyclase domain. This observation provided a possible route to obtain dehydrated CylLS using 
truncated CylM. Therefore, a truncated CylM consisting of residues 1 to 625 that encompass the 
dehydratase domain was overexpressed and used to modify the substrate CylLS in E. coli. The 
peptide was then purified using immobilized metal affinity chromatography. Matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis 
illustrated a mass shift corresponding to loss of four water molecules, consistent with what was 
observed for fully dehydrated CylLS (Figure 4.1). The desired mass loss indicates that the CylM 
dehydratase domain is functional in the absence of the cyclase domain. To test whether the two 
Cys residues in CylLS obtained using this strategy were cyclized, N-ethylmaleimide (NEM) was 
employed as an alkylation regent to detect free thiols in the peptide (21). Unexpectedly, 
dehydrated CylLS did not react with NEM under reducing conditions (Figure 4.2), suggesting 
the thiols of both Cys5 and Cys21 were involved in covalent linkages other than disulfide bonds. 
Removal of the leader peptide by CylA, the dedicated serine protease encoded in the cytolysin 
biosynthetic pathway (chapter 7), allowed liquid chromatography-MS (LC-MS) analysis of the 
modified core peptide. One major peak with a mass corresponding to fully dehydrated CylLS was 
observed on the LC chromatogram and the retention time matched that of the cytolysin S peptide 
modified by full length CylM (Figures 4.3a and 4.4a). Notably, a minor peak with the same 
mass but a different retention time was also detected on the LC chromatogram (Figure 4.3a). 
Further MS/MS analyses of both peaks revealed a similar fragmentation pattern as wild type 
cytolysin S (Figures 4.3b and 4.4b), indicating that CylLS peptide obtained in this way was 
already in its cyclized form and that the regioselectivity of cyclization was the same as that in the 
CylM-catalyzed reaction. The minor product could be a diastereomer of wild type cytolysin S. 
These observations were quite surprising as they indicate that regioselective cyclization of CylLS 
could be achieved without the cyclase domain, and may suggest that dehydrated CylLS attains an 
organized conformation that auto-cyclizes even without the presence of a catalyst. 
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Figure 4.1 MALDI-TOF mass spectrum for CylLS modified by the CylM dehydratase domain in E. 
coli. Calculated M–4H2O: 8,330, average mass; observed M–4H2O+H
+
: 8,334, average mass. Partial 
gluconoylation at the N terminus of dehydrated CylLS occurred when expressing the peptide in E. coli 
BL21(DE3), resulting in a +178 Da peak in addition to the desired peptide mass (22). 
 
Figure 4.2 NEM analysis of CylLS modified by the CylM dehydratase domain in E. coli. Overlaid 
mass spectra of dehydrated CylLS (a) (blue trace) and the peptide treated with NEM (magenta trace). 
Unmodified CylLS (b) was employed as a control. Two NEM adducts were observed for unmodified 
CylLS that contains two free thiols, whereas no NEM adducts were detected for dehydrated CylLS, 
suggesting that both thiols in this peptide were involved in thioether crosslinks. For dehydrated CylLS, 
calculated M–4H2O: 8,330, average mass; observed M–4H2O+H
+
: 8,334, average mass; for dehydrated 
CylLS treated by NEM, calculated M–4H2O+0NEM: 8,330, average mass; observed M–
4H2O+0NEM+H
+
: 8,330, average mass. For unmodifed CylLS, calculated M: 8,883, average mass; 
observed M+H
+
: 8,883, average mass; for unmodifed CylLS treated by NEM, calculated M+2NEM: 
9,133, average mass; observed M+2NEM+H
+
: 9,133, average mass. 
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Figure 4.3 MS analyses of cytolysin S peptide modified by the CylM dehydratase domain in E. coli. 
(a) Extracted ion chromatogram (m/z = 1017) of CylLS core peptide modified by the CylM dehydratase 
domain. The ESI mass spectrum corresponding to the major peak is shown in the insert. For fully 
modified CylLS core peptide, calculated [M–4H2O+2H]
2+
: 1,016.52, monoisotopic mass; observed [M–
4H2O+2H]
2+
: 1,016.51, monoisotopic mass. (b) ESI MS/MS analysis of the major peak on the LC 
chromatogram and a proposed structure deduced from the fragmentation pattern. Both MS and MS/MS 
results suggest that the dehydrated CylLS purified from E. coli is in its cyclized form. 
 
Figure 4.4 MS analyses of in vivo non-enzymatically cyclized cytolysin S. (a) Overlaid extracted ion 
chromatograms (m/z = 1017) of the CylLS core peptides modified by CylM (cyan trace) or the CylM 
dehydratase domain (red trace) in E. coli. (b) ESI MS/MS analysis of the minor product of in vivo 
cyclized cytolysin S and a proposed structure deduced from the fragmentation pattern.  
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Figure 4.5 ESI-LC-MS analysis of linear CylLS peptide in its oxidized form. Extracted ion 
chromatogram (m/z = 1052) of the LC trace for oxidized CylLS core peptide is shown in dark red and the 
corresponding mass spectrum is shown in the insert. Linear CylLS peptide was expressed from E. coli and 
purified in its oxidized form. No peak corresponding to reduced CylLS core peptide was detected in the 
LC trace. Oxidized CylLS core peptide with a disulfide linkage, calculated [M+2H]
2+
: 1,051.53, 
monoisotopic mass; observed [M+2H]
2+
: 1,051.53, monoisotopic mass. 
 
Figure 4.6 MS analyses of oxidized and dehydrated CylLS peptide. (a) MALDI-TOF mass spectrum 
of oxidized CylLS modified by CylM. For oxidized and dehydrated CylLS peptide, calculated M–4H2O: 
7,058, average mass; observed M–4H2O+H
+
: 7,059, average mass. (b) Extracted ion chromatogram (ESI, 
m/z = 1016.5) of the LC trace for oxidized and dehydrated CylLS core peptide with the corresponding 
mass spectrum inserted. Dhb1 was hydrolyzed to a ketone after leader peptide removal, resulting in a 
mass increase of 1 Da. Oxidized and dehydrated CylLS core peptide, calculated [M–4H2O–NH+O+2H]
2+
: 
1,016.00, monoisotopic mass; observed [M–4H2O–NH+O+2H]
2+
: 1,016.00, monoisotopic mass. 
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To rule out the possibility that some E. coli proteins facilitated the Michael-type addition, 
the cyclization reaction of dehydrated CylLS was conducted in vitro. The two cysteines in CylLS 
were first protected as an intramolecular disulfide, and the oxidized CylLS was supplied to CylM 
(Figure 4.5). As no free thiols were available, cyclization could not take place during the 
process. CylM accepted oxidized CylLS as substrate and eliminated four water molecules 
(Figure 4.6), albeit with a lower efficiency compared to linear CylLS. The 4-fold dehydrated 
CylLS peptide was then purified by reversed phase high performance liquid chromatography 
(RP-HPLC) (Figure 4.7). Subsequent incubation with dithiothreitol at pH 7.5 released the thiols 
and allowed the non-enzymatic cyclization to proceed. Free thiols could no longer be detected 
after 12 hours of incubation at room temperature (Figure 4.8). Further treating the peptide with 
the peptidase CylA and analysis of the core peptide using LC-MS again revealed a major peak on 
the LC chromatogram corresponding to fully cyclized CylLS as well as a minor peak with the 
same mass (Figure 4.9a). ESI MS/MS analyses of both products demonstrated the formation of 
the correct ring topology (Figures 4.9b and 4.9c). As a result, the in vitro results are in good 
agreement with the in vivo observations, suggesting that the dehydrated CylLS cyclizes non-
enzymatically into the correct ring topology. 
I next examined the stereochemistry of (Me)Lan residues in non-enzymatically cyclized 
CylLS that was obtained from E. coli. A similar GC-based method was employed as described in 
chapter 2. Signals corresponding to LL-MeLan and DL-Lan were predominantly observed 
(Figure 4.10), suggesting that stereoselective cyclization of dehydrated CylLS could be achieved 
non-enzymatically. A notable LL-Lan peak was also detected in the GC trace, which is not 
observed for CylM-cyclized CylLS (9). This particular LL diastereomer of Lan was attributed to 
a diastereomer of cytolysin S containing an LL-MeLan in the A ring and an LL-Lan in the B 
ring, which corresponds to the minor peak on the LC chromatogram of non-enzymatically 
cyclized CylLS core peptide (Figures 4.3a and 4.9a).  
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Figure 4.7 HPLC traces of CylM (a) and oxidized CylLS modified by CylM (b). 
 
Figure 4.8 NEM analysis of in vitro non-enzymatically cyclized CylLS. Overlaid MALDI-TOF mass 
spectra of dehydrated CylLS (a) (blue trace) and non-enzymatically cyclized CylLS peptide treated with 
NEM (magenta trace). Unmodified CylLS (b) was employed as a control. Two NEM adducts were 
observed for unmodified CylLS that contains two free thiols, whereas no NEM adducts were detected for 
non-enzymatically cyclized CylLS. A large +16 peak was observed after 12 hours of incubation at room 
temperature for non-enzymatically cyclized CylLS, which was attributed to oxidation mainly in the leader 
peptide region, as little such adduct was detected when analyzing the core peptide (see Figure 4.9). For 
oxidized and dehydrated CylLS, calculated M–4H2O: 7,058, average mass; observed M–4H2O+H
+
: 7,059, 
average mass; for non-enzymatically cyclized CylLS treated by NEM, calculated M–4H2O+0NEM: 7,060, 
average mass; observed M–4H2O+0NEM+H
+
: 7,062 and 7,078 (possibly M–4H2O+0NEM+O+H
+
), 
average mass. For unmodifed CylLS, calculated M: 8,883, average mass; observed M+H
+
: 8,883, average 
mass; for unmodifed CylLS treated by NEM, calculated M+2NEM: 9,133, average mass; observed 
M+2NEM+H
+
: 9,134, average mass. 
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Figure 4.9 MS analyses of in vitro non-enzymatically cyclized cytolysin S peptide. (a) Extracted ion 
chromatogram (m/z = 1017) of the LC trace for in vitro non-enzymatically cyclized CylLS core peptide. 
The mass spectrum corresponding to the major peak is shown in the insert. For modified cytolysin S 
peptide, calculated [M–4H2O+2H]
2+
: 1,016.52, monoisotopic mass; observed [M–4H2O+2H]
2+
: 1,016.40, 
monoisotopic mass. (b) ESI MS/MS analysis of the major product of non-enzymatically cyclized 
cytolysin S and a proposed structure deduced from the fragmentation pattern. (c) ESI MS/MS analysis of 
the minor product of non-enzymatically cyclized cytolysin S and a proposed structure deduced from the 
fragmentation pattern. 
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Figure 4.10 GC-MS traces for hydrolyzed/derivatized Lan/MeLan residues obtained from non-
enzymatically cyclized CylLS in E. coli and co-injections with derivatized Lan/MeLan standards 
(selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized 
MeLan residues from non-enzymatically cyclized CylLS. (b) Hydrolyzed and derivatized Lan residues 
from non-enzymatically cyclized CylLS. (c) Hydrolyzed and derivatized MeLan residues from non-
enzymatically cyclized CylLS (red line) and co-injected with derivatized DL-MeLan standard (blue line). 
(d) Hydrolyzed and derivatized MeLan residues from non-enzymatically cyclized CylLS (red line) and co-
injected with derivatized LL-MeLan standard (blue line). (e) Hydrolyzed and derivatized Lan residues 
from non-enzymatically cyclized CylLS (red line) and co-injected with derivatized DD-Lan standard (blue 
line). (f) Hydrolyzed and derivatized Lan residues from non-enzymatically cyclized CylLS (red line) and 
co-injected with derivatized DL-Lan standard (blue line). (g) Hydrolyzed and derivatized Lan residues 
from non-enzymatically cyclized CylLS (red line) and co-injected with derivatized LL-Lan standard (blue 
line). Traces of derivatized Lan and MeLan residues from non-enzymatically cyclized CylLS (red lines) 
used for overlay were adjusted to 70% intensity for clarity.  
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The observations that dehydrated CylLS cyclizes mainly into the correct product without any 
cyclase raised the question whether the CylM cyclase domain is required for cytolysin S 
synthesis. However, both in vitro and in vivo non-enzymatic cyclization resulted in a minor 
product corresponding to a diastereomer of cytolysin S, where the configuration of the Lan 
residue in the B ring was inverted from DL to LL. Therefore, I wondered whether the CylM 
cyclase domain could improve the fidelity for the cyclization of the B ring in CylLS. To test this 
hypothesis, the CylM cyclase domain consisting of residues 626 to 993 and the CylM 
dehydratase domain were expressed together with CylLS and allowed to modify the peptide in 
trans in E. coli. Fully dehydrated and cyclized product was obtained (Figures 4.11 and 4.12), 
and indeed, the minor peak corresponding to the diastereomer of cytolysin S was greatly 
diminished in intensity when analyzing the core peptide by LC-MS (Figure 4.13). The LL-Lan 
signal on the GC chromatogram also returned to a basal level (Figure 4.14), resulting in a similar 
GC trace as what was observed for CylM-modified CylLS. Collectively, these results suggest a 
role of the CylM cyclase domain in CylM-catalyzed modifications with respect to the 
stereochemical fidelity of Lan formation. 
 
 
Figure 4.11 MALDI-TOF mass spectrum for CylLS modified by the CylM dehydratase domain and 
the CylM cyclase domain in trans in E. coli. Calculated M–4H2O: 8,330, average mass; observed M–
4H2O+H
+
: 8,334, average mass. Partial gluconoylation at the N terminus of CylLS occurred when 
expressing the peptide in E. coli BL21(DE3), resulting in a +178 Da peak in addition to the peak with the 
desired mass (22). 
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Figure 4.12 NEM analysis of CylLS modified by CylM dehydratase domain and CylM cyclase 
domain in trans in E. coli. Overlaid MALDI-TOF mass spectra of CylLS modified by CylM dehydratase 
domain and CylM cyclase domain in trans (a) (blue trace) and the peptide treated with NEM (magenta 
trace). Unmodified CylLS (b) was employed as a control. Two NEM adducts were observed for linear 
CylLS that contains two free thiols, whereas no NEM adducts were detected for CylLS modified by CylM 
dehydratase domain and CylM cyclase domain in trans, indicating the peptide was fully cyclized. For 
CylLS modified by CylM dehydratase domain and CylM cyclase domain in trans, calculated M–4H2O: 
8,330, average mass; observed M–4H2O+H
+
: 8,334, average mass; for such a peptide treated with NEM, 
calculated M–4H2O+0NEM: 8,330, average mass; observed M–4H2O+0NEM+H
+
: 8,331, average mass. 
For unmodifed CylLS, calculated M: 8,883, average mass; observed M+H
+
: 8,883, average mass; for 
unmodifed CylLS treated by NEM, calculated M+2NEM: 9,133, average mass; observed M+2NEM+H
+
: 
9,133, average mass. 
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Figure 4.13 ESI MS analyses of cytolysin S peptide modified by CylM dehydratase domain and 
CylM cyclase domain in trans in E. coli. (a) Extracted ion chromatogram (m/z = 1017) of the LC trace 
for CylLS core peptide modified by CylM dehydratase domain and CylM cyclase domain in trans. The 
mass spectrum corresponding to the product peak is shown in the insert. For fully modified CylLS core 
peptide, calculated [M–4H2O+2H]
2+
: 1,016.52, monoisotopic mass; observed [M–4H2O+2H]
2+
: 1,016.51, 
monoisotopic mass. (b) MS/MS analysis of CylLS core peptide that was modified by CylM dehydratase 
domain and CylM cyclase domain in trans and a proposed structure deduced from the fragmentation 
pattern. 
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Figure 4.14 GC-MS traces for hydrolyzed/derivatized Lan/MeLan residues obtained from CylLS 
peptide modified by CylM dehydratase domain and CylM cyclase domain in trans in E. coli and co-
injections with derivatized Lan/MeLan standards (selected ion monitoring, SIM, at 365 Da for Lan 
and 379 Da for MeLan). (a) Hydrolyzed and derivatized MeLan residues from the target peptide. (b) 
Hydrolyzed and derivatized Lan residues from the target peptide. (c) Hydrolyzed and derivatized MeLan 
residues from the target peptide (red line) and co-injected with derivatized DL-MeLan standard (blue 
line). (d) Hydrolyzed and derivatized MeLan residues from the target peptide (red line) and co-injected 
with derivatized LL-MeLan standard (blue line). (e) Hydrolyzed and derivatized Lan residues from the 
target peptide (red line) and co-injected with derivatized DD-Lan standard (blue line). (f) Hydrolyzed and 
derivatized Lan residues from the target peptide (red line) and co-injected with derivatized DL-Lan 
standard (blue line). (g) Hydrolyzed and derivatized Lan residues from the target peptide (red line) and 
co-injected with derivatized LL-Lan standard (blue line). Traces of derivatized Lan and MeLan residues 
from the target peptide (red lines) used for overlay were adjusted to 70% intensity for clarity. A small 
amount of epimerization of (Me)Lan occurs during acid hydrolysis of the peptides as has been reported 
previously (23). 
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As described in chapter 2, the formation of the unusual LL stereochemistry has been linked 
to a “Dhx-Dhx-Xxx-Xxx-Cys” motif present in the substrate peptide, and the second 
dehydroamino acid in such a motif was shown to be important for the stereoselective cyclization 
of the A ring of another lanthipeptide haloduracin β (Halβ) (16). To test whether the second Dhb 
is important for CylM-catalyzed cyclization of the “Dhb-Dhb-Pro-Ala-Cys” sequence (A ring of 
dehydrated CylLS), Thr2 was substituted by Ala in CylLS to investigate if such a mutation would 
result in an inversion of the original LL stereochemistry. CylLS-T2A peptide was modified by 
CylM in E. coli, and the resulting peptide was purified. MALDI-TOF MS analysis indicated the 
desired loss of three water molecules and no free thiols were present in the peptide (Figures 4.15 
and 4.16). The modified CylLS-T2A peptide was then hydrolyzed in acid, derivatized and 
analyzed by GC-MS. Surprisingly, signals corresponding to LL-MeLan and DL-Lan were 
exclusively detected (Figure 4.17), similar to what is observed for wild type cytolysin S. The 
selective formation of LL-MeLan in the A ring of CylLS-T2A by CylM can be explained in two 
ways: 1) the second Dhb is not a crucial component for the “Dhb-Dhb-Pro-Ala-Cys” sequence to 
form an LL-MeLan; and/or 2) the synthetase CylM has a preference for the LL stereochemistry 
and catalyzes the formation of LL-MeLan even when the second Dhb is missing in the substrate 
motif. 
To attempt to differentiate these two possibilities, I employed the non-enzymatic cyclization 
system described above and expressed CylLS-T2A together with the CylM dehydratase domain 
in E. coli. As expected three dehydrations were observed, corresponding to fully dehydrated 
CylLS-T2A (Figure 4.18). However, NEM analysis indicated one of the two thiols in the peptide 
remained free, different from what was observed previously for wild type CylLS modified by the 
CylM dehydratase domain and for CylLS-T2A modified by full length CylM (Figure 4.19). 
Further removal of the leader peptide and MS analysis of the resulting mutated core peptide 
confirmed that it was the A ring that was not properly cyclized as hydrolysis of the N-terminal 
Dhb to 2-oxobutyrate was exclusively observed (Figure 4.20). The partially cyclized CylLS-T2A 
peptide was purified and non-enzymatic cyclization of the A ring was pursued in vitro. 
Unfortunately, little ring closure activity was observed after 15 hours of incubation at pH 9 
(Figure 4.21). Collectively, these results suggest that the cyclization of the A ring of dehydrated 
CylLS-T2A requires the cyclase activity of CylM, and that non-enzymatic cyclization is greatly 
aided by the second Dhb in the “Dhb-Dhb-Pro-Ala-Cys” motif. 
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Figure 4.15 MALDI-TOF mass spectrum of CylLS-T2A modified by CylM in E. coli. Calculated M–
3H2O: 8,318, average mass; observed M–3H2O+H
+
: 8,318, average mass.  
 
Figure 4.16 NEM analysis of CylM-modified CylLS-T2A peptide. Overlaid MALDI-TOF mass spectra 
of CylM-modified CylLS-T2A (a) (blue trace) and the peptide treated with NEM (magenta trace). 
Unmodified CylLS (b) was employed as a control. Two NEM adducts were observed for linear CylLS that 
contains two free thiols, whereas no NEM adducts were detected for CylM-modified CylLS-T2A, 
indicating that both cysteines in the peptides are involved in (Me)Lan rings. For CylM-modified CylLS-
T2A, calculated M–3H2O: 8,318, average mass; observed M–3H2O+H
+
: 8,319, average mass; for CylM-
modified CylLS-T2A treated by NEM, calculated M–3H2O+0NEM: 8,318, average mass; observed M–
3H2O+0NEM+H
+
: 8,317, average mass. For unmodifed CylLS, calculated M: 8,883, average mass; 
observed M+H
+
: 8,883, average mass; for unmodifed CylLS treated by NEM, calculated M+2NEM: 
9,133, average mass; observed M+2NEM+H
+
: 9,132, average mass. 
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Figure 4.17 GC-MS traces for hydrolyzed and derivatized Lan/MeLan residues obtained from 
CylM-modified CylLS–T2A in E. coli and co-injections with derivatized Lan/MeLan standards 
(selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized 
MeLan residues from CylM-modified CylLS–T2A. (b) Hydrolyzed and derivatized Lan residues from 
CylM-modified CylLS–T2A. (c) Hydrolyzed and derivatized MeLan residues from CylM-modified 
CylLS–T2A (red line) and co-injected with derivatized DL-MeLan standard (blue line). (d) Hydrolyzed 
and derivatized MeLan residues from CylM-modified CylLS–T2A (red line) and co-injected with 
derivatized LL-MeLan standard (blue line). (e) Hydrolyzed and derivatized Lan residues from CylM-
modified CylLS–T2A (red line) and co-injected with derivatized DD-Lan standard (blue line). (f) 
Hydrolyzed and derivatized Lan residues from CylM-modified CylLS–T2A (red line) and co-injected with 
derivatized DL-Lan standard (blue line). (g) Hydrolyzed and derivatized Lan residues from CylM-
modified CylLS–T2A (red line) and co-injected with derivatized LL-Lan standard (blue line). Traces of 
derivatized Lan and MeLan residues from CylM-modified CylLS–T2A (red lines) used for overlay were 
adjusted to 70% intensity for clarity. A small amount of epimerization of (Me)Lan occurs during acid 
hydrolysis of the peptides as has been reported previously (23). 
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Figure 4.18 MALDI-TOF mass spectrum for CylLS-T2A peptide modified by the CylM 
dehydratase domain in E. coli. Calculated M–3H2O: 8,318, average mass; observed M–3H2O+H
+
: 
8,319, average mass. A small +307 peak is attributed to a glutathione (GSH) addition to the peptide. 
 
Figure 4.19 NEM analysis of CylLS-T2A peptide modified by the CylM dehydratase domain in E. 
coli. Overlaid MALDI-TOF mass spectra of CylLS-T2A modified by the CylM dehydratase domain (a) 
(blue trace) and the peptide treated with NEM (magenta trace). Unmodified CylLS (b) was employed as a 
control. Two NEM adducts were observed for linear CylLS that contains two free thiols, whereas one 
NEM adduct was detected for CylLS-T2A modified by the CylM dehydratase domain, indicating that one 
of the two cysteines in the peptide was free. For CylLS-T2A modified by the CylM dehydratase domain, 
calculated M–3H2O: 8,318, average mass; observed M–3H2O+H
+
: 8,319, average mass; for CylLS-T2A 
modified by CylM dehydratase domain and treated with NEM, calculated M–3H2O+1NEM: 8,443, 
average mass; observed M–3H2O+1NEM+H
+
: 8,444, average mass. For unmodifed CylLS, calculated M: 
8,883, average mass; observed M+H
+
: 8,883, average mass; for unmodifed CylLS treated by NEM, 
calculated M+2NEM: 9,133, average mass; observed M+2NEM+H
+
: 9,133, average mass. 
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Figure 4.20 MALDI-TOF mass spectrum of the core peptide of CylLS–T2A modified by the CylM 
dehydratase domain in E. coli. Hydrolysis of Dhb1 to 2-oxobutyrate resulted in a mass increase of 1 Da. 
Calculated M–3H2O–NH+O: 2,020.0, monoisotopic mass; observed M–3H2O–NH+O+H
+
: 2,020.8, 
monoisotopic mass.  
 
Figure 4.21 Non-enzymatic cyclization of dehydrated and partially cyclized CylLS-T2A peptide in 
vitro. Overlaid MALDI-TOF mass spectra of CylLS-T2A modified by CylM dehydratase domain (a) 
(blue trace) and the peptide incubated at basic pH to facilitate non-enzymatic cyclization and treated with 
NEM (magenta trace). Unmodified CylLS (b) was employed as a control. Two NEM adducts were 
observed for linear CylLS that contains two free thiols, whereas one NEM adduct was dominantly 
detected for the target peptide, indicating that non-enzymatic cyclization of the A ring hardly proceeded 
under the tested condition. For dehydrated and partially cyclized CylLS-T2A, calculated M–3H2O: 8,318, 
average mass; observed M–3H2O+H
+
: 8,319, average mass; for dehydrated and partially cyclized CylLS-
T2A treated with NEM, calculated M–3H2O+1NEM: 8,443, average mass; observed M–
3H2O+1NEM+H
+
: 8,444, average mass. For unmodifed CylLS, calculated M: 8,883, average mass; 
observed M+H
+
: 8,883, average mass; for unmodifed CylLS treated by NEM, calculated M+2NEM: 
9,133, average mass; observed M+2NEM+H
+
: 9,134, average mass. 
87 
 
These results seem to argue against to the first explanation as the property of the mutated A 
ring of CylLS is clearly different from the original sequence. However, it is not conclusive 
whether the capability of cyclizing the “Dhb-Ala-Pro-Ala-Cys” sequence in CylLS-T2A to form 
an LL-MeLan residue is a specific property of CylM that differs from other LanM proteins. To 
answer this question, I tested whether a different LanM, the Halβ synthetase HalM2, would 
modify CylLS-T2A to form an LL-MeLan in the A ring. A gene encoding a chimeric peptide 
with the leader peptide of Halβ connected to the CylLS-T2A core peptide was constructed and 
coexpressed with halM2 in E. coli. HalM2 carried out the desired three dehydrations of the 
CylLS-T2A core peptide (Figure 4.22). The efficiency of the cyclization reaction was evaluated 
using the NEM assay. Partially cyclized HalA2-CylLS-T2A peptide with one free thiol was 
detected almost exclusively (Figure 4.23), suggesting that HalM2 is inefficient in catalyzing the 
cyclization of the A ring of dehydrated CylLS-T2A. Further GC-MS analysis indicated that only 
a very small amount of A ring was formed as much lower signal intensity was observed for 
MeLan compared to Lan. For the peptide with a cyclized A ring, both LL- and DL-MeLan were 
detected and the DL-MeLan-containing peptide appeared to be the major product (60%) (Figure 
4.24). As expected, a signal corresponding to DL-Lan was exclusively detected for Lan on the 
GC chromatogram (Figure 4.24). These data suggest that HalM2 is inefficient in cyclizing the 
“Dhb-Ala-Pro-Ala-Cys” sequence in the CylLS-T2A peptide, and that the stereoselectivity of 
HalM2 with respect to such a substrate sequence is different from that of CylM. 
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Figure 4.22 MALDI-TOF mass spectrum for HalA2-CylLS-T2A modified by HalM2 in E. coli. 
Calculated M–3H2O: 8,029, average mass; observed M–3H2O+H
+
: 8,029, average mass. Partial 
gluconoylation at the N terminus occurred when expressing the peptide in E. coli BL21(DE3), resulting in 
a +178 Da peak in addition to the peak with the desired mass (22). The small +307 peak is attributed to a 
glutathione (GSH) addition to HalM2-modified HalA2-CylLS-T2A peptide. 
 
Figure 4.23 NEM analysis of HalA2-CylLS-T2A peptide modified by HalM2 in E. coli. Overlaid 
MALDI-TOF mass spectra of HalM2-modified HalA2-CylLS-T2A (a) (blue trace) and the peptide treated 
with NEM (magenta trace). Unmodified CylLS (b) was employed as a control. Two NEM adducts were 
observed for linear CylLS that contains two free thiols, whereas one NEM adduct was detected for 
HalM2-modified HalA2-CylLS-T2A almost exclusively, indicating that one of the two cysteines in the 
peptide was not cyclized. For HalM2-modified CylLS-T2A, calculated M–3H2O: 8,029, average mass; 
observed M–3H2O+H
+
: 8,029, average mass; for HalM2-modified CylLS-T2A treated with NEM, 
calculated M–3H2O+1NEM: 8,154, average mass; observed M–3H2O+1NEM+H
+
: 8,155, average mass. 
For unmodifed CylLS, calculated M: 8,883, average mass; observed M+H
+
: 8,883, average mass; for 
unmodifed CylLS treated by NEM, calculated M+2NEM: 9,133, average mass; observed M+2NEM+H
+
: 
9,133, average mass. 
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Figure 4.24 GC-MS traces for hydrolyzed/derivatized Lan/MeLan residues obtained from HalM2-
modified HalA2-CylLS–T2A in E. coli and co-injections with derivatized Lan/MeLan standards 
(selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan). (a) Hydrolyzed and derivatized 
MeLan residues from HalM2-modified HalA2-CylLS–T2A. (b) Hydrolyzed and derivatized Lan residues 
from HalM2-modified HalA2-CylLS–T2A. (c) Hydrolyzed and derivatized MeLan residues from HalM2-
modified HalA2-CylLS–T2A (red line) and co-injected with derivatized DL-MeLan standard (blue line). 
(d) Hydrolyzed and derivatized MeLan residues from HalM2-modified HalA2-CylLS–T2A (red line) and 
co-injected with derivatized LL-MeLan standard (blue line). (e) Hydrolyzed and derivatized Lan residues 
from HalM2-modified HalA2-CylLS–T2A (red line) and co-injected with derivatized DD-Lan standard 
(blue line). (f) Hydrolyzed and derivatized Lan residues from HalM2-modified HalA2-CylLS–T2A (red 
line) and co-injected with derivatized DL-Lan standard (blue line). (g) Hydrolyzed and derivatized Lan 
residues from HalM2-modified HalA2-CylLS–T2A (red line) and co-injected with derivatized LL-Lan 
standard (blue line). Traces of derivatized Lan and MeLan residues from HalM2-modified HalA2-CylLS–
T2A (red lines) used for overlay were adjusted to 70% intensity for clarity. A small amount of 
epimerization of Lan occurs during acid hydrolysis of the peptides as has been reported previously (23). 
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4.3 Discussion 
In this chapter, I reconstituted the non-enzymatic cyclization of CylLS, both in E. coli and in 
vitro using a dehydrated peptide and confirmed that the dehydratase and cyclase activities of 
CylM can be independently accessed using truncated CylM proteins. The in vitro auto-
cyclization of dehydrated CylLS proceeded efficiently at nearly neutral pH, which was 
unexpected before this work because of results obtained for another group of lanthipeptides, the 
prochlorosins, where the non-enzymatically catalyzed Michael-type addition required a higher 
pH to activate the thiols and was extremely slow, especially for the formation of MeLan residues 
(24). These observations suggest that dehydrated CylLS adopts a pre-organized conformation in 
which the cysteine thiols have increased reactivity towards the dehydroamino acids, which 
allows the cyclization to proceed even in the absence of a catalyst. Previous computational 
simulation of the dehydrated A ring of CylLS demonstrated that the overall geometry of the 
optimal transition state structure of such a sequence for a Re-face cyclization efficiently 
stabilizes the negative charge of the enolate intermediate (16), which accounts significantly for 
the lower activation energy barrier for the Michael-type addition to yield LL stereochemistry and 
might be the reason why this reaction can proceed efficiently without a cyclase.  
Moreover, the formation of the correct ring topology for CylLS by non-enzymatic 
cyclization supports a previous hypothesis of substrate-controlled selectivity for lanthipeptide 
biosynthesis and suggests that both regioselectivity and stereoselectivity for cytolysin S synthesis 
are encoded in the CylLS sequence (25). There are in total 144 possible products for the 
cyclization process of dehydrated CylLS, considering different ring topologies and 
stereochemistries of (Me)Lan residues with a fixed L configuration for the former Cys residue 
that does not alter during the process. However, only one major product was observed for CylLS 
that was cyclized non-enzymatically, indicating that dehydrated CylLS has a sufficiently well-
organized scaffold that the preferred product out competes the other 143 possibilities and 
dominates the reaction (Figures 4.25 and 4.26). Collectively, these observations reinforce the 
idea of substrate-controlled reactivity and selectivity for lanthipeptide biosynthesis.  
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Figure 4.25 GC-MS traces for hydrolyzed and derivatized (Me)Lan residues from CylLS and 
CylLS–T2A peptides that are cyclized using different set ups. Gas chromatograms showing signals 
corresponding to derivatized MeLan (left panel) and Lan (right panel) residues from CylLS peptides 
cyclized by CylM (black trace) (9), by the CylM cyclase domain (blue trace) or without a cyclase (brown 
trace), and CylLS–T2A peptide cyclized by CylM (magenta trace) were overlaid.  
 
 
Figure 4.26 Summary of the CylLS and CylLS–T2A peptides that are cyclized under different 
conditions. Generic protein structures are shown for CylM, HalM2, CylM dehydratase domain and CylM 
cyclase domain. Ring topologies of the final products were deduced form MS/MS fragmentation patterns, 
whereas configurations of (Me)Lan rings were assigned using GC-MS. Ratio of product mixture was 
estimated based on integration results of LC trace (for non-enzymatically cyclized CylLS) or GC trace (for 
HalM2-modified CylLS–T2A peptide with cyclized A ring). LP: leader peptide. 
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The second dehydroamino acid in a “Dhx-Dhx-Xxx-Xxx-Cys” motif has been proposed to 
be crucial for the formation of an LL-(Me)Lan as mutation of the second Dhb to Ala resulted in 
an inversion of the LL stereochemistry to DL for the A ring of Halβ cyclized by HalM2 (9). 
However, CylM cyclizes the A ring of CylLS-T2A to form an LL-MeLan residue even when the 
second Dhb is missing (Figures 4.25 and 4.26). Unfortunately, the “Dhb-Ala-Pro-Ala-Cys” 
sequence was very unreactive towards non-enzymatic cyclization and cyclization by HalM2 
(Figure 4.26). However, the limited amount of HalM2-cyclized product contained 
predominantly the DL stereochemistry. These observations imply coevolution of CylM with its 
substrate to promote stereoselective MeLan synthesis in the A ring of CylLS. This coevolution 
phenomenon distinguishes CylM from other lanthionine synthetases, including those that also 
catalyze the formation of LL stereochemistry in their substrates. Specifically, HalM2 appears to 
not have been optimized because it could no longer maintain the LL configuration when the 
second dehydroamino acid is missing in HalA2. In this case, the synthetase may only be 
responsible for activating the cysteine thiol for the Michael-type addition, whereas the selective 
formation of the LL stereochemistry is only induced by the substrate sequence (Figure 4.27). A 
minor product corresponding to a diastereomer of cytolysin S with an LL B ring was observed 
for the non-enzymatically cyclized CylLS, which was not detected if the CylM cyclase domain 
was supplied in the reaction (Figures 4.25 and 4.26), suggesting a role of the cyclase domain of 
CylM with respect to the stereoselective ring closure for the B ring of CylLS. Collectively, these 
observations indicate that the stereoselectivity of CylM is more complicated than a simple 
preference for a certain configuration. 
The reason why CylM coevolved with its substrates to introduce the LL stereochemistry 
remains unknown. Both units of cytolysin contain the unusual LL stereochemistry, and cytolysin 
is unique in the lanthipeptide family for its lytic activity against eukaryotic cells (7, 9). The 
unusual LL stereochemistry may therefore be an essential feature that accounts for the virulence 
of cytolysin. However, whether there is a structure-activity correlation between the unusual LL 
stereochemistry and the toxin activity of cytolysin requires further investigation.  
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Figure 4.27 Hypothetic substrate patches on lanthionine synthetases that favor the formation of 
either DL or LL stereochemistry. In the proposed model, the majority of LanMs have substrate grooves 
on the protein surface that are optimized for the formation of DL-(Me)Lan (blue ribbons, upper panel). 
The specific motif “Dhx-Dhx-Xxx-Xxx-Cys” may introduce a turn in the substrate which forces a Re face 
addition onto the reacting Dhx, resulting in the formation of the LL stereochemistry (blue ribbons, middle 
panel). The stereoselectivity cannot be maintained once the structural-determining Dhx (non-reacting) is 
missing in the substrate as the enzyme groove has not been evolved to favor the formation of the LL 
stereochemistry. However, some LanMs, like CylM, may have coevolved with their substrates to contain 
a specific substrate patch optimized for LL ring closure (red ribbons, lower panel), which allows the 
formation of the unusual LL stereochemistry even the substrate induced turn is absent. 
94 
 
4.4 Methods 
General methods 
Similar general methods and materials as what were described in chapter 2 were employed 
in this chapter unless specified otherwise. LC-ESI-Q/TOF MS and MS/MS analyses were 
conducted using a Synapt G2S instrument with an Acquity UPLC system (Waters), which was 
equipped with a BEH C18 column (1.7 µm; 130Å; 50 x 2.1 mm; Waters). GC-MS analysis was 
performed in the Mass Spectrometry Laboratory (School of Chemical Sciences, UIUC) or the 
Roy J. Carver Metabolomics Center (UIUC) on an Agilent 7890 gas chromatograph with a CP-
Chirasil-L-Val fused silica column (25 m x 0.25 mm x 0.15 µm) (Agilent). An Agilent 1260 
Infinity Quaternary LC System was employed for analytical scale HPLC, whereas preparative 
HPLC was performed using a Waters Delta 600 instrument. Solid phase extraction was carried 
out with Strata-X polymeric RP columns (Phenomenex). Expression vector pET15b was 
obtained from Novagen. 
 
Construction of the pRSFDuet-1/CylLS/CylM-1-625-2 plasmid 
The cylLS gene was cloned into the multiple cloning site 1 (MCS1) of a pRSFDuet-1 vector, 
resulting in a pRSFDuet-1/CylLS plasmid. The cylM-1-625 gene was amplified from the 
pRSFDuet-1/CylM plasmid and cloned into the MCS2 of pRSFDuet-1/CylLS to generate 
pRSFDuet-1/CylLS/CylM-1-625-2. Primer sequences are listed in Table 4.1. 
 
Construction of the pACYCDuet-1/ CylM-626-993-2 plasmid 
The cylM-626-993 gene was amplified from the pRSFDuet-1/CylM plasmid and cloned into 
the MCS2 of a pACYCDuet-1 vector to generate pACYCDuet-1/CylM-626-993-2. Primer 
sequences are listed in Table 4.1. 
 
Construction of pRSFDuet-1 derivatives for coexpression of CylM with CylLS-T2A, HalM2 
with HalA2-CylLS-T2A, and CylM-1-625 with CylLS-T2A 
The genes cylLS-T2A and halA2-CylLS-T2A are generated using overlap extension PCR 
based on cylLS and halA2 and cloned into the MCS1 of plasmids pRSFDuet-1/CylM-2 (9), 
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pRSFDuet-1/HalM2-2 (26) and pRSFDuet-1/CylM-1-625-2, respectively, resulting in 
pRSFDuet-1/CylLS-T2A/CylM-2, pRSFDuet-1/HalA2-CylLS-T2A/HalM2-2 and pRSFDuet-
1/CylLS-T2A/CylM-1-625-2. Primer sequences are listed in Table 4.1. 
 
Table 4.1 Primer sequences used in this chapter.  
Primer Name Primer Sequence (5'-3') 
HalA2_BamHI_FP AAAAA GGATCC G ATGGTAAATT CAAAAGATTT 
CylLS_EcoRI_FP AAAAA GAATTCG CTGAATA AAGAAAATCA G 
CylLS_NotI_RP AAAAA GCGGCCGC TTAGCAA AATTTTGCGC T 
CylLS_BamHI_FP AAAAA GGATCCG CTGAATA AAGAAAATCA G 
CylLS_HindIII_RP AAAAA AAGCTT TTAGCAA AATTTTGCGC T 
CylLS_Leader_RP T TCTGCCTGAA CATCACCGCT 
CylLS_T2A_FP GATGTTCAGGCAGAAACCGCACCGGCATGTTTTACCATTGGT 
HalA2_Leader_RP TTGTGCAT GCACATCTCC TGA 
HalA2_CylLS_T2A _FP GATGTGCATGCACAA ACC GCA CCGGCATGTTTTACC ATTGGT 
CylM_NdeI_FP AAAAA CATATG GAAGATA ATCTGATTAA T 
CylM_KpnI_RP AAAAA GGTACC TTACAGT TCAAACAGCA G 
CylM625_KpnI_RP AAAAA GGTACC TTA GTACGGGTTA TAAATATTCA G 
CylM626_NdeI_FP  AAAAA CATATG TATATCAATGATCTGAAAAAC 
 
Production and purification of His6-CylLS modified by CylM dehydratase domain, His6-
CylLS–T2A modified by CylM, His6-CylLS–T2A modified by CylM dehydratase domain 
and His6-HalA2-CylLS–T2A modified by HalM2 
E. coli BL21 (DE3) cells were transformed with the pRSFDuet-1/CylLS/CylM-1-625-2, 
pRSFDuet-1/CylLS-T2A/CylM-2, pRSFDuet-1/HalA2-CylLS-T2A/HalM2-2 and pRSFDuet-
1/CylLS-T2A/CylM-1-625-2 plasmids, and plated on an LB plate containing 50 mg/L 
kanamycin. A single colony was picked and grown in 10 mL of LB with 50 mg/L kanamycin 
aerobically at 37 
o
C for 10-16 h and the resulting culture was used to inoculate 1 L of LB. Cells 
were cultured at 37 
o
C until the OD at 600 nm reached 0.5, cooled to ~ 10 
o
C and IPTG was 
added to a final concentration of 0.1 mM. The culture was allowed to grow at 18 
o
C for another 
18 h before harvesting. The cell pellet was resuspended at room temperature in LanA start buffer 
(500 mM NaCl, 0.5 mM imidazole, 20% glycerol, 20 mM NaH2PO4, pH 7.5 at 25
 o
C) or LanA 
buffer 1 (6 M guanidine hydrochloride, 500 mM NaCl, 0.5 mM imidazole, 20 mM NaH2PO4, pH 
7.5 at 25
 o
C) followed by lysis via sonication. The lysed sample was then centrifuged at 
23,700×g for 30 min and the supernatant was passed through 0.45-µm syringe filters. His-tagged 
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modified peptides were purified by immobilized metal affinity chromatography (IMAC) loaded 
with nickel as previously described (27). The eluted fractions with the desired peptide were 
desalted by preparative RP-HPLC using a Waters Delta-pak C4 column (15 µm; 300 Å; 25 x 100 
mm) or by Strata-X polymeric RP solid phase extraction columns (Phenomenex). The desalted 
peptides were lyophilized and stored at −20 oC for future use. 
 
Production and purification of His6-CylLS modified by CylM dehydratase domain and 
CylM cyclase domain in trans 
E. coli BL21 (DE3) cells were transformed with both pRSFDuet-1/CylLS/CylM-1-625-2 and 
pACYCDuet-1/CylM-626-993-2 plasmids, and plated on an LB plate containing 50 mg/L 
kanamycin and 25 mg/L chloramphenicol. A single colony was picked for overexpression 
purposes. A similar procedure as that was described above was employed for expression and 
purification of the modified peptide. 
 
Overexpression and purification of His6-CylLS and His6-CylM 
Same procedure was followed for expression and purification of His6-CylLS peptide and 
His6-CylM protein as described in chapter 5 (19). 
 
Production and purification of oxidized and dehydrated CylLS 
His6-CylLS was expressed in E. coli and purified in its oxidized form with an intramolecular 
disulfide (see main text for more information). Due to high hydrophobicity, the peptide solubility 
in aqueous phase is poor. It could not dissolve completely in water even at low µM 
concentrations. As a result, a suspension of 2 mg/mL peptide was made for His6-CylLS as a stock 
solution. The peptide stock was vortexed to a homogenized suspension each time before any 
peptide was taken. However, given the presence of precipitation, the peptide concentration could 
not be tightly controlled.  
To a reaction vessel containing 50 mM HEPES (pH = 7.5), 10 mM MgCl2, 5 mM ATP and 
10
-5
 U thrombin (for in situ removal of the His-tag), 150 µM of His6-CylLS was supplied 
followed by the addition of CylM to a final concentration of 2 µM. The reaction was allowed to 
proceed at room temperature for more than 24 h and complete loss of four water molecules in 
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CylLS was confirmed by MALDI-TOF MS. Subsequent separation of oxidized and dehydrated 
CylLS from CylM was achieved by analytical scale HPLC. Solvents used for the HPLC 
purification were: solvent A = 0.1% trifluoroacetic acid (TFA) in ddH2O and solvent B = 0.086% 
TFA in 80% acetonitrile/20% ddH2O. The reaction mixture was applied onto a Jupiter Proteo 
C12 column (5 µm; 90 Å; 250 x 4.6 mm; Phenomenex) and subsequent elution was carried out 
using a linear gradient from 2% to 100% B over 45 min. Fractions containing the desired peptide 
product were collected, lyophilized to dryness and kept at −20 oC until future usage. 
 
In vitro non-enzymatic cyclization of dehydrated CylLS 
Oxidized and dehydrated CylLS obtained using the above described procedure was dissolved 
in ddH2O to make a solution. The peptide could not be quantified by weighing as very limited 
amount of materials was obtained after HPLC purification. A concentration of 20~200 µg/mL 
was estimated based on the peak absorbance at 220 nm during HPLC purification. To such a 
peptide solution, 50 mM HEPES (pH = 7.5) and 5 mM DTT were added. The reaction was 
allowed to proceed at room temperature for 12 h before analysis. A parallel reaction with 20 µM 
unmodified CylLS was set up as a control. 
For non-enzymatic cyclization of the A ring of dehydrated and partially cyclized CylLS-
T2A, 40 µM peptide was supplied to a reaction system containing 10 mM DTT and 50 mM Tris 
buffer (pH = 8.9). The reaction was incubated at room temperature for 15 h before analysis by 
NEM assay. A parallel reaction with 20 µM unmodified CylLS was set up as a control. 
 
NEM analysis 
For pure peptide samples, a two-step reaction was employed for NEM analysis, including a 
reduction step and a subsequent alkylation reaction. The typical set up for the reduction reaction 
included 0.3~0.6 mg/mL (30~80 µM) target peptides, 50 mM phosphate buffer (pH = 5.5) and 5 
mM TCEP (tris(2-carboxyethyl)phosphine). The reaction mixture was kept at room temperature 
for 2 to 6 h to reduce all disulfide linkages in the peptide samples. Subsequent addition of 100 
mM phosphate buffer (pH = 7.2) adjusted the pH of the reaction mixture to 6.5~7.0, to which 
NEM was added to a final concentration of 10 mM. The alkylation reaction was allowed to 
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proceed at 37 
o
C for 5 min before analysis by MALDI-TOF MS. Parallel reactions using 
unmodified His6-CylLS (20 µM) were always performed as a positive control. 
For NEM analysis of in vitro cyclized CylLS, 10 mM NEM was directly added into a 
reaction aliquot (the peptide was in its reduced form) and incubated at 37 
o
C for 5 min before 
analysis. A parallel reaction using unmodified CylLS treated with the same procedure (described 
in the previous section) was employed as a positive control. 
For NEM analysis of in vitro cyclization trials for CylLS-T2A (for the A ring), 100 mM 
HEPES buffer (pH = 6.5) was added into a reaction aliquot to bring the pH to ~ 7, followed by 
the addition of 10 mM NEM. The alkylation reaction was incubated at 37 
o
C for 5 min before 
analysis. A parallel reaction using unmodified CylLS treated with the same procedure (described 
in the previous section) was employed as a positive control. 
 
Leader peptide removal of CylLS and CylLS-T2A peptides  
To a peptide solution or a reaction mixture with a buffered pH around 7.5, 0.01~0.1 mg/mL 
CylA was added. DTT was supplied to a final concentration of 5 mM when desired. The reaction 
was allowed to proceed at room temperature for 1~6 h before analysis. Complete consumption of 
the full length peptide was confirmed by MALDI-TOF MS. 
 
LC-ESI-Q/TOF MS and MS/MS analyses 
Peptide samples of 100~500 ng (approximated by precursor peptide weight) were applied 
onto a BEH C18 column (1.7 µm; 130Å; 50 x 2.1 mm; Waters) that was pre-equilibrated in 
aqueous solvent A. The solvents used for LC were: solvent A = 0.1% formic acid in 95% 
ddH2O/5% acetonitrile and solvent B = 0.1% formic in 5% ddH2O/95% acetonitrile. Flow rate 
was set to 0,5 or 0.3 mL/min. A linear gradient from 0% to 60% B was employed from 0.5 min 
to 12.5 min and the fractionated sample was directly subjected to ESI-Q/TOF MS analysis using 
a Waters Synapt G2S mass spectrometer. The mass spectrometer was calibrated before any 
sample was injected. Data were acquired in ESI positive mode. The trap collision energy was set 
to 6 V for MS analysis. For MSMS analysis, a trap collision energy ramp ranging from 20-30 V 
was applied on 2+ parent ions to achieve fragmentation. Leucine-enkephalin was directly infused 
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as lock mass with lock spray sampling. The acquired spectra were processed using MaxEnt3 
software and analyzed by Protein/Peptide Editor in BioLynx 4.1 (Waters). 
 
GC-MS analysis 
The synthesis of Lan and MeLan standards and the preparation of samples for GC-MS 
analysis were carried out following a reported procedure published elsewhere (28, 29). The 
modified full length peptides with their leader peptides attached were hydrolyzed and the 
resulting solutions were dried and directly used for derivatization. The derivatized samples were 
analyzed by GC-MS using an Agilent 7890 gas chromatograph equipped with a CP-Chirasil-L-
Val fused silica column (25 m x 0.25 mm x 0.15 µm). Samples were dissolved in methanol and 
introduced to the instrument via a split (1:5 or 1:20) injection at a flow rate of 1.7 mL/min or 2.0 
mL/min helium gas. The temperature method used was 160 
o
C for 2 min, 160 
o
C to 180 
o
C at 3 
o
C/min, and 180 
o
C for 2 min. The selected-ion monitoring (SIM) was achieved by extracting the 
total ion spectra for peaks containing the characteristic fragment masses of 365 Da for Lan and 
379 Da for MeLan residues. 
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Chapter 5. Mechanistic Studies of the Enterococcal Cytolysin Synthetase 
CylM 
  
5.1 Introduction 
Cytolysin is produced by many clinical isolates of Enterococcus faecalis and consists of two 
lanthipeptides (cytolysin L and S) (1, 2). For more details about the clinical importance of the 
enterococcal cytolysin and the biosynthesis of lanthipeptides, see chapters 1 and 2. The two-step 
post-translational modification of cytolysin that includes dehydration and cyclization of the 
precursor peptides CylLL and CylLS is catalyzed by CylM, a bifunctional lanthionine synthetase. 
At present at least four distinct routes to lanthipeptides have been discovered, illustrating 
that the cyclic thioether motif is a privileged structural scaffold that has been independently 
accessed multiple times during evolution (3). These four routes differ primarily in the 
mechanism of dehydration (section 1.3 of chapter 1). For the class I, III, and IV lanthipeptides, 
the mechanism of dehydration has been illuminated by crystallographic characterization of the 
dehydratases or close sequence homologs (4-7), but the mechanism of dehydration for class II 
lanthipeptide synthetases that include CylM has remained enigmatic as the enzymes do not show 
any sequence homology with other proteins and structural information has not been available. In 
this work, the structure of CylM was determined, which demonstrates that the dehydration 
domain of this enzyme has structural similarity with eukaryotic lipid kinases despite the absence 
of notable sequence homology (crystalization and structural elucidation of CylM were performed 
by Dr. Shi-Hui Dong and Prof. Satish K. Nair). Structure-based generation of mutants provided 
insights into the mechanism of dehydration. 
 
5.2 Results 
5.2.1 In vitro reconstitution of CylM activity 
Previously, I showed that CylM could dehydrate and cyclize its substrates, CylLL and CylLS, 
in Escherichia coli (chapter 2) (8). To investigate the elusive mechanism of dehydration, I also 
reconstituted the CylM activity in vitro. CylM and its substrate peptides were expressed in E. 
coli as N-terminal hexahistidine-tagged proteins and purified by metal affinity chromatography 
(Figure 5.1). Incubation of His6-CylM with CylLL or CylLS in the presence of dithiothreitol, 
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MgCl2, and ATP demonstrated the expected dehydration and cyclization of the peptides (Figure 
5.2). Subsequent removal of the leader peptides of modified CylLL or CylLS was achieved by 
CylA, the dedicated serine protease encoded by the cytolysin biosynthetic pathway (chapter 7). 
Electrospray ionization (ESI) MS analysis confirmed a mass shift of 144 or 126 Da for CylLL, 
corresponding to a loss of 8 or 7 water molecules, with the 7-dehydrated peptide as the major 
product, and a mass shift of 72 Da for CylLS, corresponding to a loss of 4 water molecules 
(Figure 5.3). These results are consistent with the reported mass of CylLL” and CylLS” as well as 
my previous observations using an E. coli coexpression system, where 7 dehydrations and 4 
dehydrations were detected (chapter 2) (8, 9). Tandem MS (MS/MS) analysis indicated the 
desired ring systems were formed for both peptides (Figure 5.4). 
 
Figure 5.1 SDS-PAGE image of purified His6-CylM. Theoretical molecular weight: 118 kDa. 
 
Figure 5.2 MALDI/TOF mass spectra for CylLL (a) and CylLS (b) peptides incubated with 
(magenta traces) or without (blue traces) CylM. Linear CylLL, calculated M: 7,082, average mass; 
observed M+H
+
: 7,084, average mass. CylM modified CylLL, calculated M–7H2O: 6,956, average mass; 
observed M–7H2O+H
+
: 6,958, average mass. CylLS, calculated M: 7,132, average mass; observed M+H
+
: 
7,134, average mass. CylM modified CylLS, calculated M–4H2O: 7,060, average mass; observed M–
7H2O+H
+
: 7,062, average mass. 
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Figure 5.3 ESI/Q-TOF mass spectra for CylLL (a) and CylLS (b) core peptides modified by CylM in 
vitro. [M+3H]
3+
 ion is shown for the CylLL core peptide and [M+2H]
2+
 ion is shown for the CylLS core 
peptide. CylM modified CylLL core peptide, calculated [M–7H2O+3H]
3+
: 1146.2, monoisotopic mass; 
observed [M–7H2O+3H]
3+
: 1146.2, monoisotopic mass. CylM modified CylLS core peptide, calculated 
[M–4H2O+2H]
2+
: 1016.5, monoisotopic mass; observed [M–4H2O+2H]
2+
: 1016.5, monoisotopic mass. 
 
Figure 5.4 MS/MS analysis of CylLL (a) and CylLS (b) core peptides modified by CylM in vitro. 
 
5.2.2 Structure of CylM 
To further investigate the mechanism for both dehydration and cyclization afforded by a 
single enzyme, the 2.3 Å resolution structure of CylM, in complex with AMP, was determined 
by Dr. Shi-Hui Dong and Prof. Satish K. Nair. CylM consists of two distinct domains- an N-
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terminal dehydration domain, composed of residues Asn4 through Pro624, and a C-terminal 
cyclization domain encompassed by Tyr641 through Glu992 (Figure 5.5a). Consistent with prior 
predictions, the cyclization domain is homologous to the stand-alone class I lanthionine cyclase 
NisC including the conserved zinc ligands (Cys875, Cys911, and His912) (Figure 5.5b) (4). The 
C-terminal cyclization domain of CylM contains a β-sheet region composed of three antiparallel 
strands (Figures 5.5a and 5.5c). A similar antiparallel β-stranded element that interacts with the 
substrate leader peptide was identified in the class I lanthionine dehydratase NisB (7), and is a 
conserved feature in other enzymes involved in RiPP biosynthesis (Figure 5.5c) (10). 
While class II dehydratases lack detectable sequence similarities with known proteins, the 
CylM structure reveals that this domain is architecturally similar to the catalytic core of 
phosphoinositide 3-kinase (PI3K) (Figures 5.5a and 5.5d) (11, 12). The structural similarity with 
kinases is consistent with the proposed mechanism of dehydration via first phosphorylation of 
Ser and Thr residues, followed by elimination of the phosphate (13). Despite the structural 
homology, the topology of the CylM dehydration domain is quite different from those of 
canonical kinases (Figures 5.5e).  
Like canonical kinases, the CylM dehydration domain is composed of an N-lobe and a C-
lobe (Figure 5.6a). All protein and lipid kinases contain a requisite ~30-residue segment termed 
the activation loop that is important for both regulation and function. Kinase activity is typically 
controlled through activation-induced conformational changes, involving a disorder-to-order 
transition of the activation loop. Unlike most kinases, the activation loop in the CylM 
dehydration domain is well defined in the absence of bound peptide (Figure 5.6a). The 
stabilization of the activation loop is established through interactions with a LanM-specific KA 
domain (kinase-activation domain), which, is itself held in place by the “capping helices” (a two 
helical insert created by Ile180 through Tyr200) (Figure 5.6a). The observation that the 
activation loop stays in a catalytically competent conformation is consistent with the fact that the 
ATPase activity of LanM enzymes is not dependent on the supply of peptide substrate. 
In the CylM-AMP cocrystal structure, the AMP is trapped in the cliff between the two lobes 
(Figures 5.6a and 5.6b). The phosphate-binding loop (P-loop) is composed of residues Ser247 
through Thr262, including Asp252 and His254 (Figure 5.6b). Mutational analysis suggests a 
second possible role for these residues in the elimination of phosphate from the phosphorylated 
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peptide intermediates (section 5.2.3). The adenine is situated in a hydrophobic pocket common 
across other structurally characterized kinases (14, 15). The proposed mechanism for protein 
kinases involves a conserved DxH motif, and LanM-conserved residues Asp347 and His349 in 
CylM are poised for catalysis (Figure 5.6b). His349 may serve as a general base and receive a 
proton from Ser/Thr in the substrate peptide. Asp347 likely orients the Ser/Thr oxygen of the 
substrate peptide for nucleophilic attack onto the γ-phosphate of ATP. Additionally, two 
conserved residues, Asn352 and Asp364, coordinate divalent metal ligands for stabilization of 
the incipient charge in the transition state. The CylM cocrystal structure further suggests a model 
for how the substrate peptide can bind to the two active sites (Figures 5.5c and 5.6c). 
 
Figure 5.5 Crystal structure of CylM. (a) Overall structure of CylM. (b) Structure of the class I 
lanthipeptide cyclase NisC illustrating the structural homology with the C-terminus of CylM. (c) 
Comparison of the putative peptide-binding β-strands of CylM with the peptide binding regions of other 
RiPP biosynthetic enzymes including NisB (involved in nisin biosynthesis, PDB 4WD9) and LynD 
(involved in cyanobactin biosynthesis, PDB 4V1T). (d) Structure of the lipid kinase PI3K that shares 
homology with the dehydration domain of CylM. (e) Domain organization of LanMs in comparison with 
that of lipid kinases. RBD, Ras-binding domain. Figure made by Prof. Satish K. Nair. 
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Figure 5.6 Active site geometry of CylM. (a) Two views, rotated by 180
o
, of the kinase active site of 
CylM showing the insertions specific to LanMs. Secondary structural elements are colored as in Figure 
5.5a and the superimposed structure of PI3K is colored in gray. (b) Close up of the CylM dehydratase 
active site showing the bound nucleotide, and the residues that are important for phosphorylation and 
phosphate elimination. (c) Solvent occluded surface showing the roles of the capping helices and KA 
domain in orientating the activation loop. Figure made by Prof. Satish K. Nair. 
 
5.2.3 Site-directed mutagenesis of active site residues 
Given the unanticipated lipid kinase fold, I focused the mechanistic studies of CylM on the 
dehydratase domain (residues 1-624). The four residues in the ATP binding loop in CylM 
(Asp347, His349, Asn352, Asp364) are conserved in the LanM family (16). The importance of 
these residues was investigated by replacement with Ala in the E. coli coexpression system with 
CylLS as substrate. Dehydration activity was not detected for any of the mutants, with the 
exception of CylM-H349A that produced a small amount of dehydrated CylLS as determined by 
MALDI-TOF MS (Figure 5.7).  
The activities of these CylM phosphorylation-deficient mutants were also tested in vitro 
using purified proteins (Figure 5.8). With linear CylLS serving as the substrate, wild type CylM 
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finished the modification by eliminating 4 water molecules within 30 min of incubation when 
characterized using MALDI-TOF MS. In comparison, the four phosphorylation-deficient 
mutants were unable to convert the starting material into modified peptide using the same set up 
(Figure 5.9). A small amount of dehydrated product was observed for CylM-H349A, which 
afforded partially dehydrated intermediates when analyzed using the E. coli coexpression system 
(Figure 5.7). I further increased the incubation time to 10 hours at room temperature to facilitate 
the detection of any minimal level activity. Indeed, almost full modification of CylLS was 
achieved by CylM-H349A (Figure 5.10). Partially modified products with one dehydration and 
one phosphorylation were observed for the reaction catalyzed by CylM-N352A, but CylLS 
remained unmodified in the presence of CylM-D347A and CylM-D364A even with elongated 
incubation time (Figure 5.10). 
 
Figure 5.7 MALDI-TOF mass spectra of CylLS peptides coexpressed with CylM and CylM 
phosphorylation-deficient mutants in E. coli. M = unmodified CylLs; P = phosphorylation. 
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Figure 5.8 SDS-PAGE image of CylM phosphorylation-deficient mutants. 
 
 
Figure 5.9 MALDI-TOF mass spectra of CylLS peptides incubated with CylM and CylM 
phosphorylation-deficient mutants in vitro for 30 min. M = unmodified CylLs; P = phosphorylation. 
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Figure 5.10 MALDI-TOF mass spectra of CylLS peptides incubated with CylM and CylM 
phosphorylation-deficient mutants in vitro for 10 hours. M = unmodified CylLs; P = phosphorylation. 
 
Previous mutagenesis studies identified four conserved residues in LanMs that are important 
for the elimination reaction (13, 17). Inspection of the CylM structure shows that these four 
residues (Asp252, His254, Arg506, Thr512) are in close proximity despite being apart by > 250 
amino acids in primary sequence (Figure 5.6) and are located adjacent to the phosphorylation 
site. The function of each residue was investigated using alanine substitution. Phosphorylated 
intermediates were detected for all four mutants, with partially dehydrated products observed for 
all except CylM-T512A (Figure 5.11). In vitro characterization of the four elimination-deficient 
mutants of CylM also provided similar phenotypes as what were observed using the 
coexpression system, except that CylM-H254A afforded fully modified CylLS after an elongated 
incubation period (Figures 5.12-5.14), indicating that mutating histidine 254 to alanine slows 
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down but does not abolish the phosphate-elimination activity of CylM. The T512A mutant did 
not eliminate the phosphate even with increased reaction time (Figure 5.14), suggesting that 
Thr512 is critical for the elimination activity of CylM. 
 
Figure 5.11 MALDI-TOF mass spectra of CylLS peptides coexpressed with CylM elimination-
deficient mutants in E. coli. M = unmodified CylLs; P = phosphorylation. 
 
Figure 5.12 SDS-PAGE image of CylM elimination-deficient mutants. 
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Figure 5.13 MALDI-TOF mass spectra of CylLS peptides incubated with CylM elimination-
deficient mutants in vitro for 30 min. M = unmodified CylLs; P = phosphorylation. 
 
Figure 5.14 MALDI-TOF mass spectra of CylLS peptides incubated with CylM elimination-
deficient mutants in vitro for 10 hours. M = unmodified CylLs; P = phosphorylation. 
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Both Asp252 and His254 are residues within the kinase domain P loop, which is thought to 
facilitate ATP activation by interacting with the γ phosphate, and it is of interest to note that 
these residues may play a similar role of phosphate stabilization during the elimination reaction. 
Lastly, both Arg506 and Thr512 are located within the KA domain, suggesting that, in addition 
to stabilizing LanMs in an active conformation, this domain may also provide residues to assist 
in the elimination of phosphate from the phosphorylated peptide intermediate. 
 
5.2.4 ADP is required for CylM-catalyzed phosphate elimination 
Unlike the class III lanthipeptide synthetases for which phosphorylated intermediates 
accumulate (18), such intermediates are usually not detected during catalysis by LanM proteins. 
Class III synthetases are made up of separate protein kinase, phosphoSer/phosphoThr 
elimination, and cyclase domains that are readily recognized by sequence homology (6). The two 
distinct domains for dehydration require the phosphorylated peptides to translocate from the 
kinase to the lyase active site. The adjacency of the phosphorylation and elimination active sites 
in CylM provides an explanation for the absence of phosphorylated peptides in LanM proteins as 
elimination may occur faster than peptide dissociation. To further investigate the elimination 
step, a mixture of phosphorylated CylLS peptides carrying different numbers of phosphate esters 
was obtained by coexpression of CylLS with elimination-deficient CylM-R506A in E. coli. The 
phosphorylated CylLS peptides were incubated with wild type CylM in the presence or absence 
of adenosine nucleotides. Without addition of nucleotides, CylM did not eliminate the 
phosphates. However, when ADP was supplied, phosphorylated CylLS was consumed, resulting 
in a mixture of CylLS peptides that differed in the number of dehydrations (Figures 5.15 and 
5.16). Collectively, these results are consistent with an ordered kinetic mechanism in which 
binding of the phosphorylated peptide requires ADP to be bound first or in which the presence of 
ADP within the active site increases the affinity of phosphorylated intermediates. 
 
5.2.5 Conclusion 
The unexpected structural homology of bacterial LanM proteins with eukaryotic lipid 
kinases and related protein kinases may have implications for the function of the three LanC-like 
proteins that are found in mammals (19-21). Recent studies indicated interactions between the 
human LanCL2 and the kinases Akt and the mechanistic target of rapamycin complex 2 
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(mTORC2) (22). The structure of CylM shows that the LanC domain interacts with the 
activation loop and the k11 helix of the kinase domain, providing a potential preview of the 
intermolecular interaction of LanCL proteins with mammalian kinases.  
 
Figure 5.15 MALDI-TOF mass spectra of phosphorylated CylLS intermediates incubated with CylM in 
the absence of nucleotides (black trace), and in the presence of AMP (adenosine 5’-monophosphate 
disodium salt) (blue trace), non-hydrolyzable ADP (adenosine 5’-(β-thio)diphosphate trilithium salt) 
(magenta trace), or non-hydrolyzable ATP (adenosine 5’-(β,γ-imido)triphosphate lithium salt hydrate) 
(red trace). M = unmodified CylLs; P = phosphorylation. The data are shown for non-hydrolyzable 
analogs of ADP and ATP to distinguish whether the observed activity is due to the presence of these 
nucleotides, or to the activated phosphor-anhydride groups of ADP/ATP.  See also Figure 5.16. 
 
116 
 
 
Figure 5.16 MALDI-TOF mass spectra of CylLS peptides incubated with CylM in the absence of 
nucleotides (black trace), and in the presence of AMP (adenosine 5’-monophosphate disodium salt) (blue 
trace), non-hydrolyzable ADP (adenosine 5’-(β-thio)diphosphate trilithium salt) (magenta trace), or non-
hydrolyzable ATP(adenosine 5’-(β,γ-imido)triphosphate lithium salt hydrate) (red trace). M = unmodified 
CylLs; P = phosphorylation. 
 
5.3 Methods 
General methods 
Similar general methods and materials as what were described in chapter 2 were employed 
in this chapter unless specified otherwise. LC-ESI-Q/TOF MS analyses were conducted using a 
Synapt G2 MS system equipped with Acquity UPLC (Waters). Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was carried out on a 
Bruker Daltonics UltrafleXtreme MALDI-TOF/TOF mass spectrometer. C18 zip-tip pipet tips 
were obtained from Millipore to desalt samples for MS analysis.  Chemicals were ordered from 
Sigma Aldrich. Expression vectors (pET15b and pRSFDuet-1) were obtained from Novagen. 
 
117 
 
Cloning of cylM, cylLL, and cylLS genes into expression vectors 
The cylM gene was cloned into the multiple cloning site 1 of a pRSFDuet-1 vector using 
EcoRI and NotI restriction sites to generate pRSFDuet-1/CylM plasmid. Primer sequences used 
are listed in Table 5.1. CylLL and cylLS genes were cloned into a pET15b vector using NdeI and 
BamHI restriction sites, resulting in pET15b/CylLL or pET15b/CylLS plasmids, respectively. 
 
Table 5.1 Primer sequences used for cloning of cylM and its mutants. 
Primer Name Primer Sequence (5'-3') 
CylM_EcoRI_Duet_FP AAAAA GAATTCG GAAGATA ATCTGATTAA T 
CylM_NotI_Duet_RP AAAAA GCGGCCGC TTACAGT TCAAACAGCA G 
CylM_D252A_QC_FP AGGGT GCA AGCCAT AGCCGTGGTAAAACCGTT AGC 
CylM_D252A_QC_RP ATGGCT TGC ACCCT GGC TTTCGCTAAT GCTATTCAGT 
CylM_H254A_QC_FP GATAGC GCT AGCCGT GGT AAAACCGTT AGCACCCTG 
CylM_H254A_QC_RP ACGGCT AGC GCTA TC ACCCTGGC TTTCGCTAAT G 
CylM_D347A_QC_FP GTTACC GCT CTGCAT TATGAAAACATCATTGCCCATGGC 
CylM_D347A_QC_RP AT GCAG AGC GGT AAC ATTAAAC AGAAAGGCAA TGCCAATCAG 
CylM_H349A_QC_FP CCGATCTG GCT TATGAAAA CATCATTGCCCATGGCGAATA 
CylM_H349A_QC_RP TTTTCATA AGC CAGATCGG T AACATTAAAC AGAAAGGCAA 
TGCCAAT 
CylM_N352A_QC_FP CATTATGAA GCC ATCATTGC CCATGGCGAATATCCG GTGATT 
CylM_N352A_QC_RP GCAATGAT GGC TTCATAATG CAGATCGGT AACATTAAAC 
AGAAAGGC 
CylM_D364A_QC_FP GTGATTATT GCT AATGAAACC 
TTTTTTCAGCAGAATATTCCGATTGAATTT 
CylM_D364A_QC_RP GGTTTC ATT AGC AATA ATCAC CGGAT ATTCGCCATG GGC 
CylM_R506A_QC_FP TGATTGTG GCC AATGTTAT TCGTCCGACCCAGCGTTA 
CylM_R506A_QC_RP A TAACATT GGC CACAATCA GA TTCTGCAGAT TATTATTAAT 
ATAGGCCAGA 
CylM_T512A_QC_FP GTCCG GCC CAG C GTTATGCAGATATGCTGGAA TTTAGC 
CylM_T512A_QC_RP CTG GGCCGGAC GAA TAACATTGCG CACAATCAGA 
 
Construction of pRSFDuet-1 derivatives for expression of CylM mutants and for 
coexpression of CylLS with CylM mutants 
The plasmids pRSFDuet-1/CylM-D347A, pRSFDuet-1/CylM-H349A, pRSFDuet-1/CylM-
N352A, pRSFDuet-1/CylM-D364A, pRSFDuet-1/CylM-D252A, pRSFDuet-1/CylM-H254A, 
pRSFDuet-1/CylM-R506A, pRSFDuet-1/CylM-T512A, pRSFDuet-1/CylLS/CylM-D347A-2, 
pRSFDuet-1/CylLS/CylM-H349A-2, pRSFDuet-1/CylLS/CylM-N352A-2, pRSFDuet-
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1/CylLS/CylM-D364A-2, pRSFDuet-1/CylLS/CylM-D252A-2, pRSFDuet-1/CylLS/CylM-
H254A-2, pRSFDuet-1/CylLS/CylM-R506A-2 and pRSFDuet-1/CylLS/CylM-T512A-2 were 
generated using QuikChange methodology using pRSFDuet-1/CylM and pRSFDuet-
1/CylLS/CylM-2 as templates, respectively (8). Primer sequences are listed in Table 5.1. 
 
Expression and purification of His6-CylLL and His6-CylLS peptides 
E. coli BL21 (DE3) cells were transformed with pET15b/CylLL or pET15b/CylLS and 
plated on a LB plate containing 100 mg/L ampicillin. A single colony was picked and grown in 
20 mL of LB in the presence of ampicillin at 37 
o
C for 12 h. The cell suspension was directly 
used to inoculate 2 L of fresh LB media. Cells were cultured at 37 
o
C until the OD at 600 nm 
reached 0.5, and IPTG was added to a final concentration of 0.2 mM. Cells were cultured at 37 
o
C for another 3-5 h before harvesting. The cell pellet was resuspended at room temperature in 
LanA start buffer (20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol, pH 7.5 at 
25
 o
C) and lysed by sonication. The resulting sample was then centrifuged at 23,700×g for 30 
min and supernatant was discarded. The remaining pellet was resuspended in LanA buffer 1 (6 
M guanidine hydrochloride, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5 at 25
 
o
C) and sonicated. Centrifugation was performed afterwards to pellet the debris and the soluble 
portion was passed through 0.45-µm syringe filters. His-tagged peptides were purified by 
immobilized metal ion affinity chromatography (IMAC) eluting with LanA elute buffer (4 M 
guanidine hydrochloride, 20 mM NaH2PO4, 500 mM NaCl, 1 M imidazole , pH 7.5 at 25
 o
C). 
The eluted fractions were desalted by preparative HPLC using a Waters Delta-pak C4 column 
(15 µm 300 Å 25 x 100 mm). The resulting peptides were lyophilized to dryness and kept at −20 
o
C until future use. 
 
Expression and purification of His6-CylM and CylM mutants 
E. coli BL21 (DE3) cells were transformed with pRSFDuet-1/CylM, pRSFDuet-1/CylM-
D347A, pRSFDuet-1/CylM-H349A, pRSFDuet-1/CylM-N352A, pRSFDuet-1/CylM-D364A, 
pRSFDuet-1/CylM-D252A, pRSFDuet-1/CylM-H254A, pRSFDuet-1/CylM-R506A or 
pRSFDuet-1/CylM-T512A, and plated on a LB plate containing 50 mg/L kanamycin. A single 
colony was picked and grown in 20 mL of LB in the presence of kanamycin at 37 
o
C for 12 h. 
The cell suspension was directly used to inoculate 2 L of LB and cells were cultured at 37 
o
C 
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until the OD at 600 nm reached 0.5. The culture was cooled down on ice followed by the 
addition of IPTG to a final concentration of 0.1 mM. Cells were cultured at 18 
o
C for additional 
18 h before harvesting. The harvested cells were resuspended on ice in LanM start buffer (20 
mM HEPES, 1 M NaCl, pH 7.5 at 25
 o
C) and lysed using a homogenizer. Insoluble debris was 
removed by centrifugation at 23,700×g for 45 min at 4 
o
C and the supernatant was passed 
through 0.45-µm syringe filters. His-tagged proteins were purified by IMAC, eluting with a 
linear concentration gradient of imidazole from 30 mM to 200 mM. The eluted fractions were 
analyzed using SDS-PAGE. Fractions containing the desired protein were combined and 
concentrated using a centrifugal filtering device, and the buffer was exchanged to LanM start 
buffer using a gel-filtration column. Protein concentration was quantified by its absorbance at 
280 nm. The extinction coefficient for His6-CylM was calculated as 140,110 M
-1
 cm
-1
. Aliquoted 
protein solutions were flash-frozen and kept at −80 oC until further usage. 
 
Expression and purification of His6-CylLS peptides coexpressed with CylM mutants 
E. coli BL21 (DE3) cells were transformed with pRSFDuet-1/CylLS/CylM-D347A-2, 
pRSFDuet-1/CylLS/CylM-H349A-2, pRSFDuet-1/CylLS/CylM-N352A-2, pRSFDuet-
1/CylLS/CylM-D364A-2, pRSFDuet-1/CylLS/CylM-D252A-2, pRSFDuet-1/CylLS/CylM-
H254A-2, pRSFDuet-1/CylLS/CylM-R506A-2 or pRSFDuet-1/CylLS/CylM-T512A-2, and 
plated on a LB plate containing 50 mg/L kanamycin. A single colony was picked and grown in 
10 mL of LB in the presence of kanamycin at 37 
o
C for 12 h. The cell suspension was directly 
used to inoculate 1 L of LB and cells were cultured at 37 
o
C until the OD at 600 nm reached 0.5. 
The culture was cooled down on ice followed by the addition of IPTG to a final concentration of 
0.1 mM. Cells were cultured at 18 
o
C for 18 h before harvesting. To obtain both fully modified 
and linear CylLS as well as possible intermediates (partially modified CylLS)  and reduce the bias 
introduced by peptide solubility, harvested cells were resuspended and lysed directly in LanA 
buffer 1 (6 M guanidine hydrochloride, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 
7.5 at 25
 o
C) by sonication. Debris was removed by centrifugation and the soluble portion was 
passed through 0.45-µm syringe filters. His-tagged CylLS was purified by immobilized metal ion 
affinity chromatography (IMAC), eluting with LanA elute buffer (4 M guanidine hydrochloride, 
20 mM NaH2PO4, 500 mM NaCl, 1 M imidazole, pH 7.5 at 25
 o
C). The eluted fractions were 
desalted with Strata-X polymeric reverse phase SPE columns and lyophilized to dryness.  
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Reconstitution of CylM activity in vitro 
Presumably due to high hydrophobicity, the solubility of linear CylLL or CylLS peptides is 
extremely poor. For enzyme assays, 2 mg/mL peptide suspension was made in deionized water 
as stock solution for both peptides. The stock solution was vortexed to a homogenized 
suspension each time before any peptide was taken. However, given the presence of 
precipitation, the concentration of CylLL or CylLS peptides could not be tightly controlled. 
To reconstitute the activity of CylM in vitro, 20 µM of linear peptides were supplied in a 
reaction vessel with 4 mM MgCl2, 2 mM ATP, 2 mM DTT, 1 x 10
-5
 U thrombin (to remove the 
His-tag in situ) and 50 mM HEPES (pH 7.5), followed by the addition of CylM to a final 
concentration of 0.5 µM. Reactions were incubated at room temperature for 4 h. Control 
reactions were set up with all other components in the absence of CylM. Each sample was zip-
tipped and analyzed by MALDI-TOF MS. Aliquoted samples were treated by CylA (serine 
protease encoded in the biosynthetic pathway of cytolysin) to remove the leader peptides, and the 
resulting core peptides were analyzed by LC-MS or LC-MS/MS. 
 
In vitro modification of CylLS by CylM mutants 
CylLS peptide (20 µM) was supplied to a reaction vessel in the presence of 4 mM MgCl2, 2 
mM ATP, 2 mM DTT, 1 x 10
-5
 U thrombin (to remove the His-tag in situ) and 50 mM HEPES 
(pH 7.5). CylM and CylM mutant proteins were then added to a final concentration of 0.5 µM. 
Reactions were incubated at room temperature and aliquots were quenched by adding formic 
acid to a final concentration of 0.5% at desired time points. Each sample was then zip-tipped and 
analyzed by MALDI-TOF MS.  
 
Elimination activity of CylM in the presence of adenosine derivatives 
Phosphorylated CylLS peptides carrying different numbers of phosphate esters were 
obtained by coexpression of CylLS with CylM elimination-deficient mutant CylM-R506A. The 
peptide mixture was dissolved in deionized water to make a 350 µM stock solution. Non-
hydrolyzable ATP (adenosine 5’-(β,γ-imido)triphosphate lithium salt hydrate), non-hydrolyzable 
ADP (adenosine 5’-(β-thio)diphosphate trilithium salt) and AMP (adenosine 5’-monophosphate 
disodium salt) were reconstituted in deionized water and a stock solution of 20 mM was obtained 
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for each. For elimination reactions, CylM was supplied with a final concentration of 0.5 µM in 
the presence of 1 mM MgCl2 , 2 mM DTT and 50 mM HEPES (pH 7.5) in a reaction vessel, 
followed by the addition of adenosine derivatives (final concentration 500 µM) or deionized 
water (negative control). Phosphorylated CylLS peptides were then added into the mixture to a 
final concentration of 35 µM and incubated at room temperature for 2 h. Parallel reactions were 
set up using linear CylLS with a peptide concentration of 20 µM in the presence of 1 x 10
-5
 U 
thrombin. Samples were zip-tipped and analyzed by MALDI-TOF MS.  
 
Crystallization and structural determination of CylM  
This part was performed by Dr. Shi-Hui Dong and Prof. Satish K. Nair. 
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 Chapter 6. Class II Lanthipeptides Harbor a Pool of Sequence-Specific LanP 
Proteases 
 
6.1 Introduction 
Proteases are ubiquitous in most organisms (1). They have been the focus of intense research 
not only because of their pivotal physiological functions but also because of their potential 
applications. The use of proteases has led to advances in analytical chemistry, proteomics, 
medicine, and the food, detergent and leather industries (2-4). Although much effort has been 
spent on engineering of proteases with desired sequence specificity using both rational design and 
high throughput screening (2, 5, 6), few such efforts have reached the stage of commercial 
applications (3). Major challenges are the sacrifice of efficiency and stability when engineering 
new substrate specificity, or the loss of sequence specificity when focusing on improving protein 
robustness (7-9). As a result, nature is still the major source of proteases with novel recognition 
sequences. The biosynthetic machinery responsible for the production of RiPPs (10) is a promising 
area for discovering new sequence-specific proteases, as dedicated proteolytic enzymes are 
employed to remove leader peptides with highly diverse P and P’ positions. Lanthipeptides are a 
large family of RiPPs with a subfamily that exhibit antimicrobial activities termed lantibiotics (for 
an introduction of lanthipeptides and lantibiotics, see section 1.2 in chapter 1). 
Lanthipeptides are currently classified in four classes according to the synthetases that install 
the thioether cross-linked amino acids (Figure 1.3a) (11). Compared to the well-characterized 
lanthionine synthetases, the proteases responsible for leader peptide removal are much less studied 
(12-19). Two types of proteases have been reported for the maturation of class I and II 
lanthipeptides (Figure 1.4a) - the subtilisin-like serine protease LanP employed by both classes 
and the papain-like cysteine protease domain of the LanT transporter protein involved exclusively 
in the biosynthesis of class II lanthipeptides (12-18). The cysteine protease domain is located at the 
N-terminus of LanT proteins and typically cleaves its substrate after a double Gly-type motif 
(GG/GA/GS) (15, 16). In contrast to LanT protease domains, the sequence specificity of 
subtilisin-like LanP proteins remains mostly elusive. Thus far, only three class I LanP proteases 
have been heterologously expressed and characterized in vitro (14, 20-23), whereas no such 
studies have been performed for class II LanPs, which fall into a different phylogenetic clade (23).  
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The biosynthesis of only a few known class II lanthipeptides involves LanP proteases (11). 
These enzymes remove a short N-terminal oligopeptide after a LanT protein detaches the majority 
of the leader peptide at a double Gly-type cleavage site. For example, LicP is an extracellularly 
located serine protease expressed by some strains of Bacillus licheniformis and is required for the 
production of the two-component lantibiotic lichenicidin (Figure 6.1) (18). After installation of 
the thioether rings in the precursor peptides LicA1 and LicA2, LicT removes the leader peptide of 
modified LicA1 to generate Licα as well as the majority of the leader peptide from modified LicA2 
to generate NDVNPE-Licβ (hereafter LicA2’) (Figure 6.2) (18). The maturation of Licβ requires 
one more cleavage step outside the cell, where LicP trims off the six remaining amino acids at the 
N-terminus of LicA2’ (Figure 6.2). 
 
Figure 6.1 Structure of the lantibiotic lichenicidin. Obu, 2-oxobutyryl group resulting from hydrolysis of 
an N-terminal Dhb; Abu, α-aminobutyric acid. 
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Figure 6.2 The biosynthetic gene cluster of lichenicidin and the cleavage events employed during 
lichenicidin maturation. 
 
In this study, I describe the in vitro characterization of LicP, demonstrate that the protein 
self-cleaves, and show that it recognizes a specific cleavage sequence but otherwise is very 
tolerant of the peptide sequence. In addition, by collaborating with Dr. Shi-Hui Dong and Prof. 
Satish Nair, a 2.35 Å resolution structure of LicP was obtained, which reveals an unanticipated 
intramolecular activation strategy that stabilizes the mature form of the enzyme in a 
calcium-independent manner. LicP has potential utility for sequence-specific proteolysis because 
it does not leave a scar (3, 24). Encouraged by these observations, I identified nine new class II 
LanP proteins with diverse recognition sequences, which may expand the current protease toolbox 
for specific removal of expression tags in protein chemistry or leader peptides in RiPP 
biosynthesis. 
 
6.2 Results 
6.2.1 Expression of LicP reveals a self-cleavage maturation process 
The licP gene was amplified from genomic DNA of B. licheniformis ATCC 14580 (25) and 
cloned into an expression vector. A hexa-histidine tag was installed at its N-terminus, and the first 
24 amino acids of LicP, which correspond to a secretion signal peptide, were omitted. Upon 
expression in Escherichia coli BL21 (DE3) and purification using immobilized metal affinity 
chromatography, two bands were observed by gel electrophoresis (Figure 6.3a). Analysis by 
MALDI-TOF MS demonstrated masses of 9,923 Da and 37,431 Da (Figure 6.3b). These 
molecular weights are in agreement with two fragments of LicP, an N-terminal portion 
His6-LicP-25-100 with a calculated mass of 9,924 Da and a C-terminal portion LicP-101-433 with 
a calculated mass of 37,449 Da, suggesting that a cleavage event occurred during the expression of 
His6-LicP-25-433 (hereafter referred to as wild type LicP). 
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Figure 6.3 SDS-PAGE (a) and MALDI-TOF MS (b) analysis of His6-LicP-25-433 expressed in E. coli. 
His6-LicP-25-100, calculated M: 9,924, average mass; observed M+H
+
: 9,923, average mass. 
LicP-101-433, calculated M: 37,431, average mass; observed M+H
+
: 37,449, average mass. 
 
Such proteolytic processing has been reported for several extracellular class I LanP proteases 
and was suggested to be autocatalytic (12, 13). To test whether this mechanism applied to the class 
II enzyme LicP, the predicted catalytic Ser376 was substituted by Ala. Unfortunately, 
His6-LicP-25-433-S376A was expressed almost exclusively in the insoluble fraction. I also 
mutated His186 predicted to be involved in the catalytic triad, but His6-LicP-25-433-H186A was 
again expressed insolubly. I eventually obtained a very small amount of soluble 
His6-LicP-25-433-S376A, demonstrating that indeed the proteolytic cleavage after Glu100 was 
abolished (Figure 6.4). The observation that an inactivated LicP was expressed as the full length 
protein indicates the cleavage event is indeed catalyzed by LicP rather than E. coli proteases. 
These findings mirror those of a very recent report on a protease from a non-lanthipeptide 
producing organism that has sequence homology with the lanthipeptide protease EpiP, which 
employs an autocatalytic mechanism of cleavage between Lys87 and Thr88 (26). Using 
His6-LicP-25-433 and its S376A mutant, I confirmed that such an autoproteolysis can take place 
intermolecularly, albeit slowly (Figure 6.5). 
To obtain an active form of LicP with the pro-sequence covalently attached, Glu100was 
substituted with Ala. However, His6-LicP-25-433-E100A was again expressed and purified as two 
fragments (Figure 6.6a). Surprisingly, the resulting fragments corresponded to a shifted cleavage 
site from residue Ala100 to Glu102 (Figure 6.6b). Further mutation of Glu102 to Ala abolished 
the production of soluble protein.  
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Figure 6.4 SDS-PAGE image of soluble His6-LicP-25-433-S376A. 
 
Figure 6.5 Determination if LicP cleavage is intra or intermolecular. To differentiate whether the 
self-cleavage of LicP occurred intramolecularly or intermolecularly, His6-LicP-25-433 (consisting of a 
complex of His6-LicP-25-100 and LicP-101-433) was incubated with His6-LicP-25-433-S376A in a 1:1 
ratio. The reaction was monitored by SDS-PAGE to determine whether wild type LicP catalyzes the 
proteolytic cleavage of His6-LicP-25-433-S376A. When incubated alone, His6-LicP-25-433 or 
His6-LicP-25-433-S376A did not show any changes throughout the 19-hour incubation period, whereas the 
full length protein His6-LicP-25-433-S376A was consumed gradually when incubated with 
His6-LicP-25-433, suggesting that the observed cleavage of LicP can take place intermolecularly. Proteins 
were supplied with a final concentration of 0.1 mg/mL each.  
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Figure 6.6 SDS-PAGE (a) and MALDI-TOF MS (b) analysis of His6-LicP-25-433-E100A. 
His6-LicP-25-102-E100A, calculated M: 10,096, average mass; observed M+H
+
: 10,099, average mass. 
LicP-103-433, calculated M: 37,219, average mass; observed M+H
+
: 37,207, average mass. 
 
6.2.2 In vitro characterization of LicP 
LicP has been suggested to trim off the 6-residue oligopeptide NDVNPE from LicA2’ to 
generate mature Licβ (18). In this work, dehydrated and cyclized LicA2 was obtained by 
co-expressing LicA2 with its cognate lanthionine synthetase LicM2 in E. coli (Figure 6.7a) (27). 
Instead of using the membrane-bound protein LicT to produce LicA2’, the commercial protease 
AspN was employed to generate a DVNPE-Licβ. Upon incubation with wild type LicP, the 
5-residue oligopeptide was successfully removed (Figure 6.7b), confirming LicP’s anticipated 
proteolytic activity against its substrate. When the full length modified LicA2 was incubated with 
LicP, the peptide was consumed, resulting in two fragments corresponding to the leader peptide 
and Licβ (Figure 6.7c). This observation suggests that LicP does not require prior proteolysis by 
LicT to produce Licβ. I next incubated linear LicA2 with LicP to test whether unmodified LicA2 
was also a substrate (Figure 6.8a). Cleavage of the unmodified LicA2 peptide was observed 
(Figure 6.8b), indicating that post-translational modifications are not required for substrate 
recognition by LicP. 
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Figure 6.7 In vitro activity of LicP against LicM2 modified LicA2. (a) MALDI-TOF mass spectrum of 
LicM2-modified LicA2. LicM2 modified LicA2, calculated M-12H2O: 8,714, average mass; observed 
M-12H2O+H
+
: 8,713, average mass. Gluconoylation at the N-terminus of LicA2 was introduced when 
expressing the peptide in E. coli BL21(DE3), resulting in a +178 Da peak in addition to the peak with the 
original mass (28). (b) MALDI-TOF mass spectra of DVNPE-Licβ peptide with (magenta) or without (blue) 
incubation with LicP. For DVNPE-Licβ, calculated M: 3572.6, monoisotopic mass; observed M+H+: 
3573.6, monoisotopic mass. For Licβ, calculated M: 3019.4, monoisotopic mass; observed M+H+: 3020.5, 
monoisotopic mass. (c) MALDI-TOF mass spectrum for LicM2 modified LicA2 incubated with LicP. Licβ, 
calculated M: 3,019.4, monoisotopic mass; observed M+H
+
: 3,020.6, monoisotopic mass. LicA2 leader 
peptide, calculated M: 5,711, average mass; observed M+H
+
: 5,711, average mass. 
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Figure 6.8 In vitro activity of LicP against linear LicA2. (a) MALDI-TOF mass spectrum of linear LicA2. 
LicA2, calculated M: 8,930, average mass; observed M+H
+
: 8,929, average mass. (b) MALDI-TOF mass 
spectrum for linear LicA2 incubated with LicP. LicA2 leader peptide, calculated M: 5,711, average mass; 
observed M+H
+
: 5,713, average mass. Unmodified LicA2 core peptide was not observed presumably due 
to poor ionization efficiency. 
 
Subsequently, I investigated whether the enzyme displays a preference for modified or linear 
LicA2. Liquid chromatography-based kinetic analysis was hampered by the poor solubility of the 
LicA2 and Licβ peptides. Instead, a competitive MALDI-TOF MS assay was employed for a 
semi-quantitative time-dependent analysis, in which LicP was supplied to a mixture of modified 
and linear LicA2 and the production of leader peptides was monitored over time. In order to 
differentiate the otherwise identical leader peptides after proteolysis, a Pro to Gly mutation was 
introduced between the hexa-histidine tag and the precursor peptide in linear LicA2 (G-LicA2). 
The leader peptides obtained by complete proteolysis of equimolar amounts of modified and linear 
LicA2 exhibited comparable signal intensities when monitored by MALDI-TOF MS, confirming 
that the Pro to Gly mutation does not alter the ionization efficiency significantly (Figure 6.9). LicP 
was incubated with an 800-fold excess of modified and linear LicA2, and MALDI-TOF MS 
analysis illustrated complete consumption of modified LicA2 peptide within 10 min, 
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corresponding to a rate of at least 80 min
-1
, whereas the cleavage of linear LicA2 only started after 
the modified LicA2 had been consumed and required more enzyme to be completed (Figure 6.9). 
Collectively, these observations indicate that although both are substrates for the enzyme, LicP 
strongly prefers modified LicA2 compared to the linear version. 
 
Figure 6.9 Time-dependent MALDI-TOF analysis of modified LicA2 and linear G-LicA2 peptides 
treated with LicP. For all traces, modified LicA2 and linear G-LicA2 were each supplied with a final 
concentration of 17 μM. For the purple trace, 2.1 µM of His6-LicP-25-433 was added and the reaction was 
incubated at room temperature for 12 h (asterisk); for the other traces, 21 nM His6-LicP-25-433 was 
employed. The intensity of the G-LicA2 leader peptide was set to 100% in the region of 5,500-5,900 Da, 
whereas the intensity of modified LicA2 precursor peptide was set to 100% in the region of 8,600-9,000 Da. 
Relative intensities are shown for comparison purposes. 
 
6.2.3 LicP can serve as a sequence-specific traceless protease 
The observation that LicP removes the oligopeptide NDVNPE and the entire leader peptide 
from modified or linear LicA2 suggests that it specifically recognizes the NDVNPE sequence but 
is rather tolerant of other regions of the peptides. This hypothesis was tested with other members 
of the lanthipeptide family, as site-specific removal of leader peptides is crucial for producing 
lanthipeptides in vitro and this step is often challenging as only a limited choice of proteases is 
available (29). ProcA1.7 and NisA, the precursor peptides of the lanthipeptides prochlorosin 1.7 
and nisin, were mutated to substitute the last six residues of their leader peptides with the 
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NDVNPE sequence (Figure 6.10). ProcA1.7-NDVNPE and NisA-NDVNPE were incubated with 
LicP, resulting in successful removal of their leader peptides (Figure 6.11).  
 
Figure 6.10 MALDI-TOF mass spectra for ProcA1.7-NDVNPE (a) and NisA-NDVNPE (b) and the 
primary sequences of NisA and ProcA1.7 (c). ProcA1.7-NDVNPE, calculated M: 12,244, average mass; 
observed M+H
+
: 12,246, average mass. NisA-NDVNPE, calculated M: 7,557, average mass; observed 
M+H
+
: 7,558, average mass. Gluconoylation at the N-terminus of NisA-NDVNPE was introduced when 
expressing the peptide in E. coli BL21(DE3), resulting in a +178 Da peak in addition to the peak with the 
original mass (28). 
 
Figure 6.11 MALDI-TOF mass spectra for ProcA1.7-NDVNPE (a) and NisA-NDVNPE (b) 
incubated with LicP. ProcA1.7 core peptide, calculated M: 2,256.1, monoisotopic mass; observed M+H
+
: 
2,257.6, monoisotopic mass. ProcA1.7-NDVNPE leader peptide, calculated M: 10,004, average mass; 
observed M+H
+
: 10,004, average mass. NisA core peptide, calculated M: 3,495.6, monoisotopic mass; 
observed M+H
+
: 3,496.4, monoisotopic mass. NisA-NDVNPE leader peptide, calculated M: 4,074.9, 
monoisotopic mass; observed M+H
+
: 4,075.5, monoisotopic mass. 
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Figure 6.12 MALDI-TOF mass spectra for NisA-NDVNPE peptides with various P1’ positions. 
Gluconoylation at the N-terminus of NisA-NDVNPE peptides was introduced when expressing these 
peptides in E. coli BL21(DE3), resulting in a +178 Da peak in addition to the peak of the original mass (28). 
Unknown modification of +58 Da was installed on NisA-NDVNPE-I1K, nevertheless, MALDI-TOF MS 
analysis suggested the mass peak corresponding to the correct mass as the major peak. 
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Figure 6.13 MALDI-TOF mass spectra for NisA-NDVNPE peptides with various P1’ positions 
incubated with LicP. For all reactions, 65 µM of NisA variants were included. For NisA-NDVNPE-I1T 
and NisA-NDVNPE-I1C, LicP was supplied with a final concentration of 210 nM (enzyme:substrate = 
310:1) and the reactions were incubated at room temperature for 20 hours. For other NisA variants, LicP 
was supplied with a final concentration of 2.1 µM (enzyme:substrate = 31:1) and the reactions were 
incubated at room temperature for 30 hours. 
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The experiments with linear and modified LicA as well as ProcA1.7-NDVNPE and 
NisA-NDVNPE demonstrated that LicP tolerates Dhb, Thr and Ile in the P1' position. To further 
evaluate its tolerance, the P1' position in NisA-NDVNPE was changed from Ile to eight other 
amino acids (Gly, Cys, Thr, Leu, Phe, Trp, Glu and Lys; Figure 6.12). All these mutants were 
accepted by LicP as in all cases removal of the NisA leader peptide was observed when substrate 
peptides were supplied in 30 to 300 fold excess over the enzyme (Figure 6.13). The highest 
proteolytic efficiency was obtained when the P1' position was occupied by Thr or Cys; traceless 
removal of tags in front of Cys is highly valuable for cysteine-based ligation chemistry (30, 31). 
The removal of the NisA leader peptide in front of a Gly or Ile residue was slightly less efficient, 
but complete consumption of precursor peptides was still observed. NisA-NDVNPE analogs with 
Trp, Leu, and Lys at the P1' position were also accepted by LicP, although some substrate still 
remained after 30 hours of incubation. Peptides with Glu or Phe in the P1' position turned out to be 
poor substrates. Collectively, these results show that LicP serves as a sequence-specific protease 
for non-native substrates and that its activity is highly portable with respect to the P1' position 
(Table 6.1). 
 
Table 6.1 Peptides containing cleavage sites with different P and P' sequences that are accepted by 
LicP.  
Substrate sequences P and P' positions [LicP] [Substrate]  Incubated at 
room 
temperature 
Reaction 
goes to 
completion 
LicP-95-105 NTAVNE | TESVI – – – Y 
LicP-E100A-97-107 AVNATE | SVISG – – – Y 
Modified LicA2       NDVNPE | 
DhbDhbPADhb 
21 nM 17 µM 10 min Y 
Linear LicA2 NDVNPE | TTPAT 1.1 µM 290 µM 6 h Y 
ProcA1.7-NDVNPE NDVNPE | TIGGT 210 nM 180 µM 4 h Y 
NisA-NDVNPE NDVNPE | ITSIS 2.1 µM 66 µM 30 h Y 
NisA-NDVNPE-I1T NDVNPE | TTSIS 210 nM 66 µM 20 h Y 
NisA-NDVNPE-I1C NDVNPE | CTSIS 210 nM 66 µM 20 h Y 
NisA-NDVNPE-I1G NDVNPE | GTSIS 2.1 µM 67 µM 30 h Y 
NisA-NDVNPE-I1W NDVNPE | WTSIS 2.1 µM 66 µM 30 h N 
NisA-NDVNPE-I1L NDVNPE | LTSIS 2.1 µM 66 µM 30 h N 
NisA-NDVNPE-I1K NDVNPE | KTSIS 2.1 µM 66 µM 30 h N 
NisA-NDVNPE-I1F NDVNPE | FTSIS 2.1 µM 66 µM 30 h N 
NisA-NDVNPE-I1E NDVNPE | ETSIS 2.1 µM 66 µM 30 h N 
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6.2.4 X-ray structure of LicP 
 The 2.35 Å resolution structure of LicP reveals a peptidase_S8 family serine protease fold 
common among subtilisin-like enzymes (32) (Figure 6.14a). Although LicP was cleaved, a 
non-covalent complex of the resultant two fragments was observed in the crystal structure, 
consisting of an N-terminal prodomain and a C-terminal catalytic protease domain. Interestingly, 
in the LicP structure, the calcium-binding loop that is crucial for the stability of other 
subtilisin-like proteins is missing (Figure 6.14b) (33). Instead, Trp111 from the catalytic domain 
inserts into a hydrophobic pocket that situates at a similar place of the calcium-binding site in 
subtilisin BPN' (Figure 6.14c) and such an insertion may be a necessary step in LicP maturation. 
Perhaps the observed difficulty of obtaining soluble mutants of LicP that prevent proteolytic 
processing can be attributed to the inability of Trp111 to access this hydrophobic pocket.  
 
Figure 6.14 Crystal structure of LicP. (a) Cartoon representation of the overall structure of LicP with the 
prodomain colored in green and the catalytic domain colored in purple. (b,c) Comparison of the structures 
of LicP (c) and subtilisin BPN' (b) in the vicinity of the calcium-binding region, which in LicP is replaced 
by a hydrophobic pocket into which Trp111 from the linker region binds. In panel b, the residues numbering 
refers to the subtilisin (SBT) catalytic domain, whereas in panel c and elsewhere LicP numbering is based 
on the full length protein. (d) Omit electron density map superimposed on a model of LicP bound to a 
peptide substrate. The density corresponds to residual features of the linker into which the substrate has 
been modeled. Figure made by Prof. Satish K. Nair. 
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In addition, the interaction of LicP with a NDVNPE peptide substrate was modeled using the 
spurious electron density observed in the vicinity of the LicP active site (Figure 6.14d). According 
to this model, the specificity for the P1 Glu is dictated by interactions with the side chains of 
Ser272 and His291, and weak interactions with the hydroxyl groups of Thr218 and Tyr241. 
Likewise, a pocket that consists of Ser272, His291, and Leu209 appears to dictate the P4 
specificity for a small hydrophobic residue such as Val. Lastly, the Asp at the P5 position of the 
substrate is positioned to make ionic interactions with Lys212 of LicP. The paucity of additional 
interactions with the enzyme is consistent with the tolerance of LicP for the linker that connects the 
prodomain and the catalytic domain (sequence NTAVNE) and its substrate peptide (NDVNPE). 
 
6.2.5 Class II LanP proteins: a pool of sequence-specific proteases 
LanP genes are not often found in class II lanthipeptide gene clusters. Only four class II LanPs 
have been reported to date - LicP, CylA, CerP and CrnP, which have been suggested to remove 
six-residue sequences at the N-terminus of Licβ, cytolysin, cerecidins and carnolysin, respectively 
(18, 34, 35). Among them, the proteolytic activity, and hence the identity of the cleavage sites, has 
been confirmed for CylA (17), CerP (34) and LicP (this work). To identify additional class II LanP 
proteins and potentially identify additional recognition sequences that might be useful, I 
performed a search of the UniProtKB database with the LicP protease domain (LicP-101-433) as a 
query or the non-redundant protein sequence database with LicA2 as a query using the default 
Blast parameters for proteins provided by National Center for Biotechnology Information (NCBI) 
website. The first 250 hits were subjected to further analysis and quite a few are correlated to class 
II lanthipeptide biosynthesis with clustered LanM proteins. Nine representative class II 
lanthipeptide gene clusters with LanP genes were listed, all of which contain multiple genes for 
LanA substrates (Figure 6.15 and Table 6.2). These LanP proteins share a minimal identity of 30% 
with LicP protease domain with E values lower than e
-26
. The putative cleavage sites for these 
LanP enzymes were proposed to locate immediately C-terminal to the double Gly-type motif used 
by LanT enzymes and upstream of the Thr/Ser/Cys rich core peptides (Figure 6.15). Interestingly, 
all putative LanP recognition sequences consist of six residues with the exception of the A1-A3 
peptides from Bacillus cereus FIR-35, which contain eight residues with two additional amino 
acids at the N-terminus. An Asp at the P5 position and a Val at P4 position are conserved among 
most clusters with the precursor peptides from Bacillus cereus VD045 being exceptions. Pro and 
139 
 
Ala are frequently found at the P2 position, whereas the P1 position is almost exclusively occupied 
by polar/charged residues, such as Asp, Glu, His or Arg, but the putative P1 position of the A1 
peptide from Bacillus thuringiensis DB27 is occupied by Ala. 
 
Figure 6.15 (cont. on next page) 
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Figure 6.15 Thirteen class II lanthipeptide biosynthetic gene clusters containing LanP genes. Genes 
with unknown functions are indicated with X. Substrate LanA sequences are listed under the genetic 
pathways and the putative LanP recognition sequences are highlighted. 
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Table 6.2 Class II LanP proteins and their predicted secretion signal peptide sequences.  
Secretion signal peptide sequences are predicted using an online tool PrediSi (36). 
Name Organism Accession number Signal peptide 
(residue) 
LicP Bacillus licheniformis ATCC 14580 AAU42937.1 1-24 
CylA Eenterococcus faecalis AFJ74725.1 1-24 
CerP Bacillus cereus Q1 ACM15351.1 1-36 
CrnP Carnobacterium maltaromaticum AHF21241.1 1-30 
LanP Bacillus licheniformis 9945A AGN34600.1 1-37 
LanP Bacillus cereus FRI-35 AFQ13336.1 1-25 
LanP Kyrpidia tusciae DSM 2912 ADG07479.1 1-31 
LanP Enterococcus caccae ATCC 
BAA-1240 
EOL44526.1 1-28 
LanP Bacillus cereus VPC1401 YP_004050051.1 1-31 
LanP Bacillus bombysepticus AHX21587.1 1-31 
LanP Bacillus thuringiensis DB27 CDN38711.1 1-36 
LanP Planomicrobium glaciei CHR43 ETP67278.1 1-30 
LanP Bacillus cereus VD045 EJR29324.1 1-27 
 
6.3 Discussion 
In this chapter, I describe the heterologous expression and in vitro characterization of a class 
II LanP protease, a protein class that has not been experimentally characterized before. LicP was 
obtained from E. coli as two fragments that bound tightly to each other in a 1:1 ratio, and the 
observed cleavage is autocatalytic. Such an autocatalytic cleavage has been reported for two class 
I LanPs, NisP and EpiP, which lack the first 195 and 99 amino acids in their mature forms, 
respectively (12, 13). The cleavage event was recently confirmed to be intramolecular for a 
homolog of EpiP (26). Here I show that for LicP, such cleavage can proceed intermolecularly, but 
because such cleavage requires hours of incubation, it is likely that the autoproteolysis also occurs 
intramolecularly under physiological conditions. Interestingly, the E100A mutant was still 
expressed as two fragments with a shift in the cleavage site by two residues to Glu102. This 
observation suggests that a Glu at the P1 position is essential for LicP activity. However, the 
cleavage at Glu102 is still surprising because residues 95-100 in LicP do not appear to be 
homologous to residues 97-102 in LicP-E100A except the cleavage site glutamate (Table 6.1), and 
because ProcA1.7-NDVNPE contains seven glutamates (Figure 6.10), and yet LicP only cleaved 
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after the engineered glutamate at position −1 under the conditions used. Presumably, the linker 
sequence for autocatalytic processing is precisely positioned to maintain a high effective 
concentration such that cleavage at alternative Glu sites is still relatively efficient. 
In addition to its physiological role of trimming a six-residue oligopeptide from LicA2’, LicP 
removed the entire leader peptides from modified and linear LicA2. A substrate consumption rate 
of >80 min
-1
 was observed for LicA2 with the post-translational modifications installed, indicating 
LicP is a highly efficient protease. NisP, the class I LanP responsible for the maturation of the 
lantibiotic nisin, in vivo only accepts modified NisA as its substrate but not the linear version (37, 
38). In accord with these findings, our observations suggest that LicP also favors modified 
substrate in vitro. Such substrate selectivity by LanP proteins is beneficial as it prevents undesired 
consumption of unmodified precursor peptides.  
Although LicP favors modified LicA2 over linear LicA2, which indicates that 
post-translational modifications in the core peptide contribute to LicP’s substrate recognition in 
addition to the NDVNPE sequence, my observations with substrate analogs demonstrate its 
application as a sequence-specific protease for traceless removal of leader peptides or potentially 
expression tags. Collectively, LicP accepted a range of residues at the P1' site (Table 6.1) such as 
glycine, small polar residues (Thr, Cys) and large aliphatic residues (Ile). Also substrates, but less 
efficient, were peptides with Leu, aromatic (Phe, Trp) and charged (Lys, Glu) residues at the P1' 
position. Additional favorable properties include its stability as LicP remained active after 12 
weeks at 4 
o
C, and no obvious decrease of activity was observed after multiple rounds of 
freeze-thaw procedures.  
The thermostability of subtilisin BPN' and related proteases is enhanced significantly in the 
presence of calcium ions, which are necessary for maturation, and subsequent stabilization of a 
large loop in the catalytic domain (39). The calcium dependence constitutes a drawback for 
industrial utility of subtilisin BPN'. Much effort has been spent on engineering thermostable 
mutants of subtilisin that function in a calcium-independent manner (40, 41). The structural and 
biochemical analysis of LicP reveals an elegant solution to this limitation, as maturation and 
subsequent stabilization of the enzyme is facilitated not by metal ions, but rather by the insertion of 
Trp111, liberated by cleavage of the linker between the prodomain and the catalytic domain, into a 
hydrophobic pocket located in the same vicinity as the calcium-binding site in subtilisin BPN'. A 
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recent structure of the class I lanthipeptide protease NisP also demonstrated loss of a calcium 
binding site, although unlike the structure of LicP, the prodomain was not present in the NisP 
structure (22). 
Over the past several decades, the toolbox of useful proteases has been significantly enlarged. 
Several proteases with strict recognition sequences have been commercialized for biochemical or 
industrial applications, including factor Xa, enterokinase, and Tobacco Etch Virus (TEV) protease. 
Factor Xa and enterokinase exhibit trypsin-like activity and cleave after an Arg or Lys. TEV 
protease recognizes a larger motif and exhibits better reliability in terms of specificity, but TEV 
protease requires either a Gly or Ser at the P1' position for efficient cleavage. LicP is 
complementary in that it specifically cleaves after a Glu in the NDVNPE sequence, and is quite 
tolerant of various residues in the P1' position. I also identified nine new class II lanthipeptide gene 
clusters containing lanP genes, suggesting they are more widely distributed than previously 
expected (11). Although the putative recognition sequences of these newly identified LanPs show 
a certain level of homology, they also exhibit considerable diversities. Similar to other proteases, 
most of these LanPs are predicted to cleave after charged residues such as arginine, glutamate or 
aspartate, but a few appear to cleave after unusual P1 residues such as histidine or alanine that are 
rarely the site of cleavage for other proteases (Figure 6.15). Hence, this naturally occurring 
protease family may serve as a basis to construct a general protease pool for traceless tag removal 
purposes (5, 42, 43). For characterization of another class II LanP, CylA, see chapter 7. 
 
6.4 Methods 
General methods 
Similar general methods and materials as what were described in chapter 2 were employed 
in this chapter unless specified otherwise. Solid phase extraction was performed with a Strata-X 
polymeric reverse phase column (Phenomenex). FPLC was carried out using an AKTA FPLC 
system (Amersham Pharmacia Biosystems). Matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) was carried out on a Bruker Daltonics 
UltrafleXtreme MALDI-TOF/TOF mass spectrometer. The detection of peptides with low 
molecular weights (700-3,500 Da), peptides with medium molecular weights (3,500-20,000 Da) 
and proteins with high molecular weights (20,000-50,000 Da) was achieved by using different 
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instrument settings optimized for these mass ranges. C18 zip-tip pipet tips were obtained from 
Millipore to desalt samples for MS analysis. The lichenicidin producing strain, Bacillus 
licheniformis ATCC 14580, was obtained from American Type Culture Collection. 
 
Extraction of genomic DNA from Bacillus licheniformis ATCC 14580 
Bacillus licheniformis ATCC 14580 was cultured in LB medium at 37 
o
C aerobically for 12 h 
and the genomic DNA was extracted using an UltraClean microbial DNA isolation kit following 
the manufacturer’s protocol. 
 
Construction of pRSFDuet-1 derivatives for expression of LicP-25-433 and LicA2 
licP and licA2 genes were amplified from the genomic DNA of Bacillus licheniformis ATCC 
14580 using appropriate primers and cloned into the multiple cloning site 1 (MCS1) of a 
pRSFDuet-1 vector to generate pRSFDuet-1/LicP-25-433 and pRSFDuet-1/LicA2 plasmids, 
respectively. Primer sequences are listed in Table 6.3. 
 
Construction of pRSFDuet-1 derivatives for expression of ProcA1.7-NDVNPE and 
NisA-NDVNPE 
Engineered peptide genes were generated by multi-step overlap extension PCR. First, the 
amplification of the 5’ leader part was carried out by 30 cycles of denaturing (95 °C for 10 s), 
annealing (55 °C for 30 s), and extending (72 °C for 15 s) using forward primers for procA1.7 and 
nisA and appropriate leader peptide reverse primers containing the mutations (Table 6.3) to 
generate a forward megaprimer (FMP). In parallel, PCR reactions using forward primers and 
reverse primers for procA1.7 and nisA core peptides (Table 6.3) were performed to produce the 3’ 
core fragments (termed reverse megaprimer, RMP). The 5’ FMP fragment and 3’ RMP fragment 
were purified by 2% agarose gel, combined in equimolar amounts and amplified using the same 
PCR conditions as above with procA1.7 and nisA primers. The resulting PCR products were 
purified, digested and then cloned into the MCS1 of a pRSFDuet-1 vector to generate 
pRSFDuet-1/ProcA1.7-NDVNPE and pRSFDuet-1/NisA-NDVNPE plasmids. 
 
145 
 
Construction of pRSFDuet-1 derivatives for expression of LicP-25-433-S376A, 
LicP-25-433-H186A, LicP-25-433-E100A, LicP-25-433-E100A-E102A, G-LicA2, 
NisA-NDVNPE-I1G, NisA-NDVNPE-I1T, NisA-NDVNPE-I1C, NisA-NDVNPE-I1L, 
NisA-NDVNPE-I1F, NisA-NDVNPE-I1W, NisA-NDVNPE-I1K and NisA-NDVNPE-I1E 
The expression plasmids pRSFDuet-1/LicP-25-433-S376A, 
pRSFDuet-1/LicP-25-433-H186A, pRSFDuet-1/LicP-25-433-E100A, 
pRSFDuet-1/LicP-25-433-E100A-E102A, pRSFDuet-1/G-LicA2, 
pRSFDuet-1/NisA-NDVNPE-I1G, pRSFDuet-1/NisA-NDVNPE-I1T, 
pRSFDuet-1/NisA-NDVNPE-I1C, pRSFDuet-1/NisA-NDVNPE-I1L, 
pRSFDuet-1/NisA-NDVNPE-I1F, pRSFDuet-1/NisA-NDVNPE-I1W, 
pRSFDuet-1/NisA-NDVNPE-I1K and pRSFDuet-1/NisA-NDVNPE-I1E  were generated using 
QuikChange methodology based on pRSFDuet-1/LicP-25-433, pRSFDuet-1/LicA2 and 
pRSFDuet-1/NisA-NDVNPE as templates. Primer sequences are listed in Table 6.3. 
 
Construction of pRSFDuet-1 derivatives for co-expression of LicM2 with LicA2 
LicM2 was amplified from the genomic DNA of Bacillus licheniformis ATCC 14580 using 
appropriate primers and cloned into the MCS2 of a pRSFDuet-1 vector to generate 
pRSFDuet-1/LicM2-2. The expression plasmid pRSFDuet-1/LicA2/LicM2-2 was constructed by 
inserting the licA2 gene into the MCS1 of the pRSFDuet-1/LicM2-2 plasmid. Primer sequences 
are listed in Table 6.3. 
 
Table 6.3 Primer sequences for cloning of licP-25-433, licM2, licA2, licP-25-433-S376A, 
licP-25-433-H186A, licP-25-433-E100A, licP-25-433-E100A-E102A, G-licA2, procA1.7-NDVNPE, 
nisA-NDVNPE, nisA-NDVNPE-I1G, nisA-NDVNPE-I1T, nisA-NDVNPE-I1C, nisA-NDVNPE-I1L, 
nisA-NDVNPE-I1F, nisA-NDVNPE-I1W, nisA-NDVNPE-I1K and nisA-NDVNPE-I1E.  
Primer Name Primer Sequence (5'-3') 
LicP_25_BamHI_FP AAAAA GGATCCG AAAGAACAAGCAGGAGAACAG 
LicP_NotI_RP AAAAA GCGGCCGC TCACTCCTTG TTCATCATTT T 
LicA2_BamHI_FP AAAAA GGATCCG ATGAAAACAA TGAAAAATTC A 
LicA2_NotI_RP AAAAA GCGGCCGC CTAGCATCGG CTTGTACACT T 
LicM2_NdeI_FP AAAAA CATATG GTTTTCT TCGCCAAAGG GATG 
LicM2_KpnI_RP AAAAA GGTACC TCACCTGCCC GTCGGAATAT C 
G-LicA2_ _QC_FP CCAGGAT GGT ATGAAAAC AATGAAA AATTCAGCTGCCCGT 
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Table 6.3 (cont.)  
G-LicA2_QC_RP GTTTTCAT ACC ATCCTGG CT GTGGTGATGA TGGTGATGG 
ProcA1.7_EcoRI_FP GGT GCG AGG AAT TCG ATG AAG CAT AGA CAA CTA AAT 
CTG 
ProcA1.7_NotI_RP ATA ATA TCG CGG CCG CTC AGC ACA TTT TCC C 
NisA_BamHI_FP CTA GAT GGA TCC GAT GAG TAC AAA AGA TTT TAA CTT GG  
NisA_HindIII_RP CTA GAA GCT TTT ATT TGC TTA CGT GAA TAC TAC AAT G  
LicP-S376A_QC_FP GGAACA GCA TTGGCC GCCCCG CAGGTAGCT 
LicP-S376A_QC_RP GG CCAA TGC TGT TCC GTATGAG AGGGAATATC 
CCTTTGGGAT 
LicP-H186A_QC_FP ACA GGA GCC GGAAC ACAA ACAGCCGGGATGATCAATATC 
LicP-H186A_QC_RP G TTCC GGC TCC TGT CGGATCT CCGGATACAG GC 
LicP-E100A_QC_FP CAGTAAAC GCA ACGGAATC A GTCATCAGCGGTTCGCC 
LicP-E100A_QC_RP GATTCCGTTGCGTTTACTG CTGTATT TGCAATCGGC 
TTTTCAATGAC 
LicP-E100A-E102A_QC_FP GCAACG GCA TCAGTC ATCAGCGGTTCGCCTG 
LicP-E100A-E102A _QC_RP GACTGA TGC CGTTGC GTTTA CTGCTGTATT TGCAATCGGC 
ProcA1.7_core_FP ACCATTGGGGGA ACCATTGTG 
ProcA1.7- NDVNPE _RP GGTTCC CCCAATGGT TTCAGGATTGACGTCATT CAG 
CTCAGCATCA GACAGGT 
NisA_core _FP ATTACAAGTATTTCGCTATGT 
NisA- NDVNPE _RP CGAAATACTT GTAAT TTCAGGATTGACGTCATT ATCTTTC 
TTCGAAACAG ATA 
NisA-NDVNPE-I1G_QC_FP CAATCCTGAA GGT ACAAGTATTTC GCTATGTACACC 
CGGTTGTAAAAC 
NisA-NDVNPE-I1G_QC_RP GAAATACTTGT ACC TTCAGGATTG 
ACGTCATTATCTTTCTTCGAAACAGATACC 
NisA-NDVNPE-I1C_QC_FP CAATCCTGAA TGT ACAAGTATTTC GCTATGTACACC 
CGGTTGTAAAAC 
NisA-NDVNPE-I1C_QC_RP GAAAT ACTTGT ACA TTCAGGATTG 
ACGTCATTATCTTTCTTCGAAACAGATACC 
NisA-NDVNPE-I1T_QC_FP CAATCCTGAA ACC ACAAGTATTTC GCTATGTACACC 
CGGTTGTAAAAC AG 
NisA-NDVNPE-I1T_QC_RP GAAATACTTGT GGT TTCAGGATTG 
ACGTCATTATCTTTCTTCGAAACAGATACCA 
NisA-NDVNPE-I1L_QC_FP CAATCCTGAA CTT ACAAGTATTTC GCTATGTACACC 
CGGTTGTAAAAC 
NisA-NDVNPE-I1L_QC_RP GAAATACTTGT AAG TTCAGGATTG 
ACGTCATTATCTTTCTTCGAAACAGATACC 
NisA-NDVNPE-I1F_QC_FP CAATCCTGAA TTT ACAAGTATTTC GCTATGTACACC 
CGGTTGTAAAAC 
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Table 6.3 (cont.)  
NisA-NDVNPE-I1F_QC_RP GAAATACTTGT AAA TTCAGGATTG 
ACGTCATTATCTTTCTTCGAAACAGATACC 
NisA-NDVNPE-I1W_QC_FP CAATCCTGAA TGG ACAAGTATTTC GCTATGTACACC 
CGGTTGTAAAAC 
NisA-NDVNPE-I1W_QC_RP GAAATACTTGT CCA TTCAGGATTG 
ACGTCATTATCTTTCTTCGAAACAGATACC 
NisA-NDVNPE-I1K_QC_FP CAATCCTGAA AAA ACAAGTATTTC GCTATGTACACC 
CGGTTGTAAAAC 
NisA-NDVNPE-I1K_QC_RP GAAATACTTGT TTT TTCAGGATTG 
ACGTCATTATCTTTCTTCGAAACAGATACC 
NisA-NDVNPE-I1E_QC_FP CAATCCTGAA GAA ACAAGTATTTC GCTATGTACACC 
CGGTTGTAAAAC 
NisA-NDVNPE-I1E_QC_RP GAAATACTTGT TTC TTCAGGATTG 
ACGTCATTATCTTTCTTCGAAACAGATACC 
 
Expression and purification of LicP and LicP mutant proteins 
E. coli BL21 (DE3) cells were transformed with one of the following plasmids: 
pRSFDuet-1/LicP-25-433, pRSFDuet-1/LicP-25-433-S376A, pRSFDuet-1/LicP-25-433-H186A, 
pRSFDuet-1/LicP-25-433-E100A or pRSFDuet-1/LicP-25-433-E100A-E102A, and plated on an 
LB plate containing 50 mg/L kanamycin. A single colony was picked and grown in 20 mL of LB 
with kanamycin at 37 
o
C for 12 h and the resulting culture was inoculated into 2 L of LB. Cells 
were cultured at 37 
o
C until the OD at 600 nm reached 0.5, cooled and IPTG was added to a final 
concentration of 0.1 mM. The cells were cultured at 18 
o
C for another 10 h before harvesting. The 
cell pellet was resuspended on ice in LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5 at 25
 o
C) and 
lysed by homogenization. The lysed sample was centrifuged at 23,700×g for 30 min and the pellet 
was discarded. The supernatant was passed through 0.45-µm syringe filters and the protein was 
purified by immobilized metal affinity chromatography (IMAC) loaded with nickel as previously 
described (44). The proteins were generally eluted from the column at an imidazole concentration 
between 150 mM and 300 mM and the buffer was exchanged using a GE PD-10 desalting column 
or a gel-filtration column pre-equilibrated with LanP buffer. Protein concentration was quantified 
by its absorbance at 280 nm. The extinction coefficient for His6-LicP-25-433 was calculated as 
46,300 M
-1
 cm
-1
. His6-LicP-25-433-S376A was expressed dominantly in the inclusion body. 
Soluble protein was obtained by combining fractions eluted from the nickel column with the 
desired protein and concentrating to a small volume. No gel filtration was performed for the 
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mutant protein. Yield was determined to be 50 µg for 1 L culture. Aliquoted protein solutions were 
flash-frozen and kept at −80 oC until further usage. 
 
Expression and purification of modified His6-LicA2 
Modified LicA2 was obtained using a similar procedure described previously using the 
corresponding co-expression vector (45, 46).  
 
Expression and purification of unmodified His6-LicA2, His6-G-LicA2, 
His6-ProcA1.7-NDVNPE, His6-NisA-NDVNPE, His6-NisA-NDVNPE-I1G, 
His6-NisA-NDVNPE-I1T, His6-NisA-NDVNPE-I1C, His6-NisA-NDVNPE-I1L, 
His6-NisA-NDVNPE-I1F, His6-NisA-NDVNPE-I1W, His6-NisA-NDVNPE-I1K and 
His6-NisA-NDVNPE-I1E 
E. coli BL21 (DE3) cells were transformed with one of the following plasmids:  
pRSFDuet-1/LicA2, pRSFDuet-1/G-LicA2, pRSFDuet-1/ProcA1.7-NDVNPE, 
pRSFDuet-1/NisA-NDVNPE, pRSFDuet-1/NisA-NDVNPE-I1G, 
pRSFDuet-1/NisA-NDVNPE-I1T, pRSFDuet-1/NisA-NDVNPE-I1C, 
pRSFDuet-1/NisA-NDVNPE-I1L, pRSFDuet-1/NisA-NDVNPE-I1F, 
pRSFDuet-1/NisA-NDVNPE-I1W, pRSFDuet-1/NisA-NDVNPE-I1K or 
pRSFDuet-1/NisA-NDVNPE-I1E. Then the cells were plated on an LB plate containing 50 mg/L 
kanamycin. A single colony was picked and grown in 10 mL of LB with kanamycin at 37 
o
C for 12 
h and the resulting culture was inoculated into 1 L of LB. Cells were cultured at 37 
o
C until the OD 
at 600 nm reached 0.5 and IPTG was added to a final concentration of 0.2 mM. The cells continued 
to be cultured at 37 
o
C for another 3 h before harvesting. The cell pellet was resuspended at room 
temperature in LanA start buffer (20 mM NaH2PO4, pH 7.5 at 25
 o
C, 500 mM NaCl, 0.5 mM 
imidazole, 20% glycerol) and lysed by sonication. The sample was centrifuged at 23,700×g for 30 
min and the supernatant was discarded. The pellet was then resuspended in LanA buffer 1 (6 M 
guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25
 o
C, 500 mM NaCl, 0.5 mM imidazole) 
and sonicated again. The insoluble portion was removed by centrifugation at 23,700×g for 30 min 
and the soluble portion was passed through 0.45-µm syringe filters. His-tagged peptides were 
purified by IMAC as previously described (44). The eluted fractions were desalted using reverse 
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phase HPLC or a Strata X polymeric reverse phase SPE column. The desalted peptides were 
lyophilized and stored at −20 oC for future use. 
 
Intermolecular cleavage of His6-LicP-25-433-S376A by His6-LicP-25-433 
His6-LicP-25-433-S376A and His6-LicP-25-433 proteins were both diluted with LanP buffer 
to a final concentration of 0.2 mg/mL. Parallel reactions were set up for His6-LicP-25-433 only 
with a final protein concentration of 0.1 mg/mL in LanP buffer, His6-LicP-25-433-S376A only 
with a final protein concentration of 0.1 mg/mL in LanP buffer, and His6-LicP-25-433-S376A and 
His6-LicP-25-433 together with a final protein concentration of 0.1 mg/mL each. The three 
reactions were allowed to proceed at room temperature for 0, 2, 4, 7 and 19 h before being stopped 
by addition of SDS loading buffer and boiling at 95 
o
C for 10 min. 
 
Sequential proteolytic cleavage of modified LicA2 
HPLC-purified LicM2-modified LicA2 was dissolved in H2O to a final concentration of 3 
mg/mL (340 µM). To a 17 μL solution of peptide (final peptide concentration 290 µM), 2 μL of 
500 mM HEPES buffer (pH 7.5) was added followed by 1 μL of 0.5 mg/mL AspN. The reaction 
mixture was kept at room temperature for 12 h before 0.5 μL of 0.1 mg/mL LicP (final protein 
concentration 50 nM) was added. The reaction was then incubated at room temperature for one 
more hour. MALDI-TOF MS analysis was performed after each step.  
 
Removal of leader peptides of modified or linear LicA2 
Modified or linear LicA2 peptides were dissolved in H2O to make a 3 mg/mL solution (340 
µM). To a 17 μL solution of peptide (final peptide concentration 290 µM), 2 μL of 500 mM 
HEPES buffer (pH 7.5) was added followed by 1 μL of 1 mg/mL LicP (final protein concentration 
1.1 µM). The reaction was incubated at room temperature for 6 h followed by MS analysis. 
 
Competition assay of LicP activity with modified and linear LicA2 
To a reaction vessel with 70 μL deionized H2O, 5 μL each of 3 mg/mL modified LicA2 and 
linear G-LicA2 peptides were added (final peptide concentration 17 µM each) followed by 10 μL 
of 500 mM HEPES buffer (pH 7.5). Then, 10 μL of 0.01 mg/mL LicP was supplied (final protein 
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concentration 21 nM) and the reaction was incubated at room temperature before being stopped by 
addition of formic acid to a final concentration of 1% at different time points. To observe the 
complete consumption of both peptides, the same concentration and combination of substrate 
peptides were employed, to which 10 μL of 1 mg/mL LicP was added (final protein concentration 
2.1 μM). The reaction mixture was kept at room temperature for 12 h before being stopped with 1% 
formic acid for MS analysis.  
 
Proteolytic cleavage of the leader peptides of engineered peptides 
ProcA1.7-NDVNPE was dissolved in H2O to a final concentration of 3 mg/mL (250 µM), 
whereas for NisA-NDVNPE and its mutant peptides, a 10 mg/mL peptide solution was made (1.3 
mM). For ProcA1.7-NDVNPE, 15 µL of peptide solution (final peptide concentration 190 µM) 
was pre-mixed with 1 µL of 50 mM DTT and 2 μL of 500 mM HEPES buffer (pH 7.5), to which 2 
µL of 0.1 mg/mL LicP (final protein concentration 210 nM) was added. The reaction was 
incubated at room temperature for 4 h before analysis. For NisA-NDVNPE-I1T and 
NisA-NDVNPE-I1C, 1 µL of peptide (final peptide concentration 65 µM) was pre-mixed with 1 
µL of 50 mM DTT and 2 μL of 500 mM HEPES buffer (pH 7.5) in 14 µL H2O, to which 2 µL of 0.1 
mg/mL LicP (final protein concentration 210 nM) was added. The reaction was incubated at room 
temperature for 20 h before analysis. For NisA-NDVNPE and other NisA mutant peptides, 1 
mg/mL LicP (final protein concentration 2.1 µM) was employed instead of 0.1 mg/mL and the 
reaction was kept at room temperature for 30 h before being stopped for MS analysis.  
 
Crystallization of LicP  
This part was performed by Dr. Shi-Hui Dong and Prof. Satish K. Nair. 
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Chapter 7. Characterization of CylA, a Protease Involved in Toxin 
Biosynthesis 
 
7.1 Introduction 
As described in chapter 2, cytolysin is a unique lanthipeptide produced by many clinical 
isolates of Enterococcus faecalis that displays lytic activities against eukaryotic cells including 
human immune cells, in addition to its antimicrobial activities. Cytolysin has been linked to 
virulence enhancement in animal models infected by E. faecalis and acute patient mortality in 
the clinic (1, 2). 
CylA is an extracellular serine protease required for the biosynthesis of cytolysin that 
belongs to the class II LanP family introduced in sections 1.4 and 6.1. The production of the 
toxin initiates with the synthesis of the linear precursor peptides CylLL and CylLS by the 
ribosome followed by the installation of thioether rings by the lanthionine synthetase CylM. 
Subsequently, CylB, a LanT protein, removes the majority of the leader peptide to generate 
CylLL’ and CylLS’ (Figure 7.1) (3). Extracellularly, CylA further trims these peptides by 
removing six amino acids at the N-terminus of the core peptides to form CylLL” and CylLS” 
(cytolysin L and S), the two peptides that make up mature cytolysin (Figure 7.1) (4). The study 
presented in chapter 6 suggests that after cleavage of the zymogen, the N- and C-terminal 
fragments are stabilized as a complex by extensive hydrophobic interactions, which is different 
from most subtilisin-related proteases (5). 
 
Figure 7.1 The biosynthetic gene cluster of enterococcal cytolysin and the sequential cleavage event 
employed during cytolysin maturation.  
156 
 
All currently annotated class II LanP proteins contain an N-terminal secretion signal peptide 
and are therefore believed to be extracellularly located (5). It has been confirmed for LicP that 
the removal of such a secretion signal peptide is achieved by an autocatalytic mechanism, with 
which the first 100 amino acids are tailored during maturation (5). Similar observations were 
reported for two class I LanPs, NisP and EpiP, which lack the first 195 and 99 amino acids in 
their mature forms, respectively (6, 7). The removal of a pro-sequence was suggested to activate 
the protease for its LanA substrate (6). However, to date the full length proteins have never been 
accessed for any of these LanPs. As a result, no activity comparison has been performed between 
the mature, processed form of LanP and its full length version to confirm the activation upon 
removal of the pro-sequence.  
In order to better understand the maturation process of the enterococcal cytolysin and to 
mine more lanthipeptidases with novel sequence-specificities, in this chapter, I described the 
reconstitution of the activity of CylA in vitro, provide evidence that it self-activates, and 
demonstrate that it recognizes a specific cleavage sequence but is rather tolerant of sequence 
context. Similar to other sequence-specific proteases, CylA may have a broad range of 
applications in biotechnology (8, 9).  
 
7.2 Results 
The gene encoding CylA was synthesized codon-optimized for E. coli expression. Residues 
1-26 that are predicted to constitute a secretion signal peptide were omitted. The protein was 
expressed in E. coli with an N-terminal His6-tag and purified by immobilized metal affinity 
chromatography. Purified CylA showed 3 bands when analyzed by SDS-PAGE, with one band 
corresponding to the full length His6-CylA-27-412 and two other bands appearing at molecular 
weights of about 35 kDa and 10 kDa (Figure 7.2a). MALDI-TOF MS analysis indicated masses 
of 9,591 Da and 34,815 Da (Figure 7.2b), consistent with an N-terminal fragment 
(His6-CylA-27-95; calculated mass 9,591 Da) and a C-terminal fragment (CylA-96-412; 
calculated mass 34,812 Da). This observation suggested a cleavage event after Glu95, in 
accordance with a previous report (4). Moreover, His6-CylA-27-412-E95A was expressed and 
purified only as the full length protein, confirming the proposed cleavage site (Figure 7.3).  
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Figure 7.2 Analysis of His6-CylA-27-412. (a) SDS-PAGE gel of His6-CylA-27-412. MALDI-TOF mass 
spectra of the N-terminal fragment (b), and the C-terminal fragment and full length form (c) of 
His6-CylA-27-412.  
 
Figure 7.3 SDA-PAGE (a) and MALDI-TOF MS (b) analyses of His-CylA-27-412-E95A. (Calculated 
M: 44328, average mass; observed M+H
+
: 44319, average mass.) 
CylA is a subtilisin-like serine protease with a conserved catalytic triad consisting of 
aspartate, histidine and serine. To test whether the observed cleavage was autocatalytic, another 
CylA mutant was constructed with the catalytic Ser359 substituted by Ala, which was also 
purified only in its full length form (Figure 7.4). Therefore, it is concluded that CylA itself 
catalyzes the cleavage at position 95. These findings mirror two very recent reports, one on the 
class I lanthipeptidase EpiP and one on the class II peptidase LicP, both of which employ an 
autocatalytic mechanism to cleave a pro-sequence from the mature protease (5, 10). Incubation 
of His6-CylA-27-412-S359A with His6-CylA-27-412 revealed that such a cleavage could 
proceed intermolecularly (Figure 7.5). 
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Figure 7.4 SDS-PAGE (a) and MALDI-TOF MS (b) analyses of His-CylA-27-412-S359A. 
(Calculated M: 44370, average mass; observed M+H
+
: 44348, average mass.) 
 
Figure 7.5 Determination if CylA cleavage is intra or intermolecular. To differentiate whether the 
self-cleavage of CylA occurred intramolecularly or intermolecularly, His6-CylA-27-412 (a mixture of 
His6-CylA-27-412 and partial cleaved products His6-CylA-27-95 and CylA-95-412) and 
His6-CylA-27-412-S359A were incubated alone or together. The reaction was monitored by SDS-PAGE 
to determine whether wild type CylA catalyzes the proteolytic cleavage of His6-CylA-27-412-S359A. 
When incubated alone, His6-CylA-27-412 self-cleaves into 2 fragments, while His6-CylA-27-412-S359A 
did not show any changes throughout the 22-hour period when incubated alone. When the two proteins 
were incubated together, His6-CylA-27-412-S359A was gradually consumed, suggesting that the observed 
cleavage of CylA can take place intermolecularly. For all reactions, His6-CylA-27-412 was supplied with 
a final concentration of 0.8 mg/mL, while His6-CylA-27-412-S359A was supplied with a final 
concentration of 0.2 mg/mL.  
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Figure 7.6 In vitro activity of CylA. (a) MALDI-TOF mass spectra of CylLL” (left) and CylLS” (right) 
with a 5-amino acid peptide (DVQAE) remaining from the leader incubated with (magenta) or without 
(blue) CylA. (DVNPE-CylLL”, calculated M: 3980.6, average mass; observed M+H
+
: 3981.1, average 
mass. CylLL”, calculated M: 3438.0, average mass; observed M+H
+
: 3438.5, average mass. 
DVNPE-CylLS”, calculated M: 2575.0, average mass; observed M+H
+
: 2575.4, average mass. CylLS”, 
calculated M: 2032.4, average mass; observed M+H
+
: 2034.0, average mass.) (b) MALDI-TOF mass 
spectra of modified CylLL (left) and CylLS (right) incubated with CylA. (CylLL leader, calculated M: 
4806, average mass; observed M+H
+
: 4804, average mass. CylLS leader, calculated M: 6316, average 
mass; observed M+H
+
: 6323, average mass.) (c) Antimicrobial activities of protease digested peptides 
against L. lactis HP. Spots 1 and 2: CylM-modified and trypsin-digested CylLL-E−1K and CylLS-E−1K, 
respectively; spot 3, samples 1+2; spots 4 and 5: CylM-modified and CylA-digested CylLL and CylLS, 
respectively; spot 6, samples 4+5. For all samples, 500 pmol were spotted. (d) Hemolytic activity of 
mature cytolysin obtained by CylA digestion. (e) MALDI-TOF mass spectra of linear CylLL (left) and 
CylLS (right) incubated with CylA. (CylLL leader, calculated M: 4806, average mass; observed M+H
+
: 
4804, average mass. CylLS leader, calculated M: 6796, average mass; observed M+H
+
: 6796, average 
mass.) 
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I next tested the activity of CylA with the CylLL and CylLS peptides. Dehydrated and 
cyclized CylLL and CylLS were obtained by coexpression with their lanthionine synthetase CylM 
in E. coli (11). Instead of using the membrane protein CylB (12), the commercial protease AspN 
was employed, which specifically cleaved N-terminal to Asp−5, leaving five amino acids 
(DVQAE) on the core peptides. These peptides were incubated with CylA and the five amino 
acids were successfully removed (Figure 7.6a). I also incubated CylA with full-length modified 
CylLL and CylLS, and MS analysis demonstrated clean removal of the entire leader peptides 
(Figure 7.6b). Cytolysin obtained in this way exhibited the anticipated antimicrobial activity 
against Lactococcus lactis HP (Figure 7.6c) and hemolytic activity against rabbit red blood cells 
(Figure 7.6d). Similar results were observed for lichenicidin, where the pre-treatment with LicT 
is not absolutely necessary for LicP recognition (5). Importantly, CylA did not require 
post-translational modifications of the precursor peptides as it also removed the leader peptides 
from linear CylLL and CylLS (Figure 7.6e). 
To further understand the substrate preference of CylA with respect to linear or modified 
substrates, I performed a MALDI-TOF MS-based competitive assay for semi-quantitative 
analysis, where CylA was supplied to a mixture of equimolar amounts of modified and linear 
CylLS and the consumption of precursor peptides as well as the production of leader peptides 
was monitored over time. A Pro to Gly mutation was introduced between the hexa-histidine tag 
and linear CylLS peptide (G-CylLS) to differentiate the otherwise identical leader peptides (ΔMr 
= 40 for resulting leader peptides). A 60-fold excess of modified and linear CylLS were incubated 
with CylA and complete consumption of modified CylLS was achieved in about 20 min. In 
comparison, the cleavage of linear CylLS was slower and required 160 min to complete (Figure 
7.7). As a result, these observations suggest that, although both can be accepted as substrates, 
CylA prefers modified CylLS over its linear version. 
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Figure 7.7 Time-dependent MALDI-TOF MS analysis of modified CylLS and linear G-CylLS 
treated with CylA. Peptides were each supplied with a final concentration of 12 μM in the presence of 
0.2 μM His6-CylA-27-412. The intensity of modified CylLS precursor peptide was set to 100% for starting 
materials in the region of 8,280-8,420 Da, whereas the intensity of CylLS P–1G leader peptide was set to 
100% for reactions proceeding 160 min and 540 min (final product) in the region of 6,220-6,380 Da. For 
other traces, relative signal intensities in precursor peptide region and leader peptide region were adjusted 
to make the percentage of leader peptide peak comparing to the corresponding final product peak 
(percentage of formed product) and the percentage of precursor peptide peak comparing to the 
corresponding starting material peak (percentage of starting material left) added up to 1. 
 
It has been suggested that sequence-specific cleavage could be generally achieved by class 
II lanthipeptidases with LicP as one example (5). To test whether this hypothesis is applicable for 
CylA, I engineered the proposed recognition sequence GDVQAE into two linear peptides - 
ProcA1.7 and NisA (Figure 7.8). The putative recognition sequence was installed between the 
leader and core peptides by substituting the residues at positions −6 to −1. Upon incubation with 
CylA, the leader peptides of both ProcA1.7-GDVQAE and NisA-GDVQAE were successfully 
removed (Figure 7.9). 
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Figure 7.8 Precursor peptide sequences of lanthipeptides used in this chapter. 
 
Figure 7.9 MALDI-TOF mass spectra for ProcA1.7-GDVQAE (a) and NisA-GDVQAE (b) peptides 
treated with CylA. (ProcA1.7 leader, calculated M: 9935, average mass; observed M+H
+
: 9936, average 
mass. Oxidized ProcA1.7 core, calculated M–2H: 2254.1, isotopic mass; observed M–2H+H+: 2255.8, 
isotopic mass. NisA leader, calculated M: 4008, average mass; observed M+H
+
: 4005, average mass.) 
 
The tolerance of CylA for the amino acid at the P1’ position was evaluated by altering this 
position in ProcA1.7-GDVQAE from threonine to glycine, phenylalanine or tryptophan. CylA 
specifically cleaved after Glu−1 for all three mutant peptides, albeit with a lower efficiency for 
the T−1G mutant as demonstrated by MALDI-TOF MS (Figure 7.10). Peptides with N-terminal 
Cys residues have great utilization in native chemical ligation or expressed protein ligation (13, 
14). However, such peptides are often not accessible by target site proteolytic cleavage as quite a 
few commonly used proteases do not accept a Cys at the P1’ position of substrates. Yet CylA 
tolerates P1’ Cys well by cleanly removing the leader peptides of both ProcA1.7-GDVQAE-T1C 
and NisA-GDVQAE-I1C peptides (Figure 7.11). Collectively, these results show that the 
activity of CylA is highly portable (Table 7.1). 
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Figure 7.10 MALDI-TOF mass spectra for ProcA1.7-GDVQAE-T1G (a), ProcA1.7-GDVQAE-T1F 
(b), and ProcA1.7-GDVQAE-T1W (c) treated with CylA. Different instrument settings were used for 
the peptides shown in the insets. (ProcA1.7 leader, calculated M: 9935, average mass; observed M+H
+
: 
9936 (a), 9935 (b), 9936 (c), average masses. ProcA1.7-T1G core, calculated M: 2212.1, monoisotopic 
mass; observed M+H
+
: 2212.0, monoisotopic mass. ProcA1.7-T1F core, calculated M: 2302.1, 
monoisotopic mass; observed M+H
+
: 2302.4, monoisotopic mass. ProcA1.7-T1W core, calculated M: 
2341.1, monoisotopic mass; observed M+H
+
: 2341.1, monoisotopic mass.) 
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Figure 7.11 MALDI-TOF mass spectra for ProcA1.7-GDVQAE-T1C (a) and NisA-GDVQAE-T1C 
(b) treated with CylA. (ProcA1.7 leader, calculated M: 9935, average mass; observed M+H
+
: 9937, 
average mass. ProcA1.7-T1C core, calculated M: 2258.1, monoisotopic mass; observed M+H
+
: 2259.5, 
monoisotopic mass. NisA leader, calculated M: 4008, average mass; observed M+H
+
: 4006, average mass. 
NisA-T1C core, calculated M: 3485.6, monoisotopic mass; observed M+H
+
: 3482.9, monoisotopic mass.) 
 
To expand the possible utility of CylA for mining novel RiPPs, I tested CylA’s tolerance 
with post-translationally modified peptides. The GDVQAE sequence was engineered into HalA1 
and HalA2, the precursor peptides for haloduracin α and β (Halα and Halβ), which constitute a 
two-component lantibiotic (15). HalA1-GDVQAE and HalA2-GDVQAE peptides were 
co-expressed with their cognate lanthionine synthetases HalM1 or HalM2 in E. coli, resulting in 
the anticipated post-translational modifications including three thioether crosslinks for HalA1 
and four such rings in addition to three extra dehydrations in HalA2 (Figures 7.12 and 7.13). 
These modified peptides were then incubated with CylA and their leader peptides were 
successfully removed (Figures 7.12 and 7.13), suggesting that unnatural amino acids located in 
close proximity to the cleavage site do not significantly decrease CylA’s proteolytic activity. 
Encouraged by these results, I further engineered the cleavage site between the hexa-histidine tag 
and modified ProcA1.7 peptide (16). Incubation with CylA indeed resulted in clean removal of 
the hexa-histidine sequence (Figure 7.14), confirming that CylA could be applied for expression 
tag removal purposes. 
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Figure 7.12 MALDI-TOF mass spectra for HalM1-modified HalA1-GDVQAE peptide with (b) or 
without (a) the treatment of CylA. (HalM1 modified HalA1-GDVQAE, calculated M: 9626 (with a 
disulfide linkage), average mass; observed M+H
+
: 9625, average mass. HalA1 leader, calculated M: 6598, 
average mass; observed M+H
+
: 6599, average mass. HalA1 core, calculated M: 3048 (reduced), average 
mass; observed M+H
+
: 3048, average mass.) 
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Figure 7.13 Leader peptide removal of HalA2-GDVQAE peptide catalyzed by CylA. (a) 
MALDI-TOF mass spectrum for HalM2-modified HalA2-GDVQAE peptide. (HalM2 modified 
HalA2-GDVQAE, calculated M: 8332, average mass; observed M+H
+
: 8333, average mass.) (b) 
MALDI-TOF mass spectrum of modified HalA2-GDVQAE peptide incubated with CylA. (HalA2 leader, 
calculated M: 6018, average mass; observed M+H
+
: 6819, average mass. HalA2 core, calculated M: 
2330.0, monoisotopic mass; observed M+H
+
: 2331.0, monoisotopic mass.) (c) Antimicrobial activity of 
mature Halβ obtained by CylA in combination with Halα against Lactococcus lactis HP. 1, 500 pmol Halα 
+ 500 pmol Halβ; 2, 500 pmol Halα; 3, 500 pmol Halβ; 4, 500 pmol Halα + 500 pmol HalA2-GDVQAE; 
5, 500 pmol HalA2-GDVQAE; 6, 500 pmol Halα + 500 pmol HalA2-GDVQAE treated with CylA; 7, 
500 pmol HalA2-GDVQAE treated with CylA; 8, 100 pmol nisin. 
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Figure 7.14 MALDI-TOF mass spectra for ProcM-modified His6-GDVQAE-ProcA1.7 peptide with 
(b) or without (a) the treatment of CylA. (ProcM modified His6-GDVQAE-ProcA1.7, calculated M: 
12600, average mass; observed M+H
+
: 12604, average mass. ProcA1.7, calculated M: 10859, average 
mass; observed M+H
+
: 10862, average mass. His6-GDVQAE, calculated M: 1758.7, monoisotopic mass; 
observed M+H
+
: 1759.4, monoisotopic mass.) 
 
 I next returned to the importance of the autocatalytic processing step for activity. To assess 
the effect of self-cleavage on the rate of substrate cleavage, CylA-96-412 and 
His6-CylA-27-412-E95A were incubated with modified CylLS, and the formation of CylLS’’ was 
monitored by liquid chromatography MS. CylA-96-412 catalyzed substrate proteolysis at a rate 
of 20 min
-1
 under the conditions used, whereas His6-CylA-27-412-E95A exhibited an 
approximate 10-fold lower rate (Figure 7.15). Thus, the self-cleavage event leads to activation of 
CylA, although the autoproteolysis is not absolutely required for protease activity under the 
tested conditions. The recent X-ray structure of a homolog of the class I protease EpiP illustrates 
that upon cleavage, the pro-domain interacts non-covalently with the catalytic domain through 
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complementary electrostatic surfaces (10). This leaves the active site of the processed enzyme 
more exposed, which may explain the increased activity observed in this work for processed 
CylA. 
 
Figure 7.15 Kinetic analysis of CylA’s proteolytic activities against modified CylLS with full length 
CylA(a), and after autoproteolytic processing (b). CylA-96-412 (a) and His6-CylA-27-412-E95A (b) 
were at concentrations of 22 nM and 110 nM, respectively, with modified CylLS supplied at a 
concentration of 36 μM. Proteolytic reactions were stopped at different time points by 1% TFA and 
analyzed by LC/MS. Extracted ion chromatographs for mature CylLS” that was produced were overlayed. 
Proteolytic reactions that were allowed to proceed for 24 hours were treated with the same procedure and 
serve as positive controls with 100% product formation. 
 
7.3 Discussion 
CylA’s activity was successfully reconstituted in vitro, which demonstrated that it accepts 
both modified and linear cytolysin precursor peptides. Consistent with what has been reported 
for NisP, LicP and a prolyloligopeptidase-type protease FlaP identified for the biosynthesis of 
class III lanthipeptide flavipeptin (5, 6, 17), CylA cleaves modified CylLS more efficiently than 
linear CylLS. Moreover, I provided evidence that CylA can serve as a sequence-specific protease 
that exhibits considerable tolerance for the P1’ site and cleaves before glycine, cysteine, aromatic 
residues (phenylalanine, tryptophan), or branched residues (isoleucine) (Table 7.1), supporting 
the previous hypothesis regarding sequence-specific cleavage of class II LanPs (5). CylA can 
also remove small expression tags when the recognition sequence is installed. The removal of 
leader peptides of lanthipeptides is often difficult as most of the currently available commercial 
proteases do not tolerate non-proteinogenic amino acids such as dehydro amino acids, 
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lanthionine or methyllanthionine located in close proximity to cleavage sites. CylA does tolerate 
these structures and provides a significant advantage when acting on such peptides, making it a 
powerful tool for synthetic biology efforts with RiPPs. A general strategy for the leader peptide 
removal step provided by CylA will also greatly aid genome mining for novel RiPPs. 
 
Table 7.1 Peptides with different P’ sequences that are accepted by CylA.  
Peptide P’ position[a] 
CylLL
[b]
 TTPVC (or MeLan) 
CylLS
[b]
 TTPAC (or MeLan) 
NisA ITSIS 
ProcA1.7 TIGGT 
ProcA1.7-T1G GIGGT 
ProcA1.7-T1F FIGGT 
ProcA1.7-T1W WIGGT 
NisA-I1C CTSIS 
ProcA1.7-T1C CIGGT 
HalA1 CAWYN  
HalA2
[c]
 TTWPC (MeLan) 
His6-ProcA1.7
[d]
 TDPNS 
[a] All peptides have the GDVQAE sequence before the P1’ position. 
[b] These peptides are substrates with the linear sequences shown and also after the Cys in the 5
th
 position 
formed a MeLan with the Thr at position 1.  
[c] Peptide contains a MeLan residue at the P1’ position.  
[d] GDVQAE sequence is inserted between the His-tag sequence and ProcA1.7. 
 
Although multiple groups have reported that mature LanPs purified from the supernatant of 
their producing strains lack the first 95-195 residues from their N-terminus (4, 6, 7), the results 
shown in this chapter serve as the first evidence in the lanthipeptide family that a LanP protease 
autocatalytically cleaves itself for activation (18). A recent study on LicP revealed a novel 
calcium-independent mechanism for stabilization of a subtilase, which involves the removal of a 
pro-sequence followed by the insertion of a tryptophan into a hydrophobic pocket in the protease 
domain (5). This model was supported by the observation that removal of the pro-sequence was 
essential for the production of soluble LicP. A different maturation/stabilization mechanism may 
be adopted by CylA, given that it can be purified as a full length protein with the pro-sequence 
attached. Structural information for CylA is needed to unveil the answers to these questions. 
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E. faecalis and E. faecium infections account for more than 90% of all enterococcal 
infections, which constitute a growing health issue worldwide (1). The secretion of cytolysin has 
been linked to the virulence of E. faecalis, supported by both infection model studies and clinical 
data (1, 19-21). The biosynthetic machinery that installs cytolysin could serve as a potential drug 
target for treating E. faecalis infections using an anti-virulence strategy (1). As the final step of 
cytolysin biosynthesis, the removal of GDVQAE oligopeptide from CylLL’ and CylLS’ by CylA 
is essential for the production of mature toxin (4). Drug targeting could be further assisted by the 
fact that CylA is secreted, unlike the other enzymes involved in cytolysin biosynthesis that 
require inhibitors to be membrane permeable. With heterologously expressed and purified CylA 
in hand, high-throughput in vitro screening of compound libraries can be performed to identify 
possible inhibitors and drug candidates. 
 
7.4 Methods 
General methods 
Similar general methods and materials as what were described in chapter 5 were employed 
in this chapter unless specified otherwise. LC-ESI-Q/TOF MS analyses were conducted using a 
Micromass Q-Tof Ultima instrument (Waters) equipped with a Vydac C18 column (5 µm; 100 Å; 
250 x 1.0 mm). Defibrinated rabbit blood was purchased from Hemostat Laboratories and used 
within 10 days of receipt. Absorbance of rabbit hemoglobin solution was measured in 96-well 
plates with a Synergy™ H4 Microplate Reader (BioTek). Negative numbers are used for amino 
acids in the leader peptide counting backwards from the leader peptide cleavage site. The gene 
encoding CylA was synthesized by GeneArt (Invitrogen) with codon usage optimized for E. coli 
expression. The DNA sequence of cylA is listed in Table 7.2. 
 
Construction of pRSFDuet-1 derivatives for expression of CylA, CylLL and CylLS 
The cylA, cylLL and cylLS genes were synthesized with codon usage optimized for E. coli 
expression, amplified using appropriate primers and cloned into the MCS1 of a pRSFDuet-1 
vector using restriction sites EcoRI and NotI to generate the plasmids pRSFDuet-1/CylA-27-412, 
pRSFDuet-1/CylLL and pRSFDuet-1/CylLS. Primer sequences are listed in Table 7.3.  
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Construction of pRSFDuet-1 derivatives for expression of ProcA1.7-GDVQAE and 
NisA-GDVQAE peptides 
Genes encoding the mutant peptides were amplified by multi-step overlap extension PCR. 
First, the amplification of the 5’ leader part was carried out by 30 cycles of denaturing (95 °C for 
10 s), annealing (55 °C for 30 s), and extending (72 °C for 15 s) using forward primers for 
procA1.7 and nisA and appropriate reverse primers (Table 7.3) to generate a forward 
megaprimer (FMP). In parallel, PCR reactions using appropriate forward primers and reverse 
primers for procA1.7 and nisA (Table 7.3) were performed to produce 3’ fragments (reverse 
megaprimer, RMP). The 5’ FMP fragment and the 3’ RMP fragment were purified by 2% 
agarose gel followed by use of a Qiagen gel extraction kit. The 2 fragments were combined in 
equimolar amounts (approximately 20 ng each for a 50 μL PCR) and amplified using the same 
PCR conditions as above with procA1.7 and nisA primers. The resulting PCR products were 
purified, digested and then cloned into the MCS1 of pRSFDuet-1 to generate 
pRSFDuet-1/ProcA1.7-GDVQAE and pRSFDuet-1/NisA-GDVQAE plasmids.  
 
Construction of pRSFDuet-1 derivatives for expression of ProcA1.7-GDVQAE-T1G, 
ProcA1.7-GDVQAE-T1F, ProcA1.7-GDVQAE-T1W, ProcA1.7-GDVQAE-T1C, 
NisA-GDVQAE-I1C peptides and CylA-27-412-E95A, CylA-27-412-S359A proteins 
Plasmids pRSFDuet-1/ProcA1.7-GDVQAE-T1G, pRSFDuet-1/ProcA1.7-GDVQAE-T1F, 
pRSFDuet-1/ProcA1.7-GDVQAE-T1W, pRSFDuet-1/ProcA1.7-GDVQAE-T1C, 
pRSFDuet-1/NisA-GDVQAE-T1C, pRSFDuet-1/CylA-27-412-E95A and 
pRSFDuet-1/CylA-27-412-S359A were generated using quick change methodology based on  
pRSFDuet-1/ProcA1.7-GDVQAE, pRSFDuet-1/NisA-GDVQAE and pRSFDuet-1/CylA-27-412, 
respectively. Primer sequences are listed in Table 7.3. 
 
Construction of pRSFDuet-1 derivatives for co-expression of HalM1 and HalM2 with 
HalA1-GDVQAE and HalA2-GDVQAE, respectively 
Mutant peptide genes were generated by a similar multi-step overlap extension PCR 
procedure as described above and cloned in the MCS1 of pRSFDuet-1/HalM1-2 and 
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pRSFDuet-1/HalM2-2, respectively, to generate pRSFDuet-1/HalA1-GDVQAE/HalM1-2 and 
pRSFDuet-1/HalA2-GDVQAE/HalM2-2 plasmids. Primer sequences are listed in Table 7.3. 
 
Construction of pRSFDuet-1 derivatives for co-expression of ProcM with 
His6-GDVQAE-ProcA1.7 
PRSFDuet-1/His6-GDVQAET-ProcA1.7G−1E/ProcM-2 was employed to produce modified 
His6-GDVQAE-ProcA1.7 peptide and was constructed using a 2-step quick change methodology 
based on a previously reported plasmid pRSFDuet-1/ProcA1.7G−1E/ProcM-2(16, 22). In the 
first quick change reaction, the gene coding GDVQAE oligopeptide was inserted between 
His6-tag and ProcA sequences, resulting in 
pRSFDuet-1/His6-GDVQAE-ProcA1.7G−1E/ProcM-2. The second step reaction provided the 
pRSFDuet-1/His6-GDVQAET-ProcA1.7G−1E/ProcM-2 plasmid by switching the Gln residue at 
the P1’ position to Thr. Primer sequences are listed in Table 7.3. 
 
Table 7.2 The DNA sequences of cylA with codon usage optimized for E. coli expression. 
cylA 
ATGAAAAAACGCGGTCTGACCTATATTCTGATCAGCTATATCTTTCTGATTCTGGGCACCACCGGTTAT
GCAAGCGATCTGAGCAACAATATCAGCTTCTTTATTGATAATAGCCAGACCACCGCCATCGAAGAAAT
TGAAAGCGAACTGAGCAGCGAGAAAGTGGATTACATTCAAGAAATTGGTCTGGTGAGCTTCAAAAAC
CTGGATGATAGCGATCGCAAATTCATCGGCAAATATTTCAATGTGAGCGAAGGTAAAAAACTGCCGGA
TTTTAAACCGGAAGAAGTGAATAGCAGCATCCTGAACATTAACATCCTGAATAAAGATTTCAAAAGCT
TTAATTGGCCGTACAAAAAAATCCTGAGCCATATTGATCCGGTGAAAGAACAGCTGGGTAAAGATATT
ACCATTGCCCTGATTGATAGCGGTATTGATCGTCTGCATCCGAATCTGCAGGACAATAATCTGCGTCTG
AAAAACTATGTGAACGACATCGAACTGGATGAATATGGTCATGGCACCCAGGTTGCCGGTGTTATTGA
TACCATTGCACCGCGTGTTAATCTGAACAGCTATAAAGTTATGGATGGCACCGATGGCAATAGCATTA
ATATGCTGAAAGCAATTGTGGATGCCACCAATGATCAGGTGGATATTATCAATGTTAGCCTGGGCAGC
TACAAAAACATGGAAATTGATGATGAACGCTTTACCGTTGAAGCCTTTCGTAAAGTTGTTAATTACGC
ACGCAAAAATAACATCCTGATTGTTGCAAGCGCAGGTAATGAAAGCCGTGATATTAGCACCGGTAACG
AAAAACACATTCCGGGTGGTCTGGAAAGCGTTATTACCGTTGGTGCAACCAAAAAAAGCGGTGATATT
GCCGATTACAGCAATTATGGTAGCAACGTGAGCATTTATGGTCCGGCAGGCGGTTATGGTGATAATTA
CAAAATCACCGGTCAGATTGATGCCCGTGAAATGATGATGACCTATTATCCGACCAGCCTGGTTAGTC
CGCTGGGTAAAGCAGCAGATTTTCCGGATGGTTATACCCTGAGCTTTGGCACCAGCCTGGCAACACCG
GAAGTTAGCGCAGCACTGGCAGCAATTATGAGCAAAAATGTGGATAACAGCAAAGACAGCAATGAAG
TTCTGAACACCCTGTTTGAAAATGCCGATAGCTTCATCGATAAAAACAGCATGCTGAAATACAAAGAA
GTGCGCATTAAATAA 
 
 
173 
 
Table 7.3 Primer sequences for cloning of cylA-27-412, cylA-27-412-E95A, cylA-27-412-S359A, cylLL, 
cylLS, procA1.7-GDVQAE, nisA-GDVQAE, nisA-GDVQAE-I1C, procA1.7-GDVQAE-T1G, 
procA1.7-GDVQAE-T1F, procA1.7-GDVQAE-T1W, procA1.7-GDVQAE-T1C, halA1-GDVQAE, 
halA2-GDVQAE and His6-GDVQAET-procA1.7-G–1E.  
Primer Name Primer Sequence (5'-3') 
CylLL_EcoRI_FP_Duet AAAAA GAATTCG GAAAATC TGAGCGTTGT T 
CylLL_NotI_RP_Duet AAAAA GCGGCCGC TTAGCAA TGTTTCAGGC T 
CylLS_EcoRI_FP AAAAA GAATTCG CTGAATA AAGAAAATCA G 
CylLS_NotI_RP AAAAA GCGGCCGC TTAGCAA AATTTTGCGC T 
HalA1_SacI_FP CGCCACTCGGAGCTCGATGACAAATCTTTT AAAAG  
HalA1_SbfI_RP ATAGTGATCCTGCAGGTTAGTTGCAAGAAGGCATG  
HalA2_BamHI_FP AAAAA GGATCC G ATGGTAAATT CAAAAGATTT 
HalA2_HindIII_RP AAAAA AAGCTT TTAGCACTGG CTTGTACACT 
ProcA1.7_EcoRI_FP GGT GCG AGG AAT TCG ATG AAG CAT AGA CAA CTA 
AAT CTG 
ProcA1.7_NotI_RP ATA ATA TCG CGG CCG CTC AGC ACA TTT TCC C 
NisA_BamHI_FP CTA GAT GGA TCC GAT GAG TAC AAA AGA TTT TAA CTT 
GG  
NisA_HindIII_RP CTA GAA GCT TTT ATT TGC TTA CGT GAA TAC TAC AAT 
G  
CylA27-EcoRI_FP AAAAA GAATTCG CTGAGCAACAATATCAGCTTC 
CylA-NotI_RP AAAAA GCGGCCGC TTA TTTAATGCGC ACTTCTTTGT A 
CylA-E95A_QC_FP CCGGATTTTAAACCG GCA GAAGTGAATAGCAGC 
CylA-E95A_QC_RP GCTG CTATTCACTT C TGC CGGTTT AAAATCCGG 
CylA-S359A_QC_FP GGCACC GCA CTG GCA ACACCGGAAGTTAGC GCAGCA 
CylA- S359A_QC_RP TGC CAG TGC GGTGCC AA 
AGCTCAGGGTATAACCATCCGG AAAATC 
ProcA1.7-GDVQAE_FP ACCATTGGGGGA ACCATTGTG 
ProcA1.7-GDVQAE_RP GGTTCC CCCAATGGT TTCTGCCTGA ACATCACC CAG 
CTCAGCATCA GACAGGT 
NisA-GDVQAE_FP ATTACAAGTATTTCGCTATGT 
NisA-GDVQAE_RP CGAAATACTT GTAAT TTCTGCCTGA ACATCACC 
ATCTTTC TTCGAAACAG ATA 
ProcA1.7-GDVQAE-T1G_QC_FP CAGGCAGAA GGT ATTGGG GGA 
ACCATTGTGTCGATAACCTGTG AG 
ProcA1.7-GDVQAE-T1G_QC_RP CCCAAT ACC T TCTGCCTG AAC ATC ACC CAG CTC AGC 
ATC A 
ProcA1.7-GDVQAE-T1F_QC_FP CAGGCAGAA TTC ATTGGG GGA 
ACCATTGTGTCGATAACCTGTG AG 
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Table 7.3 (cont.)  
ProcA1.7-GDVQAE-T1F_QC_RP CCCAAT GAA T TCTGCCTG AAC ATC ACC CAG CTC AGC 
ATC A 
ProcA1.7-GDVQAE-T1W_QC_FP AGGCAGAA TGG ATTGGG GGA 
ACCATTGTGTCGATAACCTGTG AG 
ProcA1.7-GDVQAE-T1W_QC_RP CCCAAT CCA T TCTGCCTG AAC ATC ACC CAG CTC AGC 
ATC A 
ProcA1.7-GDVQAE-T1C_QC_FP AGGCAGAA TGC ATTGGG GGA 
ACCATTGTGTCGATAACCTGTG AG 
ProcA1.7-GDVQAE-T1C_QC_RP CCCAAT GCA T TCTGCCTG AAC ATC ACC CAG CTC AGC 
ATC A 
NisA-GDVQAE-T1C_QC_FP AGGCAGAA TGC ACAAGTATT 
TCGCTATGTACACCCGGTTGTAAA 
NisA-GDVQAE-T1C_QC_RP AATACT TGT GCA TTCTGCCTG AACATC ACCATCTTTC 
TTCGAAACAG ATAC 
His-GDVQAE-ProcA1.7_QC_FP GGT GATGTTCAG GCAGAA CAGGATCCGAATTCG 
ATGAAGCAT 
His-GDVQAE-ProcA1.7_QC_RP TTCTGC CTG AAC ATC ACC GCT G TGGTGATGAT 
GGTGATGG 
His-GDVQAE-Q1T-ProcA1.7_QC_
FP 
GCAGAA ACC GATCCGA AT 
TCGATGAAGCATAGACAACT AAATCTG ATG 
His-GDVQAE-Q1T-ProcA1.7_QC_
RP 
TCGGATC GGT TTCTGC CTG AACATCACCG CTGTGGT 
HalA1-GDVQAE_FP TGCGCATGGTACAACATCAGC 
HalA1-GDVQAE_RP GTTGTACC ATGCGCA TTCTGCCTGA ACATCACC TAGAA 
TATCTTGGTC 
HalA2-GDVQAE_FP ACAACTTGGCCTTGCGCT 
HalA2-GDVQAE_RP GCAAGGCCAA GTTGT TTCTGCCTGA ACATCACC 
TGAACCA GCTAGAGA 
 
Expression and purification of CylA and CylA mutants 
E. coli BL21 (DE3) cells were transformed with pRSFDuet-1/CylA-27-412, 
pRSFDuet-1/CylA-27-412-E95A or pRSFDuet-1/CylA-27-412-S359A plasmids and plated on 
an LB plate containing 50 mg/L kanamycin. A single colony was picked and grown in 20 mL of 
LB with kanamycin at 37 
o
C for 12 h and the resulting culture was inoculated into 2 L of LB. 
Cells were cultured at 37 
o
C until the OD at 600 nm reached 0.5, cooled and IPTG was added to 
a final concentration of 0.1 mM. The cells were cultured at 18 
o
C for another 10 h before 
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harvesting. The cell pellet was resuspended on ice in LanP buffer (20 mM HEPES, 1 M NaCl, 
pH 7.5 at 25
 o
C) and lysed by homogenization. The lysed sample was centrifuged at 23,700×g for 
30 min and the pellet was discarded. The supernatant was passed through 0.45-µm syringe filters 
and the protein was purified by immobilized metal affinity chromatography (IMAC) loaded with 
nickel as previously described (23). The proteins were generally eluted from the column at an 
imidazole concentration between 150 mM and 300 mM and the buffer was exchanged using GE 
PD-10 desalting columns pre-equilibrated with LanP buffer. Protein concentration was 
quantified by its absorbance at 280 nm. The extinction coefficient for His6-CylA-27-412, 
His6-CylA-27-412-E95A and His6-CylA-27-412-S359A was calculated as 30,830 M
-1
 cm
-1
. 
Aliquoted protein solutions were flash-frozen and kept at −80 oC until further usage. 
 
Expression and purification of modified His6-CylLL, His6-CylLS, His6-HalA1-GDVQAE, 
His6-HalA2-GDVQAE and His6-GDVQAE-ProcA1.7 
Modified peptides were obtained using a similar procedure described previously using the 
corresponding co-expression plasmids (11, 22).  
 
Expression and purification of linear His6-CylLL, His6-CylLS, His6-ProcA1.7-GDVQAE, 
His6-NisA-GDVQAE, His6-ProcA1.7-GDVQAE-T1G, His6-ProcA1.7-GDVQAE-T1F, 
His6-ProcA1.7-GDVQAE-T1W, His6-ProcA1.7-GDVQAE-T1C and 
His6-NisA-GDVQAE-I1C 
E. coli BL21 (DE3) cells were transformed with pRSFDuet-1/CylLL, pRSFDuet-1/CylLS, 
pRSFDuet-1/ProcA1.7-GDVQAE, pRSFDuet-1/NisA-GDVQAE, 
pRSFDuet-1/ProcA1.7-GDVQAE-T1G, pRSFDuet-1/ProcA1.7-GDVQAE-T1F, 
pRSFDuet-1/ProcA1.7-GDVQAE-T1W, pRSFDuet-1/ProcA1.7-GDVQAE-T1C or 
pRSFDuet-1/NisA-GDVQAE-T1C plasmids and plated on an LB plate containing 50 mg/L 
kanamycin. A single colony was picked and grown in 10 mL of LB with kanamycin at 37 
o
C for 
12 h and the resulting culture was inoculated into 1 L of LB. Cells were cultured at 37 
o
C until 
the OD at 600 nm reached 0.5 and IPTG was added to a final concentration of 0.2 mM. The cells 
continued to be cultured at 37 
o
C for another 3 h before harvesting. The cell pellet was 
resuspended at room temperature in LanA start buffer (20 mM NaH2PO4, pH 7.5 at 25
 o
C, 500 
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mM NaCl, 0.5 mM imidazole, 20% glycerol) and lysed by sonication. The sample was 
centrifuged at 23,700×g for 30 min and the supernatant was discarded. The pellet was then 
resuspended in LanA buffer 1 (6 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25
 o
C, 
500 mM NaCl, 0.5 mM imidazole) and sonicated again. The insoluble portion was removed by 
centrifugation at 23,700×g for 30 min and the soluble portion was passed through 0.45-µm 
syringe filters. His-tagged peptides were purified by immobilized metal affinity chromatography 
(IMAC) loaded with nickel as previously described(23). The eluted fractions were desalted using 
reverse phase HPLC equipped with a Waters Delta-pak C4 column (15 µm; 300 Å; 25 x 100 mm) 
or a Strata XL polymeric reverse phase SPE column. Peptides were lyophilized and stored at −20 
o
C for future usage. 
 
Intermolecular cleavage of His6-CylA-27-412-S359A by His6-CylA-27-412 
Parallel reactions were set up with His6-CylA-27-412 only (final protein concentration of 0.8 
mg/mL in LanP buffer), His6-CylA-27-412-S359A only (final protein concentration of 0.2 
mg/mL in LanP buffer), and His6-CylA-27-412 and His6-CylA-27-412-S359A together (final 
protein concentrations of 0.8 mg/mL and 0.2 mg/mL, respectively). The three reactions were 
allowed to proceed at room temperature for 0, 1, 2, 4, 8 and 22 h before being stopped by 
addition of SDS loading buffer and boiling at 95 
o
C for 10 min 
 
Proteolytic cleavage of the leader peptides 
Targeted peptides were dissolved in H2O to a final concentration of 3 mg/mL. To a 85 μL 
solution of peptides, 10 μL of 500 mM HEPES buffer (pH 7.5) was added followed by 5 μL of 
0.5 mg/mL AspN protease (for modified CylLL and CylLS peptides), 0.1 mg/mL CylA protease 
(for modified and unmodified CylLL and CylLS peptides). For cleavage tests of the engineered 
GDVQAE peptides, CylA was added to a final concentration of 5 μg/mL (for 
ProcA1.7-GDVQAE-T1C and NisA-GDVQAE-T1C peptides), 25 μg/mL (for 
His6-GDVQAE-ProcA1.7) or 10 μg/mL (for all other peptides), whereas the substrate peptide 
was added to a concentration of 0.3 mg/mL in 50 mM HEPES buffer (pH 7.5). TCEP (1 mM) 
was employed for modified HalA1-GDVQAE, ProcA1.7-GDVQAE-T1C and 
NisA-GDVQAE-T1C. The protease cleavage reaction mixtures were kept at 25 
o
C for 1 to 48 h 
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or left at 37 
o
C for less than 24 h. Osmotic pressure was adjusted with 150 mM NaCl if desired. 
The digested peptide mixture was directly used for antimicrobial and hemolytic assay.  
 
Competition assay of CylA activity with modified and linear CylLS 
To a reaction vessel with 70 μL deionized H2O, 5 μL each of 2 mg/mL modified CylLS and 
linear G-CylLS peptides were added (final peptide concentration 12 µM each) followed by 10 μL 
of 500 mM HEPES buffer (pH 7.5). Then, 10 μL of 0.1 mg/mL CylA was supplied (final protein 
concentration 0.2 µM) and the reaction was incubated at room temperature before being stopped 
by addition of formic acid to a final concentration of 1% at different time points for MS analysis.  
 
Kinetic analysis of full length CylA and CylA-96-412 against modified CylLS 
As full length CylA is not available due to its self-cleavage, His-CylA-27-412-E95A was 
chosen to serve as a substituent of full length CylA as the self-cleavage was abolished whereas 
the conserved catalytic C-terminal region of CylA remained unchanged. To obtain the mature 
protease CylA-96-412, His-CylA-27-412 was aged at 4 
o
C for 12 hours to allow the 
self-cleavage to proceed until CylA-96-412 was the dominant peak monitored by MALDI-TOF 
MS. The aged protein mixture was directly used as a substituent of CylA-96-412. To test the 
proteases’ activities, CylA-96-412 and His-CylA-27-412-E95A were supplied with a final 
concentration of 22 nM and 110 nM, respectively, with modified CylLS served at a concentration 
of 36 μM. The reactions were stopped at 3 minute, 6 minute, 12 minute and 24 minute by 1% 
TFA and the formation of mature CylLS’’ was monitored by liquid chromatography MS (LC/MS). 
A 5 μL volume of sample obtained from the cleavage reaction was applied to the column that 
was pre-equilibrated in aqueous solvent A. The solvents used for LC were: solvent A = 0.1% 
formic acid in 95% water / 5% acetonitrile and solvent B = 0.1% formic in 95% acetonitrile / 5% 
water. A solvent gradient of 0%-80% B over 30 min was employed and the fractionated sample 
was directly subjected to ESI-Q/TOF MS analysis. The production of core peptide was analyzed 
by extracted ion chromatography monitoring the desired product mass 1017 (M+2H
+
). 
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Antimicrobial assay 
L. lactis HP cells were grown in GM17 media under anaerobic conditions at 25 °C for 16 h. 
Agar plates were prepared by combining 15 mL of molten GM17 agar (cooled to 42 °C) with 
150 μL of dense cell culture. The seeded agar was poured into a sterile 100 mm round dish 
(VWR) to solidify. Peptide samples were directly spotted on the solidified agar. Plates were 
incubated at 30 °C for 16 h and the antimicrobial activity was determined by the size of the zone 
of growth inhibition. Halα and Halβ were obtained by factor Xa cleavage of modified HalA1Xa 
and HalA2 Xa peptides using a reported procedure (22). CylLL” and CylLS” were prepared using 
modified CylLL-E−1K and CylLS-E−1K peptides described previously (11).  
 
Hemolytic assay for cytolysin 
A sample of 1 mL of defibrinated rabbit blood was added into 20 mL of PBS in a 50 mL 
conical tube and mixed gently. The PBS-diluted blood sample was centrifuged at 800×g for 5 
min at 4 °C and the supernatant containing lysed blood cells and released hemoglobin was 
discarded. The process was repeated 2 to 4 times until the supernatant was clear. The blood cells 
were then diluted with PBS to make a 5% solution, which was immediately used to test the 
hemolytic activity of the peptides. To an eppendorf tube, 50 μL of 5% washed red blood cell 
sample was added followed by the addition of the desired peptide samples or controls. PBS was 
used to adjust the final volume to 85 μL. All tubes were kept in a 37 oC incubator to allow the 
lytic reaction to proceed. At each time point, 8 or 10 μL of reaction mixture was taken out, 
diluted with 190 μL of fresh PBS and centrifuged at 800×g for 5 min. The supernatant (170 μL) 
was transferred to a new well and the absorbance was measured at 415 nm. The absorbance of 
prepared blood sample at each time point was analyzed in triplicate and the maximum 
absorbance was determined by adding 35 μL of 0.1% Triton in PBS to 50 μL of 5% blood 
sample and using the same analysis procedure. 
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Chapter 8. Structural Characterization of Four Prochlorosins 
 
8.1 Introduction 
Prochlorosins (Pcns) are a group of lanthipeptides produced by Prochlorococcus (1). In 
Prochlorococcus MIT9313, 30 different peptide substrates are modified by a single promiscuous 
enzyme ProcM to form the characteristic thioether rings (2). The 30 precursor peptides have 
highly conserved leader peptides but highly diverse core peptides where the posttranslational 
modifications take place (Figure 3.6). This class of lanthionine-containing peptides is of interest 
not only because of the remarkable promiscuity of the enzyme, but also because the organisms 
carrying these genes are cyanobacteria accounting for as much as half of the chlorophyll in the 
tropical and subtropical oceans with a very different lifestyle than other known lantipeptide-
producing organisms (3). They are single-celled organisms living in oligotrophic environments at 
very dilute concentrations, making it debatable whether prochlorosins serve as antimicrobial 
defenses like most known lanthipeptides (4).  
Analysis of the Global Oceanic Survey showed that the genes for production of these 
lanthionine-containing peptides are widespread (1, 5). Their transcription levels respond to 
nitrogen starvation, suggesting that the prochlorosins are functional (1). However, it remains 
unclear why the organisms produce this class of secondary metabolites and what their functions 
are. In order to address these questions as well as understand the remarkable substrate tolerance 
of ProcM, it is important to know the chemical structures of prochlorosins, including their ring 
topologies and the stereochemical configurations of their Lan and MeLan residues. 
 
  
 
Reproduced in part with the permission from: 
Tang, W., and van der Donk, W. A. (2012) Structural characterization of four prochlorosins: a 
novel class of lantipeptides produced by planktonic marine cyanobacteria, Biochemistry 51, 4271-
4279. 
Copyright 2012 American Chemical Society. 
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Prior to the work described in this chapter, preliminary structural characterization of several 
prochlorosins had been carried out by tandem mass spectrometry (MS) (1). The presence of a 
thioether crosslink prohibits fragmentation of the peptide in the ring, and therefore the 
fragmentation pattern can be used for ring topology prediction (1, 6). However, tandem MS 
encounters difficulties in elucidating the ring topology for structures that contain overlapping 
rings. In such cases, mutagenesis is usually employed to prevent the formation of one or several 
of the rings such that the topology of the remaining rings can be established using tandem MS. 
However, because ProcM showed very low substrate specificity under laboratory conditions and 
can generate a variety of ring structures, it is possible that the ring topology of the mutants is not 
that of the wild type prochlorosins. Indeed, a single point mutation in ProcA4.3 has been shown 
to change the original ring pattern (1). Therefore, tandem MS has its limitations for structure 
determination of prochlorosins and other complementary techniques are required. In this study, I 
used NMR spectroscopy to determine the ring topologies of four prochlorosins (Pcn1.1, Pcn1.7, 
Pcn3.3 and Pcn4.3) for which the precursor genes have been shown to be transcribed under 
nitrogen starvation (1).  
In addition to questions about the ring patterns of prochlorosins, the stereochemical 
configurations of their Lan and MeLan residues had not been determined prior to this work. Lan 
and MeLan residues in most documented lanthipeptides/lantibiotics exhibit the (2S, 6R) and (2S, 
3S, 6R) configurations, respectively (7), although the unusual (2R, 6R) and (2R, 3R, 6R) 
configurations have recently been identified in the entereococcal cytolysin and the β component 
of haloduracin in a specific substrate motif (chapter 2) (8). Because ProcM generates such a 
diversity of ring topologies, it was previously speculated that perhaps only some rings were 
formed enzymatically, thus pre-organizing the partially cyclized peptides for non-enzymatic 
cyclization to generate the final ring structures (1). Determination of the configuration of Lan 
and MeLan residues in prochlorosins could potentially serve to assess whether a ring is formed 
enzymatically or non-enzymatically. 
Therefore, the stereochemical configuration of Lan and MeLan residues of seven 
prochlorosins (Pcn1.1, Pcn1.7, Pcn2.8, Pcn2.11, Pcn3.2, Pcn3.3 and Pcn4.3) was investigated in 
this study by GC-MS with a chiral stationary phase and compared with synthetic standards (9-
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11). The production of milligram quantities of the selected prochlorosins was achieved by 
heterologous coexpression of the precursor peptides with ProcM in E. coli (12).  
 
8.2 Results 
8.2.1 Coexpression of ProcAs and ProcM in E. coli 
In order to obtain milligram quantities of peptides required for NMR characterization, a 
heterologous coexpression system was employed using E. coli as host (12-14). Using a 
pRSFDuet vector, ProcM and His-tagged ProcAs were coexpressed and the modified precursor 
peptides were purified by immobilized metal affinity chromatography (IMAC) followed by RP-
HPLC. Using this procedure, around 80 mg of modified prochlorosins with their leader peptides 
still attached could be obtained from 1 L of LB culture. The modified precursor peptides were 
proteolyzed by a commercial protease at an engineered cleavage site at the −1 position to remove 
the leader peptides and produce the mature core peptides. Of all the selected prochlorosin 
mutants, only the ProcA4.3G−1R and ProcA4.3G−1E mutants were not processed by ProcM, 
indicating that ProcA4.3 could not be mutated at the −1 position. As a result, wild type ProcA4.3 
was used for coexpression in order to obtain modified peptide. The Glu at position −6 was used 
as a cleavage site for endoproteinase GluC to generate a core peptide with 5 residues at its N-
terminus that remained from the leader peptide. Unlike ProcA4.3, ProcA1.7 and ProcA3.3 
mutated at position −1 (G−1R and G−1K, respectively) were still processed by ProcM to 
generate the fully modified products, but either the engineered cleavage sites were close to a 
dehydrated amino acid (ProcA3.3) resulting in greatly reduced efficiency of leader peptide 
removal by endoproteinase LysC, or the selected endoproteinase caused the cleavage in the core 
peptide (ProcA1.7) which greatly reduced the yield. In order to obtain sufficient amounts of the 
modified core peptides, the Glu at position −6 was also used for these two peptides to remove 
most of the leader peptide with GluC endoproteinase. MALDI-TOF mass spectra of the resulting 
modified core peptides are shown in Figure 8.1. 
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Figure 8.1 MALDI-TOF MS spectra of the core peptides of four selected prochlorosins modified by 
ProcM in E. coli. For peptide sequences, see Figure 8.14. (a) Pcn1.1. (b) Pcn1.7. (c) Pcn3.3. (d) Pcn4.3. 
 
8.2.2 NMR spectral assignments 
In order to determine the ring topology, the observed NMR resonances were first assigned. 
A series of 1D and 2D NMR experiments were performed for this purpose. The amino acid 
assignments were obtained primarily from TOCSY and gDQCOSY spectra. The TOCSY spectra 
of Pcn1.1, Pcn1.7, Pcn3.3 and Pcn4.3 are shown in Figure 8.3, Figure 8.4, Figure 8.5 and 
Figure 8.6, respectively. The chemical shifts of amide protons in these peptides in 90% H2O and 
10% D2O were between 7 ppm and 10 ppm, most of which showed good dispersion. The number 
of amide protons was determined by integration of 1D 
1
H NMR spectra. Each vertical line in 
each TOCSY spectrum corresponds to the spin system of one amino acid, with the amide proton 
resonance on the x-axis and the chemical shifts of the side chain proton resonances on the y-axis. 
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The N-terminal residues have no amide resonance and hence were not observed. The amide 
signals of all amino acids were observed for each of the four prochlorosins and assigned to a 
specific amino acid by taking into account their characteristic chemical shifts and numbers of 
resonances. The amide proton signals of Dhb residues always appeared as singlets in the low 
field region with chemical shifts larger than 9.3 ppm, and the β/γ proton signals of Dhb displayed 
weak correlations to their corresponding amide protons.  
Assignments of each amino acid to a specific position in the amino acid sequence were made 
primarily based on the connectivity of dNN(i,i+1) as well as dαN(i,i+1) in the NOESY spectra (Figure 
8.6 for Pcn1.1, Figure 8.7 for Pcn1.7, Figure 8.8 for Pcn3.3, and Figure 8.9 for Pcn4.3), taking 
into consideration the amino acid sequences deduced from the procA genes.  
 
Figure 8.2 Water suppressed TOCSY spectrum identifying all residues of Pcn1.1. Each vertical line 
indicates a spin system corresponding to an amino acid. A water suppressed NOESY spectrum (Figure 
8.6) along with the gene sequence was used to assign the residue numbering. 
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Figure 8.3 Water suppressed TOCSY spectrum identifying all residues of Pcn1.7. Each vertical line 
indicates a spin system corresponding to an amino acid. A water suppressed NOESY spectrum (Figure 
8.7) along with the gene sequence was used to assign the residue numbering. 
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Figure 8.4 Water suppressed TOCSY spectrum identifying all amide resonances of Pcn3.3. Each 
vertical line indicates a spin system corresponding to an amino acid. A water suppressed NOESY 
spectrum (Figure 8.8) along with the gene sequence was used to assign the residue numbering. 
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Figure 8.5 Water suppressed TOCSY spectrum identifying all amide resonances of Pcn4.3. Each 
vertical line indicates a spin system corresponding to an amino acid. A water suppressed NOESY 
spectrum (Figure 8.9) along with the gene sequence was used to assign the residue numbering. 
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Figure 8.6 Water suppressed NOESY spectrum (mixing time = 0.20 s) for resonance amide 
assignments to amino acids from Pcn1.1. 
 
Figure 8.7 Water suppressed NOESY spectrum (mixing time = 0.20 s) for resonance amide 
assignments to amino acids from Pcn1.7. 
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Figure 8.8 Water suppressed NOESY spectrum (mixing time = 0.20 s) for resonance amide 
assignments to amino acids from Pcn3.3. 
 
Figure 8.9 Water suppressed NOESY spectrum (mixing time = 0.20 s) for resonance amide 
assignments to amino acids from Pcn4.3. 
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8.2.3 Ring topology assigned by NMR spectroscopy 
In the discussion below, the fragment of the Lan residues originating from Ser will be 
designated Ala(S) and the fragment that originates from Cys will be designated Cys. Similarly, 
the fragment of MeLan residues that originates from Thr will be designated Abu(S) (for 2-
aminobutyric acid) and the fragment originating from Cys will be designated Cys. The chemical 
shifts for the β protons of putative Ala(S) and Abu(S) residues observed in the TOCSY 
experiments provided the first evidence of ring formation. Dha/Dhb residues that were converted 
into thioether crosslinks had chemical shifts of their β protons around 3 ppm, whereas Dha/Dhb 
residues that were not involved in ring formation displayed β protons chemical shifts between 6 
and 7 ppm.  
Next, NOESY spectra were acquired in D2O in order to simplify the spectrum and focus on 
the NOEs involving the Lan/MeLan protons, which allow assignment of the ring topology (15-
20) (Figure 8.10 for Pcn1.7, Figure 8.11 for Pcn1.1, Figure 8.12 for Pcn3.3, and Figure 8.13 
for Pcn4.3). A longer NOESY mixing time of 0.40 s was used for Pcn1.7 and 4.3. Intense NOE 
signals between the β protons of an Ala(S)/Abu(S) and a Cys were taken as evidence for a 
crosslink between these residues (Figure 8.10b). These assignments were further supported by 
correlations of α protons of Ala(S)/Abu(S) to the β protons of the Cys with which it was 
crosslinked as well as correlations between α protons of Cys residues with the β protons of 
Ala(S)/Abu(S) residues (Figure 8.10c). In the case of MeLan, the γ-protons on the methyl 
groups of Abu(S) residues showed additional correlations to the α and β protons of their partner 
Cys (Figure 8.10d). For some prochlorosins (i.e. prochlorosins 1.1, 3.3 and 4.3) these latter 
correlations were particularly diagnostic to confirm the deduced ring structures because less 
signal overlap was present in this region of the spectra (Figures 8.11-8.13). Collectively, this 
approach allowed assignment of all resonances to individual residues and therefore established 
the topology of the rings. The ring topologies of the four selected prochlorosins were determined 
unambiguously (Figure 8.14). For Pcn1.1, Pcn1.7, and Pcn3.3, the NMR assignments agree with 
the previous tandem MS data (1). For Pcn4.3, the NMR results in this study enabled assignment 
of the second ring that was not possible by MS (1). The NMR data clearly show that this ring is 
formed from Thr8 and Cys12, and that Ser9 remained unmodified. 
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Notably, the additional amino acids that remained from the leader peptides in prochlorosins 
1.7, 3.3, and 4.3 showed fewer correlation signals in the NOESY spectrum, suggesting that the 
N-terminus is conformationally more flexible than the modified core peptide.  
 
 
Figure 8.10 Illustration of the method used to establish thioether connectivities. (a) Schematic 
illustration of the proton correlations used to determine ring topologies. (b) Section of the NOESY 
spectrum (mixing time = 0.40 s) of Pcn1.7 in D2O showing the correlations between β-protons. (c) 
Section of the NOESY spectrum showing the correlations of the α protons with α and β protons across the 
thioether bridge. (d) Section of the NOESY spectrum showing the correlations of the γ protons with α and 
β protons across the thioether bridge. In panels b-d, correlations are assigned to the A, B, and C rings of 
Pcn1.7 (see also Figure 8.14).  
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Figure 8.11 NOESY spectrum of Pcn1.1 in D2O (mixing time = 0.20 s) for ring topology assignment. 
The assignments are indicated on the spectrum. Note that there are also un-assigned NOE signals that 
may indicate a relatively stable 3D conformation. 
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Figure 8.12 NOESY spectrum of Pcn3.3 in D2O (mixing time = 0.20 s) for ring topology assignment. 
The assignments are indicated on the spectrum. 
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Figure 8.13 NOESY spectrum of Pcn4.3 in D2O (mixing time = 0.40 s) for ring topology assignment. 
The assignments are indicated on the spectrum. 
 
Figure 8.14 Ring topology of four selected prochlorosins assigned by NMR spectroscopy in this 
work. Arrows indicate the start of the putative core peptide. Asterisks indicate prochlorosins containing 
five more residues at their N-terminus that originate from the leader peptides. Blue residues are the 
engineered cleavage sites at the −1 position in the leader peptides. 
196 
 
8.2.4 Determination of the stereochemistry of Lan and MeLan residues 
To determine the stereochemical configurations of the Lan and MeLan residues in the four 
prochlorosins for which the NMR structures were determined, the peptides were hydrolyzed in 6 
M HCl, derivatized to their corresponding pentafluoropropionamide methyl esters, and analyzed 
by GC-MS with a chiral stationary phase.  Lan and MeLan standards of different stereochemistry 
were synthesized and derivatized using previously reported methods (10). A Chirasil-L-Val 
coated GC column was used for analysis and the GC trace was monitored for a characteristic 
fragment of 365 Da for Lan and 379 Da for MeLan residues using electron-impact mass 
spectrometry. Figure 2.5 shows the GC-MS traces of three derivatized Lan standards and two 
derivatized MeLan standards. The derivatized MeLan standards with DL (2S, 3S, 6R) and LL 
(2R, 3S, 6R) configuration were well separated on the column, with retention times of 14.1-14.4 
min and 14.4-14.7 min, respectively. The derivatized Lan standards with DD (2S, 6S), DL (2S, 
6R), and LL (2R, 6R) configuration eluted later than the MeLan standards, and were also well 
separated with retention times of 18.2-18.6 min, 18.6-19.0 min and 19.0-19.4 min, respectively. 
Derivatized MeLan originating from Pcn1.7 eluted with a retention time of 14.1-14.4 min 
(Figure 8.15), indicating that the MeLan in Pcn1.7 has a DL configuration. In order to further 
confirm this result, the derivatized DL and LL MeLan standards were co-injected with the 
derivatized MeLan originating from the peptide. The derivatized MeLan fragment from Pcn1.7 
co-eluted with the DL MeLan standard but not with the LL MeLan standard (Figure 8.15). 
MeLan standards with the D-allo-L (2S, 3R, 6R) and L-allo-L (2R, 3R, 6R) configuration were 
not synthesized because the reported elution times of the derivatized MeLan diastereomers on a 
Chirasil-L-Val coated GC column are DL<LL<L-allo-L<D-allo-L (10). In this work, no 
derivatized MeLan residues were observed to elute after the LL standard for Pcn1.7, ruling out 
the presence of MeLan residues with L-allo-L or D-allo-L configuration. The MeLan residues 
present in the other three prochlorosins were analyzed using the same procedure and all had the 
DL configuration (Figure 8.16 for Pcn1.1, Figure 8.17 for Pcn3.3, and Figure 8.18 for Pcn4.3). 
Similarly, derivatized Lan originating from Pcn1.7 co-eluted with the Lan standard with the DL 
configuration but not with either the DD or the LL Lan standards (Figure 8.15). The small 
shoulders on the derivatized DL-Lan peak arising from Pcn1.7 are believed to be caused by 
partial epimerization during HCl hydrolysis, which has been reported previously (21). 
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Figure 8.15 GC-MS traces (selected ion monitoring, SIM, at 365 Da for Lan and 379 Da for MeLan) 
of derivatized Lan/MeLan obtained from Pcn1.7 and coinjections with derivatized (Me)Lan 
standards. (a) Hydrolyzed and derivatized amino acids from Pcn1.7 (dashed line) and coinjected with 
DL-MeLan standard (solid line). The trace was monitored at m/z 379. D. (b) Hydrolyzed and derivatized 
amino acids from Pcn1.7 (dashed line) and coinjected with derivatized LL-MeLan standard (solid 
line).The trace was monitored at m/z 379. (c) Hydrolyzed and derivatized amino acids from Pcn1.7 
(dashed line) and coinjected with DD-Lan standard (solid line). The trace was monitored at m/z 365. (d) 
Hydrolyzed and derivatized amino acids from Pcn1.7 (dashed line) and coinjected with DL-Lan standard 
(solid line). The trace was monitored at m/z 365. (e) Hydrolyzed and derivatized amino acids from Pcn1.7 
(dashed line) and coinjected with LL-Lan standard (solid line). The trace was monitored at m/z 365. Lan 
and MeLan from Pcn1.7 used for overlays were adjusted to 70% intensity for clarity. A small amount of 
epimerization of the (Me)Lan occurs during acid hydrolysis of the peptides as has been reported 
previously (21). 
 
Figure 8.16 GC-MS traces (selected ion monitoring, SIM, at 379 Da for MeLan) of derivatized 
(Me)Lan obtained from Pcn1.1 and coinjections with derivatized Lan/MeLan standards. (a) 
Hydrolyzed and derivatized amino acids from Pcn1.1 (red line) and coinjected with DL-Melan standard 
with Pcn1.1 (blue line). (b) Hydrolyzed and derivatized amino acids from Pcn1.1 (red line) and coinjected 
with LL-Melan standard (blue line). Traces of derivatized MeLan from Pcn1.1 (red lines) used for overlay 
were adjusted to 70% intensity for clarity. 
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Figure 8.17 GC-MS traces (selected ion monitoring, SIM, at 379 Da for MeLan) of derivatized 
(Me)Lan obtained from Pcn3.3 and coinjections with derivatized Lan/MeLan standards.. (a) 
Hydrolyzed and derivatized amino acids from Pcn3.3 (red line) and coinjected with DL-MeLan standard 
(blue line). (b) Hydrolyzed and derivatized amino acids from Pcn3.3 (red line) and coinjected with LL-
MeLan standard (blue line). Derivatized MeLan from Pcn3.3 used for overlays were adjusted to 70% 
intensity for clarity. 
 
Figure 8.18 GC-MS traces (selected ion monitoring, SIM, 365 Da for Lan and 379 Da for MeLan) 
for coinjection of derivatized (Me)Lan standards and hydrolyzed and derivatized amino acids from 
Pcn4.3. (a) Hydrolyzed and derivatized amino acids from Pcn4.3 (red line) and coinjected with 
derivatized DL-MeLan standard (blue line). (b) Hydrolyzed and derivatized amino acids from Pcn4.3 (red 
line) and coinjected with derivatized LL-MeLan standard (blue line). (c) Hydrolyzed and derivatized 
amino acids from Pcn4.3 (red line) and coinjected with derivatized DD-Lan standard (blue line). (d) 
Hydrolyzed and derivatized amino acids from Pcn4.3 (red line) and coinjected with derivatized DL-Lan 
standard (blue line). (e) Hydrolyzed and derivatized amino acids from Pcn4.3 (red line) and coinjected 
with derivatized LL-Lan standard (blue line). Traces of derivatized Lan and MeLan from Pcn4.3 (red 
lines) used for overlay were adjusted to 70% intensity for clarity.  
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The GC trace for Pcn4.3, the other prochlorosin investigated here that contains Lan, was 
more complicated. Although the derivatized DL-Lan was still the dominant peak, an additional 
peak in the GC trace accounted for about 20% of the total Lan (Figure 8.19a). The material 
giving rise to this peak was confirmed to be derivatized LL-Lan by co-injections (Figure 8.18). 
This result was in agreement with the NMR data (1D water suppressed spectrum shown in 
Figure 8.19b), which exhibited minor peaks with integration values around 25% that of the main 
peaks. These NMR data demonstrate that the LL-Lan was already present in Pcn4.3 before acid 
hydrolysis and derivatization and was not introduced by epimerization during HCl hydrolysis. 
 
Figure 8.19 The LL-Lan diastereomer in Pcn4.3 and its relative abundance. (a) GC-MS trace of 
hydrolyzed and derivatized amino acids of Pcn4.3 monitored for Lan. DD-Lan (18.2-18.6 min), DL-Lan 
(18.6-19.0min) and LL-Lan (19.0-19.4 min) eluted from the column, with the relative peak areas 
indicated. (b) 1D water-suppressed NMR spectrum of Pcn4.3. Minor peaks originate from a different 
diastereomer of Pcn4.3 containing LL-Lan as shown in panel a. Integrations of two pairs of major/minor 
peaks are shown to estimate the relative amount of the diastereomer.  
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In addition to the prochlorosins for which the NMR structures were determined, the 
stereochemistry of the Lan and MeLan residues was determined for three other ProcA substrates 
that were posttranslationally modified by ProcM in E. coli (ProcA2.8, ProcA2.11, and 
ProcA3.2). The corresponding prochlorosins could not be produced in sufficient purity after 
leader peptide removal for NMR studies, but after hydrolysis and derivatization of the resulting 
amino acids, GC-MS analysis demonstrated that they contained Lan and MeLan residues with 
the same configurations as those in the other prochlorosins (Figures 8.20-8.12).  
 
 
 
Figure 8.20 GC-MS traces (selected ion monitoring, SIM, 365 Da for Lan) for coinjection of 
derivatized (Me)Lan standards and hydrolyzed and derivatized amino acids from ProcM-modified 
ProcA2.8. (a) Hydrolyzed and derivatized amino acids from ProcM-modified ProcA2.8 (red line) and 
coinjected with derivatized DD-Lan standard (blue line). (b) Hydrolyzed and derivatized amino acids 
from ProcM-modified ProcA2.8 (red line) and coinjected with derivatized DL-Lan standard (blue line). 
(c) Hydrolyzed and derivatized amino acids from ProcM-modified ProcA2.8 (red line) and coinjected 
with derivatized LL-Lan standard (blue line). Traces of derivatized Lan and MeLan from ProcM-modified 
ProcA2.8 (red lines) used for overlay were adjusted to 70% intensity for clarity. A small amount of 
epimerization of the (Me)Lan occurs during acid hydrolysis of the peptides as has been reported 
previously (21). 
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Figure 8.21 GC-MS traces (selected ion monitoring, SIM, 365 Da for Lan and 379 Da for MeLan) 
for coinjection of derivatized (Me)Lan standards and hydrolyzed and derivatized amino acids from 
ProcM-modified ProcA2.11. (a) Hydrolyzed and derivatized amino acids from ProcM-modified 
ProcA2.11 (red line) and coinjected with derivatized DL-MeLan standard (blue line). (b) Hydrolyzed and 
derivatized amino acids from ProcM-modified ProcA2.11 (red line) and coinjected with derivatized LL-
MeLan standard (blue line). (c) Hydrolyzed and derivatized amino acids from ProcM-modified 
ProcA2.11 (red line) and coinjected with derivatized DD-Lan standard (blue line). (d) Hydrolyzed and 
derivatized amino acids from ProcM-modified ProcA2.11 (red line) and coinjected with derivatized DL-
Lan standard (blue line). (e) Hydrolyzed and derivatized amino acids from ProcM-modified ProcA2.11 
(red line) and coinjected with derivatized LL-Lan standard (blue line). Traces of derivatized Lan and 
MeLan from ProcM-modified ProcA2.11 (red lines) used for overlay were adjusted to 70% intensity for 
clarity. A small amount of epimerization of the (Me)Lan occurs during acid hydrolysis of the peptides as 
has been reported previously (21). 
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Figure 8.22 GC-MS traces (selected ion monitoring, SIM, 365 Da for Lan and 379 Da for MeLan) 
for coinjection of derivatized (Me)Lan standards and hydrolyzed and derivatized amino acids from 
ProcM-modified ProcA3.2. (a) Hydrolyzed and derivatized amino acids from ProcM-modified ProcA3.2 
(red line) and coinjected with derivatized DL-MeLan standard (blue line). (b) Hydrolyzed and derivatized 
amino acids from ProcM-modified ProcA3.2 (red line) and coinjected with derivatized LL-MeLan 
standard (blue line). (c) Hydrolyzed and derivatized amino acids from ProcM-modified ProcA3.2 (red 
line) and coinjected with derivatized DD-Lan standard (blue line). (d) Hydrolyzed and derivatized amino 
acids from ProcM-modified ProcA3.2 (red line) and coinjected with derivatized DL-Lan standard (blue 
line). (e) Hydrolyzed and derivatized amino acids from ProcM-modified ProcA3.2 (red line) and 
coinjected with derivatized LL-Lan standard (blue line). Traces of derivatized Lan and MeLan from 
ProcM-modified ProcA3.2 (red lines) used for overlay were adjusted to 70% intensity for clarity. A small 
amount of epimerization of the (Me)Lan occurs during acid hydrolysis of the peptides as has been 
reported previously (21). 
 
8.3 Discussion 
In this study I set out to investigate three aspects of prochlorosins biosynthesis: whether 
tandem MS is reliable for determination of ring topologies, whether sufficient quantities of 
material can be produced such that NMR spectroscopy can be used when MS data are 
inconclusive, and whether the Lan and MeLan residues in prochlorosins adopt the canonical 
stereochemistry as was found in most other lanthipeptides.   
To address these questions, I first produced large amounts of prochlorosins heterologously 
because less than 10 μg of impure products were obtained from 20 L of culture of 
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Prochlorococcus MIT9313 (1). Although the peptides after proteolysis are not completely 
identical to the mature prochlorosins, for determination of the ring topology and the 
stereochemistry of (Me)Lan residues, the additional five amino acids of the leader peptide are 
inconsequential. 
The NMR data reported here confirm the ring topologies of three prochlorosins that were 
previously proposed on the basis of tandem mass spectrometry in combination with site-directed 
mutagenesis. Thus, the concern that a highly promiscuous enzyme like ProcM might process a 
mutant peptide differently from a wild-type peptide appears not to be corroborated for these 
compounds. This concern arose when the B ring of Pcn4.3 could not be determined by tandem 
MS in a previous study (1). ProcA4.3 is dehydrated three times and the previously observed 
fragmentation pattern indicated that Thr1 and Ser3 were converted to Dhb1 and Dha3, 
respectively. Whether the third dehydrated residue was Thr8 or Ser9 could not be determined. 
Similarly, although the tandem MS data demonstrated that Pcn4.3 contained two non-
overlapping rings, whether Thr8 or Ser9 was converted to a thioether crosslink in the B ring 
could not be deduced  (1). Typically, such questions have been addressed by mutating the Thr 
and Ser in question (1, 22, 23). If Thr8 is dehydrated in wt ProcA4.3, mutation of Thr8 to Ala 
was expected to result in two instead of three dehydrations. Conversely, if Ser9 was dehydrated 
in wt ProcA4.3, mutation of Thr8 to Ala should not result in a difference in the number of 
dehydrations. This latter result was observed as the ProcA4.3A-Thr8Ala mutant was dehydrated 
three times and contained two Lan rings  (1). However, when Ser9 was then mutated to Ala to 
confirm this result, two dehydrations were expected but three were still observed. In other words, 
at least one of the mutants must be processed differently by ProcM than wt ProcA4.3. Therefore, 
the question whether Thr8 or Ser9 is involved in the B ring could not be answered. The NMR 
data in this study show conclusively that it is Thr8 that is dehydrated in wt ProcA4.3 and that it 
makes a thioether crosslink with Cys12 (Figure 8.14).  
Collectively, these results raise the question why mutants of ProcA1.7 and ProcA3.3 that 
were made in the previous study to deduce their ring topologies by tandem MS were processed 
correctly by ProcM, as shown by the NMR data in this study, whereas mutants of ProcA4.3 were 
not. Although this question cannot be addressed directly, processing of ProcA4.3 by ProcM 
appears to be less robust in general. Firstly, mutations at the −1 position in the precursor peptide 
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completely abolished ProcM activity in the current study whereas ProcM fully processed mutants 
at the −1 position for the other three ProcA substrates. Secondly, whereas all Lan and MeLan 
residues in Pcn1.1, Pcn1.7, and Pcn3.3 were formed in high stereochemical purity with the same 
stereochemistry (DL), the Lan in Pcn4.3 was decidedly less pure and contained about 20% of the 
LL diastereomer. As shown in Figure 8.14, the A ring of Pcn4.3 contains two Gly residues 
between the Dhb and Cys that form this lanthionine and perhaps the resulting increased 
conformational freedom allows enzymatic cyclization that results in protonation of the enolate 
from the opposite face. Alternatively, the lower stereochemical fidelity of cyclization of this 
particular Lan structure could be the result of non-enzymatic cyclization as discussed below.  
The determination of the ring topologies of four different prochlorosins in this study 
demonstrates the remarkable substrate flexibility of the ProcM enzyme. Inspection of Figure 
8.14 illustrates that the structures of the four selected prochlorosins do not exhibit any similarity 
to each other nor to any other known lantibiotics/lanthipeptides (4). The rings generated by 
ProcM contain very different numbers of amino acids, from four residues in the A rings of 
Pcn1.7 and Pcn4.3 to 11 residues in the A ring of Pcn3.3. Furthermore, the rings are generated 
either from a Cys that is located N-terminally to the dehydro amino acid with which it reacts (A 
ring of Pcn 1.7 and B ring of Pcn3.3) or from a Cys located C-terminally of its partner dehydro 
amino acid (all other rings). Finally, Pcn1.1 and 4.3 have non-overlapping rings, Pcn1.7 has 
overlapping rings, and Pcn3.3 contains a ring within a ring. Although many lantipeptide cyclases 
achieve formation of different sized rings and with different topologies, ProcM, and presumably 
its many orthologs in the world’s oceans (1), is unique in that it acts on so many different 
substrates.  
It was this unprecedented flexibility that led to a proposal that perhaps the enzyme generates 
only a subset of the rings and that the partially cyclized intermediates would have a preorganized 
structure for non-enzymatic cyclization of the remaining rings (1). This proposal was bolstered 
by the previously observed facile non-enzymatic intramolecular addition of Cys to dehydro 
amino acids located N-terminal to the Cys residue (24-30). These model studies on non-
enzymatic cyclization showed that formation of individual small rings is often stereoselective 
and results in the same stereochemistry as that observed for enzymatic cyclization. However, for 
larger rings or multiple ring structures, non-enzymatic cyclization has been shown to give 
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mixtures of diasteromers and/or constitutional isomers (26, 29, 31), and cyclization involving a 
Cys located N-terminally to its partner dehydro amino acid has been shown to be non-
stereoselective (28).  Therefore, in the current investigation the stereochemistry of the Lan and 
MeLan structures of prochlorosins was determined to test for non-enzymatic cyclization. The 
GC-MS data clearly illustrate that the Lan residues in prochlorosins have the (2S, 6R) 
configuration and that the MeLan residues have the (2S, 3S, 6R) configuration. These 
configurations are the same as those found for most lantibiotics for which the stereochemistry 
has been determined (7).  As discussed above, the only exception was the Lan in Pcn4.3, which 
was made up of a 4:1 ratio of DL and LL diastereomers. Although these results do not rule out 
non-enzymatic cyclization, they also do not provide support for non-enzymatic cyclization and 
based on the data in this study on seven prochlorosins with very different ring structures, a model 
in which ProcM does generate all thioether crosslinks is favored. This model is further supported 
by a recent report in which the non-enzymatic cyclization of a few dehydrated ProcA peptides 
was confirmed to be much slower than ProcM-catalyzed ring cyclization (32). One interesting 
unique aspect of ProcM is that based on sequence alignments, its catalytic Zn
2+
 is liganded by 
three Cys residues rather than the two Cys and one His residue that is found for all other LanM 
and LanC lanthionine cyclases investigated thus far (33-37). The Zn
2+
 has been proposed to 
activate the Cys residues of the substrate for nucleophilic attack onto the dehydro amino acids 
(33). Model studies on activation of thiolate nucleophiles by Zn
2+
 have demonstrated increased 
reactivity with increased number of thiolate ligands (38-41). Therefore, ProcM may derive its 
promiscuity in part from a highly activating Zn
2+
 site with three Cys ligands from ProcM and one 
Cys ligand from the substrate (42).  
In summary, the structures of four prochlorosins were determined by NMR spectroscopy in 
this chapter. I further show for seven prochlorosins that they contain Lan and MeLan residues of 
the same configuration as those found in other lantibiotics/lanthipeptides. These data suggest that 
most, if not all, of the rings are generated by the ProcM enzyme despite the remarkable structural 
diversity of its products. 
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8.4 Methods 
General methods 
All polymerase chain reactions (PCR) were carried out on a C1000 thermal cycler (Bio-
Rad). DNA sequencing was performed by ACGT, Inc. Preparative HPLC was performed using a 
Waters Delta 600 instrument equipped with appropriate columns. Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was carried out on a 
Voyager-DE-STR (Applied Biosystems). Overexpression and purification of the modified 
precursor peptides were performed using previously reported procedures (12). 
 
Materials 
All oligonucleotides were purchased from Integrated DNA Technologies and used as 
received. Restriction endonucleases, DNA polymerases and T4 DNA ligase were from New 
England Biolabs. Media components were obtained from Difco laboratories. E. coli DH5α and E. 
coli BL21 (DE3) cells were used as host for cloning and plasmid propagation and host for 
expression, respectively. Endoproteinases were ordered from Roche Biosciences. Chemicals 
were purchased from Sigma Aldrich, Fisher Scientific or CalBiochem. 
 
Construction of pRSFDuet-1 derivatives for coexpression of ProcM and ProcAs 
The genes encoding ProcA1.1G−1E and ProcA4.3 were cloned from previously reported 
pET15b plasmids containing these genes (1) and inserted into the multiple cloning site 1 of 
pRSFDuet-1/procM-2 plasmid (12) using the EcoRI and NotI restriction sites. Primer sequences 
used are shown in Table 8.1. Negative numbers are used for amino acids in the leader peptide 
counting backwards from the putative leader peptide cleavage site. The sequences of the 
constructed plasmids were confirmed by DNA sequencing. The pRSFDuet-1/procM-2, 
pRSFDuet-1/procA3.3G−1K/procM-2, pRSFDuet-1/procA1.7G−1R/procM-2, pRSFDuet-
1/procA2.8/procM-2, pRSFDuet-1/procA2.11G−1K/procM-2, pRSFDuet-1/procA3.2/procM-2, 
pRSFDuet-1/procA4.3G−1R/procM-2  and pRSFDuet-1/procA4.3G−1E/procM-2  plasmids 
were obtained as reported previously (12). 
 
207 
 
Table 8.1 Primer sequences for cloning of ProcAs. 
Primer Name Primer Sequence (5'-3') 
ProcA1.1_EcoRI_FP_Duet AAG AAT TCG ATG AAA AAG CGA CTC AAC 
ProcA1.1_NotI_RP_Duet AAG CGG CCG CTC AGC ACA CAT TGA TAG 
ProcA4.3_EcoRI_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTG AAG GC 
ProcA4.3_NotI_RP_Duet ATG ACC TAG CGG CCG CCT AGT AAC AAA ACA TAC 
 
Protease cleavage and purification of prochlorosin core peptides  
Post-translationally modified ProcA peptides were treated with the commercial protease 
GluC to remove the leader peptides. For some peptides, other proteases were used to hydrolyze 
the leader peptides into smaller fragments which sometimes proved advantageous for 
purification (LysC for ProcA1.1G−1E and ProcA3.3G−1K, trypsin for ProcA4.3). In such 
instances, the modified core peptide was not proteolyzed even if it contained potential cleavage 
sites for LysC/trypsin, presumably because the presence of dehydrated amino acids and/or 
(Me)Lan residues greatly reduced the proteolytic efficiency. The protease cleavage reactions 
were quenched with 0.5% TFA, and the desired products were confirmed by MALDI-TOF MS 
and purified by reversed phase (RP) HPLC using a Jupiter proteo C12 column (5 µm; 90 Å; 250 
x 10.0 mm). Solvents for RP-HPLC were solvent A (0.1% TFA in water) and solvent B (0.086% 
TFA in 80% acetonitrile/20% water). The desired core peptides eluted from the column between 
40 and 60% solvent B and pure fractions were lyophilized. 
 
NMR spectroscopy 
NMR spectra were acquired at the NMR Facility (School of Chemical Sciences, University 
of Illinois at Urbana-Champaign) on either a Varian INOVA 600 MHz or 500 MHz spectrometer 
equipped with a 5 mm triple resonance (
1
H-
13
C-
15
N) triaxial gradient probe. Lyophilized peptides 
were dissolved in 90% H2O/10% D2O to a final concentration between 5 and 7 mM. NMR 
spectra were acquired at 20 
o
C for 2048 direct and 256/400 indirect data points with 16 or 32 
scans depending on the peptide concentrations. TOCSY (43) (mixing time 0.080 s), gradient 
double quantum filtered COSY (gDQCOSY) (44) and NOESY (45) (mixing time 0.20 s) spectra 
were acquired with solvent suppression by presaturation or water gate pulse sequences. The 
lyophilized peptides were dissolved in 100% D2O and NOESY spectra were acquired without 
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exchangeable proton signals. NOESY spectra of Pcn 1.1 and 3.3 were acquired with a mixing 
time of 0.20 s, while those of Pcn1.7 and 4.3 were acquired with 0.40 s for clearer NOE signals. 
Spectra were processed with NMRPipe (46) and analyzed in Sparky (47). 
 
GC-MS analysis 
The synthesis of Lan and MeLan standards and the preparation of samples for GC-MS 
analysis were carried out following a reported procedure (10). For Pcn1.1, 1.7, 3.3, and 4.3, the 
purified modified core peptides were used. For Pcn2.8, 2.11, and 3.2, the ProcM-modified 
precursor peptides with their leader sequences still attached were used for amino acid analysis. 
The derivatized samples were analyzed by GC-MS using an Agilent HP 6890N mass 
spectrometer equipped with a Varian CP-Chirasil-L-Val fused silica column (25 m x 0.25 mm x 
0.15 µm). Samples were dissolved in methanol and introduced to the instrument via a splitless 
injection at a flow rate of 1.7 or 2.0 mL/min helium gas. The temperature method used was 160 
o
C for 5 min, 160 
o
C to 180 
o
C at 3 
o
C/min, and 180 
o
C for 10 min. The mass spectrometer was 
operated in simultaneous scan/selected ion monitoring (SIM) mode, monitoring at the 
characteristic fragment masses of 365 Da for Lan and 379 Da for MeLan residues. 
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